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Abstract 
Hepatitis C virus (HCV) is a major cause of chronic hepatitis worldwide. Present estimates 
predict that between 120-130 million people worldwide are infected with HCV with the 
majority of all infections progressing to chronicity, ultimately leading to fibrosis, cirrhosis 
and hepatocellular carcinoma. The virus, which belongs to the family Flaviviridae, has a 
single-stranded RNA genome of positive polarity that codes for a unique polyprotein of 
approximately 3000 amino acids. The structural proteins E1 and E2 constitute the viral 
envelope glycoproteins. These glycoproteins have multiple functions in the viral life cycle 
such as promoting viral entry and fusion, assembly of infectious virions and aid in viral 
persistence through immune escape. Numerous cell culture-adaptive mutations have been 
reported within the HCV glycoproteins. The value of such mutations in understanding the 
virus interaction(s) with cellular receptors and neutralizing antibodies was first recognised 
from studies characterizing the E2 cell culture adaptive mutation G451R. This single 
mutation altered the affinity of HCV to the cell surface receptors CD81 and SRB1 as well 
as increasing its sensitivity to neutralizing antibodies targeting the viral glycoproteins. A 
striking observation from previously reported E2 cell culture adaptive mutations is their 
frequent occurrence within a highly conserved region of E2, spanning residues 412-423. 
Indeed, the long-term passaging of JFH1 infected cells here in this study also created an 
adapted virus with a substitution at residue 415. The aim of this study was to determine the 
phenotypic changes to viral entry caused by mutations in this region. To do this, four JFH1 
viruses containing the mutations N415D, T416A, N417S and I422L were constructed and 
characterized. These mutant viruses were found to have very similar phenotypes to the 
G451R virus, suggesting all E2 adaptive mutations are selected to alter a specific function 
in viral entry. Residues 412-423 of HCV E2 also constitute the epitope of the in-house 
generated broadly neutralizing antibody AP33. ELISA binding and virus infection 
inhibition assays using AP33 with the E2 mutant viruses provided important information 
regarding the E2 contact residues of this antibody.  
 
In a separate study, intergenotypic chimeric JFH1 viruses were generated and 
characterised. Viable intra- and intergenotypic JFH1 chimeric viruses have previously been 
generated by different research groups by replacing the core to NS2 genes of JFH1 with 
those from different genotypes. Many of these chimeric viruses required numerous cell 
culture adaptive mutations to permit efficient infectious virus production. In the present 
study, 5 intergenotypic viruses were constructed by replacing the JFH1 envelope genes 
VII 
 
with those from other HCV genotypes. Despite these chimeric genomes replicating 
efficiently, none were capable of producing infectious virus. These viral genomes also 
failed to acquire infectivity during pro-longed cell passaging, suggesting that replacing the 
JFH1 envelope glycoproteins with those from other genotypes may confer total 
incompatibility for virus assembly. In addition to this work, the infectivity of a previously 
generated genotype 4a/JFH1 chimera was improved by repeatedly passaging the virus 
infected cells. The chimeric virus contained the core to NS2 genes of a genotype 4a strain 
in place of the those from the original JFH1 sequence. A total of six-adaptive mutations 
were identified throughout the adapted genome that enhanced infectivity by more than 
100-fold. Achieving higher titers with this chimera permitted studies on its viral entry 
properties as well as its sensitivity to neutralizing antibodies. The ability of the adapted 
virus 4a/JFH1 virus to spread during multiple rounds of infection was greatly reduced 
compared to WT/JFH1 due to its inefficient cell-to-cell spread. The 4a/JFH1 virions were 
also highly sensitive to neutralizing antibodies targeting both linear and conformational E2 
epitopes, suggesting that the glycoproteins are more exposed on the surface of this virus. 
 
In its totality, this study has provided key insights into the viral entry and antibody-
mediated neutralization properties of cell-culture adapted and intergenotypic chimeric 
forms of the JFH1 virus.  
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1. Introduction 
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1.1. An overview of Hepatitis C virus  
1.1.1. Discovery of Hepatits C Virus 
By the early 1970s serological tests were available that allowed the specific diagnosis of 
hepatitis A virus (HAV) and hepatitis B virus (HBV) in patients suffering of viral hepatitis. 
However, despite HAV and HBV screening, as many as 10% of blood transfusion cases 
still resulted in hepatitis, indicating the existence of a yet unknown agent (Alter et al., 
1975; Feinstone et al., 1975). This unknown agent was termed non-A, non-B hepatitis 
(NANBH). By infecting chimpanzees with blood extracted from NANBH infected patient 
it was established that the agent was capable of causing chronic infection (Alter et al., 
1978; Hollinger et al., 1978). Further work, including filtration experiment and sensitivity 
to organic solvents, suggested that the cause of NANBH was a small enveloped virus 
(Bradley et al., 1985; Feinstone et al., 1983; He et al., 1987). Due to low concentration of 
NANBH serum in chimpanzees, conventional immunological methods failed to identify 
the etiologic agent. Also, further molecular characterisation of NANBH remained obscure 
for a long time mainly by the lack of cell culture and small animal model for the 
propagation of the virus.  
 
In the late 1980s Michael Houghton’s lab at Chiron eventually succeeded in identifying the 
causative agent of NANBH. The identification was facilitated by molecular biology 
techniques such as PCR and nucleic acid methods. Houston and colleagues used a ‘blind 
immunoscreening approach’, where they first reverse transcribed nucleic acid extracted 
from NANBH infected material, followed by generating a cDNA library in bacteriophage 
that expressed polypeptide encoded by cDNA.  This cDNA library was then screened using 
serum derived from a patient diagnosed with NANBH infection. Finally, the group 
managed to isolate a single positive clone designated 5-1-1 that expressed polypeptide 
derived from NANBH viral genome (Choo et al., 1989). Further experimentation revealed 
that the infectious agent was a single-stranded RNA (ssRNA) genome of ~ 10 kb and 
possessed a single open reading frame (ORF). The new virus was named hepatitis C virus 
(HCV) and was classified in the genus Hepacivirus of the Flaviviridae family (Choo et al., 
1989). 
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1.1.2. HCV Properties and Classification 
HCV shares great similarity with flaviviruses and pestiviruses in terms of genetic 
organisation and virion morphology and thus has been classified in the Flaviviridae family 
of the Hepacivirus genus (Choo et al., 1991). Other member of the Hepacivirus genus 
includes the canine hepacivirus (CHV) that infect dogs (Kapoor et al., 2011) and 
nonprimate hepacivirus (NPHV) that infect horses (Burbelo et al., 2012). Flaviviridae 
consists of positive-sense, single-stranded RNA genome encoding a polyprotein of more 
than 3000 amino acids. Based on filtration, rate zonal-ultracentrifugation and electron 
microscopy data, HCV particles in serum are estimated to be 50 nm in diameter with 
spherical outer structure and an inner 30 nm capsid (Bradley et al., 1985; He et al., 1987; 
Kaito et al., 1994).  
 
HCV displays high genetic variability and based on the nucleotide sequence recovered 
from infected individuals HCV is classified into seven different genotypes and numerous 
subtypes (Gottwein et al., 2009; Simmonds, 2004; Simmonds et al., 2005). Moreover, 
within a single individual the virus exists as constantly evolving quasispecies. This genetic 
variabilty is primarily triggered by the error-prone nature of the RNA dependent RNA 
polymerase (RdRp), amplified by the high viral production rate of 1012 particles/day 
(Neumann et al., 1998) and further accelerated by the selective pressure exerted by the host 
immune response (Troesch et al., 2006). The genotypes differ in their nucleotide sequence 
by 30-35% across the whole viral genome. The variation, however, is not evenly spread 
throughout the genome as the greatest diversity is found within the viral glycoproteins E1 
and E2 (Simmonds, 2004). In particular, the variability is mostly confined to the so-called 
hypervariable region 1 (HVR1) of HCV E2 glycoprotein, an important target of the 
antibody response.  
 
The circulating HCV particles in clinical isolates have shown to form complex with very 
low density lipoprotein (VLDL) and low density lipoprotein (LDL), hence the name 
lipoviroparticle (LVP). In addition to VLDL and LDL, the HCV particles also form 
complex with immunoglobulin (Nielsen et al., 2006; Thomssen et al., 1993). As a result of 
these virus-host complexes, the HCV serum particles are associated with wide range of 
buoyant density and sedimentation, which varies based on the method of analysis (Andre et 
al., 2002; Choo et al., 1995; Thomssen et al., 1992). The infectious virions are found in the 
lowest density fractions (~ 1.06 g/ml), which are associated with LDL and VLDL, whereas 
the highest density particles (1.17-1.21 g/ml) display reduced infectivity (Choo et al., 
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1995; Hijikata et al., 1993b; Thomssen et al., 1992). Interestingly, the intracellular HCV 
particles exhibit a higher buoyant density (1.15-1.20 g/ml) compared to the secreted virions 
(Gastaminza et al., 2006), indicating a modification in the biochemical composition of 
HCV during viral egress.    
 
1.1.3. HCV Transmission and Epidemiology  
On a global scale more than 170 million people (~ 3%) are estimated to be infected with 
HCV according to the WHO report for 2011, making HCV the leading cause of chronic 
liver disease worldwide. In developing countries, HCV infection is largely transmitted by 
parenteral exposure to contaminated blood or blood products in the form of transfusion, 
unsafe therapeutic injections and intravenous drug use (Shepard et al., 2005; Yang & 
Roberts, 2010). Since routine screening for HCV was implemented in 1990’s, new cases of 
transfusion associated infections are nearly eliminated in economically developed 
countries and intravenous drug use accounts for the vast majority of the newly acquired 
infections (Thomson, 2009). Rare cases of perinatal transmission and sexual activity have 
also been documented however, data from different studies remain inconsistent (Alter, 
2007). The incidence of HCV infection is difficult to determine as most acute infections 
are asymptomatic and therefore remain undetected. Furthermore, some countries lack 
adequate community-based disease reporting systems and studies are performed in selected 
groups and thus does not represent the general population such as blood donors or drug 
users (Alter, 2007; Lavanchy, 1999). Although endemic in most parts of the world, the 
prevalence of HCV infection is much higher (up to 15%) in some African and Asian 
countries as compared to America (1.7 %) and Europe (1.03 %) (Te & Jensen, 2010; Yang 
& Roberts, 2010) (Figure 1.1). Egypt, for example, has the highest reported seroprevalence 
rate for HCV, up to 20% in some cases. Discontinued since 1980s, this high prevalence is a 
result of the country’s antischistosomal mass treatment campaign where many people 
acquired HCV infection due to re-use of contaminated syringes (Frank et al., 2000). 
Moreover, the seven HCV genotypes vary in their geographical distribution. Genotypes 1-
3 are very widely distributed while 4 is more prominent in Africa and Middle East, 5 in 
South Africa,  genotype 6 is primarily found in South East Asia and genotype 7 in Central 
Africa (Gottwein et al., 2009; Simmonds, 2004) (Figure 1.2). In addition to their 
geographical distribution, the HCV genotypes also differ in the severity of the disease and 
establishing persistent infection and also respond differently to therapy.  
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1.1.4. HCV Pathogenesis 
In most cases HCV is a silent disease where the acute phase may be associated with 
jaundice but more often the infection remains asymptomatic. Unfortunately, in the majority 
of cases the infection becomes chronic with the most severe manifestations being liver 
cirrhosis and hepatocellular carcinoma (Hoofnagle, 1997).    
 
1.1.4.1. Acute HCV 
The majority of HCV infections are asymptomatic during the acute phase and therefore 
remain undiagnosed. Data available of acute phase infection comes from studies conducted 
on patients who acquired infection via needle stick injury or following transfusion. In very 
few cases patients develop non-specific symptoms including decreased appetite, fatigue, 
malaise, jaundice, anorexia and fever. The acute phase is considered the first 6 months 
after infection (Alter & Seeff, 2000; McCaughan et al., 1992; Thimme et al., 2001). The 
infection is marked by viral RNA detection within 1 to 2 weeks following exposure and 
elevated serum alanine aminotransferase (ALT) levels (Farci et al., 1991; Thimme et al., 
2001). Resolution of acute infection occurs spontaneously in around 25% of the cases, 
which is marked by absence of HCV RNA and normal ALT levels (Hoofnagle, 1997). 
Cases of fulminant HCV causing liver failure during acute infection have been documented 
but are very rare (Farci et al., 1996a). Fulminant hepatic failure is a dramatic clinical 
syndrome characterized by the massive necrosis of liver cells, which in the HCV-
associated cases arises shortly following infection (2-8 weeks) (Farci et al., 1996; Kato et 
al., 2001). Such cases are though to be caused by highly virulent strains that circulate in 
the patients blood at high titers (105-108/ml) during the peak stages of infection (Farci et 
al., 1996; Kato et al., 2001). Interestingly, the only HCV strain (JFH1) to date that is 
capable of completing the full viral lifecycle in cell culture was isolated from a Japanese 
fulminant hepatitis patient (Wakita et al., 2005). 
  
1.1.4.2. Chronic HCV 
HCV infection persisting for more than six months is defined as chronic infection. In 
general around 60-80% of patients become chronically infected. The outcome of infection 
depends on a number of viral and host factors including the age of person at the time of 
exposure, ethnicity, gender, lifestyle, underlying disease, the viral genotype, viral 
quasispecies diversity and importantly the efficiency of infected individual’s immune 
response. During the chronic stage patient may remain symptomless for decades, 
experiencing fatigue as their only symptom, but will eventually develop serious liver 
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conditions including hepatic steatosis, progressive fibrosis, compensated and later 
decompensated cirrhosis and ultimately hepatocellular carcinoma (HCC) (Poynard et al., 
1997). The level of liver enzymes ALT and viral load do not usually correlate with the 
amount of liver injury. The level of HCV viremia remains relatively constant with ~ 1012 
virions produced daily (Neumann et al., 1998). Around 20% of the chronically infected 
patient will develop liver cirrhosis within 20 years of infection. Once cirrhosis is 
established, the risk of developing HCC is 1-4% each year (Hoofnagle, 2002). How HCV 
induces cirrhosis and HCC is a matter of much debate. The majority of evidence indicates 
that HCV is not significantly cytopathic in the nonimmunosuppressed state and that 
hepatocellular damage likely reflects destruction of HCV infected cells by cytotoxic 
CD8+T cells (McGuinness et al.,1996; Brillanti et al., 1993). However, patients with 
impaired cellular responses suffer a more severe course of liver disease than 
immunocompetent patients (Einav & Koziel, 2002). Thus, these observations suggest that 
liver cirrhosis induced by HCV infection could be both immune-mediated and viral-
derived. The mechanism through which HCV causes HCC is unknown however, there 
is compelling evidence regarding the potential oncogenic properties of core protein from 
studies in transgenic mice. Approximately 30 % of transgenic mice expressing core protein 
developed HCC between 16-19 months from birth, compared to a 0 % incidence in the 
control mice. Immunologic analysis found that the expression of core protein was higher in 
the tumours cells than in surrounding normal hepatocytes (Moriya et al., 1997). 
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1.1.5. Immunology 
1.1.5.1. Innate Immunity 
Both the innate and the adaptive immunity play a crucial role in clearing HCV infection. 
The innate immune response, which is the first line of defence, activates very early during 
the incubation phase of infection and slows down the progression of infection until the 
adaptive immune response gets activated. Main components of innate immunity include a 
network of cells including natural killer (NK) cells, monocytes, macrophages, leukocytes 
and dendritic cells together with production of type 1 interferons and other interferon 
stimulated genes (ISGs) by hepatocytes. Toll-like receptor 3 (TLR3) and retinoic-acid 
inducible gene I (RIG-I) are pattern recognition receptors involved in anti-HCV innate 
immunity (Saito et al., 2008; Wang et al., 2009). Detection of double stranded RNA and 
the polyuridine motif of HCV 3’ untranslated region (UTR) triggers these two pathways, 
which leads to the phosphorylation and activation of interferon regulatory factor (IRF)-3. 
IRF-3 activation results in IFN- β production and secretion from the infected cell.  Secreted 
IFN-β binds type 1 IFN-α /β receptors, resulting in autocrine/paracrine activation of JAK-
STAT signalling pathway, which in turn results in the expression of IFN-α and many 
dozens of ISGs causing an antiviral state in infected and neighbouring hepatocytes. 
Expression of ISGs such as OAS1 degrades viral and cellular RNA, ADAR1 induces 
mutation in viral dsRNA and destabilizes secondary viral RNA structures and P56 and 
PKR inhibits translation of viral and host RNAs. ISG further results in amplification of the 
IFN response through the upregulation of IFN-β production (Sumpter et al., 2005).  
 
Evidence suggests that HCV attenuates the IFN response at multiple levels and thereby 
may subvert the host innate immunity. In particular, the HCV non-structural protein 
NS3/4A protease disrupts RIG-I and TLR3 activation pathway by cleaving adaptor 
molecules TRIF and thereby blocking IRF-3 activation involved in IFN-β production (Foy 
et al., 2005). Furthermore, the HCV core protein has been shown to interact with certain 
signalling pathways and impairs the induction of ISG, while the HCV E2 and NS5A 
proteins disrupt the downstream function of ISG (Rehermann, 2009). HCV core protein 
inhibits STAT1 activation and thereby interferes with JAK/STAT signalling and ISG 
expression. NS5A has attracted considerable interest because of its potential role in 
modulating the interferon response. The first data to support this hypothesis came from 
Japan where a correlation between the high rate of mutations in NS5A, especially in NS5A 
ISDR (IFN-α sensitivity determining region), was identified to be associated with 
resistance to IFN-α treatment (Enomoto et al., 1996). Furthermore, HCV NS5A and also 
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E2 bind to and antagonize the dsRNA-activated PKR suggesting a possible mechanism by 
which HCV may evade the antiviral effect of IFN (Francois et al., 2000). Binding of HCV 
E2 to the cellular receptor CD81 have also shown to suppress the function of NK cells. NK 
cells are involved in direct lysis of infected cells and produce IFN-γ which has shown to 
have direct antiviral effect. The attenuation of innate immune signalling profoundly affects 
the subsequent activation of adaptive immune response as cytokines produced during 
innate immune response trigger the activation of adaptive immunity. 
 
 
1.1.5.2. Adaptive Immunity 
The adaptive immune response is more specific and can take weeks to develop following 
infection. The two arms of the adaptive immune response are the cell-mediated immune 
response (comprised of T-lymphocytes) and the humoral immune response (comprised of 
B-lymphocytes). 
 
1.1.5.2a. Cell-mediated Immunity 
The main components in the cell-mediated immune response are CD4 helper and CD8 
cytotoxic T lymphocytes (CTL), which appear 5-10 weeks, post infection. In both 
chimpanzees and human, a strong, broad and persistent HCV specific T-cell response 
during the acute phase of infection is associated with viral clearance, although the exact 
role of each subset of T-cells is not entirely clear. A broad response is defined as T-cells 
targeting multiple epitopes and most HCV proteins (Bowen & Walker, 2005; Gruner et al., 
2000; Lechner et al., 2000; Thimme et al., 2001; Thimme et al., 2002).  In particular, a 
vigorous and long lasting CD4 T cell response has shown to be important in resolving 
acute infection and recurrence of viremia has been associated with CD4 T cell loss 
(Gerlach et al., 1999; Urbani et al., 2006). CD8 T cells response can develop in the 
absence of CD4 T cell response without being able to control viremia, however, absence of 
CD8 T cells appears to lead to the establishment of chronic infection (Gruener et al., 
2004). CD8 T cells may eliminate virus infection by non-cytolytic mechanism involving 
cytokines such as IFN-γ or by direct cytotoxicity which is associated with rise in serum 
ALT levels and fall in viremia (Cooper et al., 1999; Shoukry et al., 2003; Thimme et al., 
2001).  
 
The broad T cell response is often lost during chronic stage and virus-specific T cells are 
found in low frequencies in the blood targeting a few epitopes (Rosen et al., 2002). 
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Although, HCV specific T cells can be derived from the liver of chronically infected 
patients, their role in controlling viral replication and contribution to the immunopathology 
are not fully clear. CD4 and CD8 memory T cells can be detected in individuals with 
resolved acute HCV infection, albeit at extremely low frequencies. Although 
immunological memory does not protect against re-infection, it does reduce the risk of 
developing chronic infection upon re-exposure (Farci et al., 1992; Lai et al., 1994; Mehta 
et al., 2002). Furthermore, the immunological memory appears to be strain specific and 
therefore limited due to viral diversity (Sugimoto et al., 2005). 
 
1.1.5.2b. Humoral Immunity.   
HCV specific antibodies are usually detectable 7 to 31 weeks post primary infection and 
persist for variable time. A large number of antibodies are produced by the B-lymphocytes 
during infection, however, data supporting their protective role in viral clearance is so far 
limited (Pawlotsky, 2004; Pawlotsky et al., 1999). In some individuals responses are 
absent while in some cases responses are present but appear to be inadequate in resolving 
infection. Some studies reveal that naturally generated HCV specific antibodies are not 
necessarily required to resolve infection, as spontaneous resolution has been observed in 
chimpanzees without seroconverion (Cooper et al., 1999). In addition, high-titer antibodies 
have been observed far more commonly in chronic patients than in those who clear 
infection (Bartosch et al., 2003; Logvinoff et al., 2004; Meunier et al., 2005). Also 
antibodies against HCV seem to play a limited role in preventing secondary infection in 
both humans and chimpanzees (Farci et al., 1992; Lai et al., 1994). However, treatment of 
HCV with antibodies has proved to be effective in blocking the infection of target cells in 
vitro (Farci et al., 1994). Furthermore, administration of immune globulin associated with 
transfusion revealed to be protective in preventing NANB hepatitis if administered before 
exposure to the virus (Yu et al., 2004). Also serum particles associated with 
immunoglobulins have proved to be less infectious than free virus particles (Hijikata et al., 
1993b). 
 
In a clinical study Lavillette and colleagues characterised the neutralising immune 
response in a cohort of 17 patients acutely infected with single HCV viral strain. It was 
found that the emergence of strong neutralising immune response correlated with a 
substantial loss of viremia, while lack of neutralising response resulted in production of 
high level of viral replication (Lavillette et al., 2005b). In a separate study, Pestka and 
colleagues studied a cohort of 49 women infected in a single-source outbreak of HCV 
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following administration of contaminated immunoglobulin preparations during pregnancy 
(Pestka et al., 2007). The data revealed that a rapid neutralising antibody induction in the 
acute phase of HCV infection correlated with viral clearance as assessed with HCV 
pseudoparticles. However, soon after resolving infection this antibody response was lost. 
In contrast, absence of, reduced or delayed humoral response during acute phase resulted 
in a chronic state. Both these studies, however, lack the involvement of cellular immune 
response. Clearly both the cellular and the adaptive immune response play an equally 
important role in clearing viral infection.  
 
Although presence of antibodies to all HCV antigens has been reported, the natural target 
of neutralising antibodies are the two envelope glycoproteins (E1/E2) which also happens 
to be the most variable region within the HCV genome. Interestingly, antibodies extracted 
from serum of HCV infected patients are usually directed against hypervariable region 1 
(HVR1) in E2, which is under constant selective pressure and thus evolve constantly. 
Hence, these circulating antibodies exhibit strain specific neutralizing activity. However, 
studies using the HCV pseudoparticle system have shown that the presence of certain 
neutralising antibodies exhibiting cross-reactivity have the potential to prevent infection 
with pseudoparticles harbouring homologous and heterologous HCV glycoproteins 
(Bartosch et al., 2003; Meunier et al., 2005; Meunier et al., 2008a).  
 
1.1.6. Disease Progression 
HCV is believed to be non-cytopathic virus that infects and persists in target cells without 
inducing inflammation or damage (Thimme et al., 2002). This is evident by the fact that 
despite high level of viremia no increase in serum ALT has been seen in patients following 
liver transplantation or in cases of accidental infection with contaminated needles during 
health care practice (Thimme et al., 2001). It is only HCV genotype 3 that has been 
associated with steatosis, the accumulation of lipids in hepatocytes (Pawlotsky, 2004). It is 
believed that liver injury and disease progression is mainly immune mediated as T-cell 
infiltration of the liver during acute infection correlates with elevated serum ALT level. 
However, rapid disease progression has been noted in immunodeficient and 
immunosuppressed patients, implying a possible role of viral factors in HCV pathogenesis. 
Indeed, cytopathic effects have been observed in cells infected with the JFH1 cell culture 
infectious virus (Rehermann, 2009). Together, the data suggest that liver damage following 
HCV infection is a consequence of both the host immune response and a direct viral effect. 
 
11 
 
 
1.1.7. Diagnosis of HCV Infection 
HCV infection during the acute phase is rarely diagnosed as a majority of the people 
remain asymptomatic during this phase. When suspected, the diagnosis involves both 
serological and virological detection methods. 
 
Serological tests detect presence of antibodies against different HCV epitopes in an 
enzyme immunoassay, given that seroconversion has occurred and sufficient antibodies are 
available for detection. This method can measure the level of antibody present in the 
serum/plasma but cannot determine whether the infection is ongoing (Chevaliez & 
Pawlotsky, 2007). 
 
Virological assays rely on virus nucleic acid amplification and give both a qualitative and 
quantitative analysis of viral load. Following extraction from plasma/serum, HCV RNA is 
amplified using either the polymerase chain reaction (PCR), transcription mediated 
amplification (TMA) or branched DNA (b-DNA) assay (Chevaliez & Pawlotsky, 2007).  
 
The serological or the virological method can be used to determine the specific HCV 
genotype a person is infected with, which is important since the genotype determines the 
dose and the duration of treatment. The HCV genome sequencing is particularly useful 
during patient follow up in order to identify resistance mutations to antiviral therapies. 
Lastly, a negative HCV RNA result should be demonstrated on multiple occasions to 
confirm the clearance of infection from a previously HCV positive patient (Chevaliez & 
Pawlotsky, 2007).  
 
 
1.1.8. Treatment of HCV Infection 
Although 20% to 25% of acute HCV infection is eradicated spontaneously by the host 
immune response, there is a very small chance of spontaneous resolution once infection 
becomes chronic. At present no vaccine is available for HCV and the standard treatment 
for chronic HCV is combination therapy of pegylated interferon alpha (IFN-α) and 
ribavirin. Several factors including patient gender and age, HCV genotype, viral load and 
stage of liver fibrossis are predictive of treatment outcome. For those who develop 
decompensated liver cirrhosis or HCC, liver transplantation is the only option available.   
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1.1.8.1. Current Treatment 
At present, a combination of IFN-α injection and ribavirin pills are adminstered for a 
period of 24 (genotype 2 or 3) or 48 weeks (genotype 1, 4 or 6) depending on the HCV 
genotype (Di Bisceglie & Hoofnagle, 2002). Fewer data are available on the treatment 
outcome of genotype 4, 5 and 6. The combination therapy results in sustained virological 
response (SVR) in 40%-50% (genotype 1 or 4) to 80% (genotype 2 or 3) of patients. 
Notably, genotype 1 infections have the lowest SVR of between 25-20% (Soriano et al., 
2009; Tsubota et al., 2011).  SVR is defined as the loss of detectable HCV RNA during 
treatment and its continuing absence at least 6 months after stopping therapy. 
Unfortunately, apart from having limited response rate, the combination of IFN-α and 
ribavirin is highly costly and further contraindicated in many patients due to severe side 
effects including fever, headache, myalgia, haemolytic anaemia and severe depression 
(Fried et al., 2002). Consequently, more effective and less toxic therapies to treat HCV are 
urgently required. 
 
The mechanism by which IFN and ribavirin exert their therapeutic effect is currently not 
clear. IFNs are a group of endogenous glycoprotein that play crucial role in the innate 
antiviral immune response and have antiviral and immunomodulatory properties. IFN-α is 
thought to act as endogenous IFN and induces expression of numerous genes which trigger 
an antiviral innate response (Feld & Hoofnagle, 2005). Interestingly, non-responsive 
patients tend to have a high constitutive expression of ISGs that cannot be further 
stimulated by treatment (Sarasin-Filipowicz et al., 2008). Moreover, several 
polymorphisms at the IL28 locus, which encodes a type of IFN-λ, have been reported to be 
associated with the therapy outcome (Ge et al., 2009). Ribavirin is a guanosine analogue 
and interestingly is effective only when used in combination with IFN-α. Being a 
nucleoside analogue it is hypothesised that Ribavirin may inhibit HCV replication after 
being misincorporated by HCV polymerase during RNA synthesis (Feld & Hoofnagle, 
2005). Another mechanism by which Ribavirin is thought to exert its anti-viral effect is by 
acting as a RNA mutagen causing an accumulation of mutations that may lead to collapse 
in viral fitness termed “error catastrophe” (Crotty et al., 2001).  
 
1.1.8.2. Novel Antivirals 
A major challenge in developing new antiviral compounds is that they should be more 
effective, better tolerated and preferably allow shorter treatment periods than the current 
therapy. In addition, the risk of developing drug resistance due to vast numbers of 
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quasispecies present during the course of infection presents another major obstacle that 
needs to be considered. With better insight in HCV molecular virology and HCV 
replication, research is focused on the production of STAT-C (specifically targeted 
antiviral therapy for hepatitis C) compounds as well as improving the current therapy with 
pegIFNα/ribavirin. In addition, immunomodulatory agents other then IFN that stimulate 
host innate and adaptive immune response are also being tested. The role of neutralising 
antibodies as a potential therapeutic approach will be discussed in section 1.5. 
 
In terms of modifying current treatment, Human Genome Sciences (HGS) in collaboration 
with Novartis AG developed Albuferon, a recombinant drug consisting of IFNα conjugated 
to human albumin. Conjugation to albumin prolongs the half life of the compound in the 
blood and thereby allowing a less frequent dosing (Qureshi et al., 2009). After obtaining 
promising data from their phase III clinical trial HGC filed an application to the FDA 
(Food and Drug Administration) in 2009 for marketing approval. 
 
STAT-C compounds specifically and directly target HCV life cycle. Table 1.1 lists the 
STAT-C drugs currently in clinical trial pipeline. The most popular targets are the NS3/4A 
serine protease and NS5B RdRp. Indeed, protease inhibitors (PI) (telaprevir and 
boceprevir) directly targeting NS3/4A serine protease has recently been approved by FDA. 
NS3/4A is the major HCV protease required for cleavage of viral polyprotein during HCV 
replication and is also believed to be the primary HCV protein responsible for evasion of 
IFN response. These PIs exert their effect by blocking the NS3/4A ability to cleave the 
HCV polyprotein and restore innate immune signalling (Rosen, 2011). Clinical data 
suggest that telaprevir or boceprevir combined with current pegIFNα/ribavirin therapy 
improve SVR by 79% and 63%, respectively, compared to 50% SVR with 
pegIFNα/ribavirin alone. The triple therapy has specifically shown improved SVR in 
difficult to treat or non-responder HCV genotype 1 infected patients (Jazwinski & Muir, 
2011; Rosen, 2011; Tsubota et al., 2011). Main adverse effects seen with telaprevir and 
boceprevir are skin rashes, nausea and anaemia.  
 
NS5B polymerase inhibitors include nucleoside analogue (chain terminators) and non-
nucleoside analogues (allosteric inhibitors). Among nucleoside analogue, R-1626 
demonstrated potent antiviral activity against all genotypes in early in vitro experiments 
(Soriano et al., 2009). However, during phase II clinical trials, patients suffered severe 
neutropenia and high rate of HCV infection relapse after completion of therapy and thus in 
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2008 its further development was halted (Pockros et al., 2008). An additional nucleoside 
analogue that so far appears to be safe and well tolerated when combined with 
pegIFNα/ribavirin is R7128, which is currently being evaluated in clinical phase II trials. 
Lastly, BMS-824 potently inhibits HCV replication by binding NS5A protein and 
demonstrated promising efficacy in phase I clinical trial (Gao et al., 2010). Extensive 
research is being put into developing IFN-free regimen for treating HCV, however so far in 
most cases STAT-C drugs under trial would have to be combined with IFN treatment to 
prevent emergence of resistance strains. 
 
 
Apart from directly targeting viral proteins, another approach is to target cellular factors 
involved in HCV life cycle. This method will eliminate the risk of developing drug 
resistance, however, major drawback of targeting cellular factors is the risk of cytotoxicty 
(Khattab, 2009). 
 
Lastly, antiviral therapy or immunomodulatory drugs combined with therapeutic vaccine 
might prove efficient especially when considering the variability of HCV. Vaccine 
research is focused on generating cytotoxic T cell response as well antibody response. 
Types of vaccines under development include epitope vaccines, vector vaccines, 
recombinant protein vaccines and DNA vaccines (Halliday et al., 2011). List and progress 
of vaccines currently in clinical trials is reviewed in table 1.2. 
 
 
1.2. HCV Genome Organization and Function 
HCV contains a small single stranded RNA genome (9.6kb) of positive polarity and 
consists of a single ORF that contains 9024 to 9111 nucleotides depending on the 
genotype. The ORF is flanked at the 5' end by an untranslated region (UTR) that functions 
as an internal ribosome entry site (IRES) and at the 3' end by a highly conserved sequence 
essential for genome replication. The polyprotein is cleaved by viral and cellular protease 
to yield structural proteins core, E1 and E2 and non-structural proteins NS2, NS3, NS4A, 
NS4B, NS5A and NS5B. The p7 protein, currently unassigned to either category, separates 
the structural proteins from the nonstructural proteins (Figure 1.3). 
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1.2.1. The 5’ UTR 
The 5’ UTR region of HCV comprising the first 341 nucleotides is a highly conserved 
sequence involved in replication and translation of viral genome (Bukh et al., 1992; Friebe 
et al., 2001; Honda et al., 1999). The 5’ UTR contains 4 highly structured domains (termed 
I-IV) consisting of numerous stem-loop motifs (Honda et al., 1996a). Domain II-IV 
together with 12-40 nucleotides of the core sequence forms the IRES that directly recruits 
40s ribosomal unit to the AUG codon and initiates protein translation in a cap-independent 
manner involving eukaryotic translation factor elF3 (Honda et al., 1999; Reynolds et al., 
1996). Domain IV is not required for ribosome binding, in fact the structural stability of 
this region is negatively correlated with the translation efficiency (Honda et al., 1996b). 
Domain I seems to be dispensable for overall IRES activity but may have a regulatory role 
in translation efficiency (Honda et al., 1996a). Apart from its importance in protein 
translation, the 5’ UTR also serves an important role in RNA replication. Domain I and II 
are sufficient for viral RNA synthesis, although the efficiency of this process is enhanced 
by the presence of the complete 5’ UTR (Friebe et al., 2001; Kim et al., 2002). Apart from 
translation factor elF3, the 5’UTR is also known to interact with a number of other cellular 
proteins (PTB, La, hnRNP L and PCBP) that are important in regulating both replication 
and translation of HCV viral genome (Ali & Siddiqui, 1995; 1997; Fukushi et al., 2001; 
Hahm et al., 1998; Jopling et al., 2005). Moreover, interactions between the liver-specific 
microRNA, miR-122, and domain I and II of the 5’UTR have shown to be essential for 
efficient HCV RNA replication both in infected chimpanzees and during infection in 
cultured cells (Jopling et al, 2005; Jopling et al, 2008; Lanford et al, 2010; Machlin et al, 
2011). It is hypothesized that miR-122 may protect HCV RNA from nucleolytic 
degradation or may prevent the activation of enzymes that induce innate immune response 
(Machlin et al, 2011). Due to its considerable importance and conservation, the 5’ UTR 
constitutes a promising target for RNA interference based therapy (Kanda et al., 2007).  
 
 
1.2.2. The 3’ UTR 
3’ UTR contains approximately 225 nucleotides and is organised into three domains 
consisting of a variable region of around 40 nucleotides, a poly (U/UC) stretch that 
regulates replication and a highly conserved 98-nucleotide X-tail (Kolykhalov et al., 1996). 
Based on biochemical and structural studies, 3’ UTR is proposed to harbour two stem 
loops in the variable region (VSL1 and VSL2) and three stem loops in the X-tail (SL1, SL2 
and SL3) (Blight & Rice, 1997; Tanaka et al., 1996). VSL1 and VSL2 are dispensable for 
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RNA replication in cell culture and for HCV infectivity in chimpanzees as small deletions 
within these regions significantly reduce the efficiency of viral replication but are not 
lethal (Friebe & Bartenschlager, 2002; Yanagi et al., 1999). However, the U/UC region 
and X-tail are essential for HCV RNA replication as deletions or substitutions within any 
of these regions often prove lethal. At least 50 nucleotides of the U/UC stretch are required 
to allow viral replication (Friebe & Bartenschlager, 2002; Yi & Lemon, 2003). Moreover, 
cis-acting replication elements (CREs) have been identified in the NS5B coding sequence 
that have shown to interacts with 3’UTR. The NS5B coding sequence contains a predicted 
cruciform structure (5BSL3) consisting of three stem loops, 5BSL3.1, 5BSL3.2 and 
5BSL3.3. Among these 5BSL3.2 have shown to be essential for RNA replication (Friebe et 
al., 2005). Apart from its role in replication, 3’UTR is also thought to enhance IRES 
dependent translation of viral RNA by increasing the efficiency of termination (Bradrick et 
al., 2006; Song et al., 2006).  
 
 
1.2.3. Core  
The HCV core protein is presumed to form the viral capsid into which the viral genome is 
packaged (McLauchlan, 2009). It is located at the N-terminus of the HCV polyprotein and 
is cleaved by host signal peptidase (SP) as a 191 amino acid precursor of 23kDa, which 
remains anchored to the cytoplasmic side of the ER memebrane via its C-terminal 
hydrophobic tail (Moradpour et al., 1996; Santolini et al., 1994; Yasui et al., 1998). 
Additional processing by signal peptide peptidase (SPP) gives rise to the mature 21 kDa 
form of the core protein (McLauchlan et al., 2002). The mature form of core is predicted to 
contain two distinct domains D1 and D2. D1 is highly hydrophilic and is principally 
involved in RNA binding (Boulant et al., 2005). The interaction with RNA motifs located 
in the 5’ UTR probably facilitates the oligomerization of the core protein and initiates the 
virus packaging reaction (Majeau et al., 2004). D2 on the other hand is more hydrophobic 
in nature and is believed to be essential for core association with lipid droplets (LDs) and 
ER membranes (McLauchlan, 2000; Moradpour et al., 1996). Following its interaction 
with LDs, core directs the redistribution of LDs into the vicinity of membranes bearing 
genome replication complexes, a process that has shown to play a major role in the 
assembly of infectious virus particles (Boulant et al., 2007; Miyanari et al., 2007). In 
addition to being a virion component, the core protein interacts with a variety of cellular 
proteins and has shown to influence numerous host cell functions including, apoptosis, 
gene transcription, cell proliferation, immune response modulation, lipid metabolism and 
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HCV-related steatosis (McLauchlan, 2000; 2009; Roingeard & Hourioux, 2008). However, 
all these observations are derived from heterologous overexpression experiments and still 
need to be confirmed in an infectious system.  
 
The translation of an alternative reading frame in the core coding sequence can also yield a 
small protein (~17 kDa), called ARFP or F protein. However, the F protein is dispensable 
for RNA replication in the HCVcc system and its possible function is unclear so far 
(McMullan et al., 2007; Vassilaki et al., 2008). However, specific immune responses 
targeting the F protein have been detected in some chronically infected patients (Xu et al., 
2001). 
 
 
1.2.4. p7 
P7 is a small (7 kDa) intrinsic membrane spanning protein with a cytoplasmic loop and its 
N- and C- termini oriented towards the ER lumen (Carrere-Kremer et al., 2002). It belongs 
to the viroporin family of proteins, which is able to oligomerise in vitro and form an 
hexameric cation-selective ion channel (Griffin et al., 2003; Luik et al., 2009; StGelais et 
al., 2007), which constitutes a potential antiviral target. Indeed, this p7 function can be 
inhibited by amantadine, a compound that inhibits the influenza A encoded M2 ion channel 
activity (Griffin et al., 2003). Furthermore, several inhibitory compounds known to 
interfere with p7 ion channel activity also repress the release of infectious virus particles in 
the HCVcc system (Griffin et al., 2008; Steinmann et al., 2007b). Indeed, p7 has been 
shown to be critical for the release of infectious HCVcc particles, but has no role in RNA 
replication (Jones et al., 2007; Steinmann et al., 2007a). Recently, it was demonstrated that 
p7 has a proton-selective ion-channel activity, the function of which is directly responsible 
for the enhancement of infectious virus production (Wozniak et al., 2010). 
  
 
1.2.5. NS2 
NS2 is a hydrophobic integral membrane protein responsible for the autoproteolytic 
cleavage at the NS2/NS3 junction of the polyprotein. The 23 kDa protein is believed to 
harbour multiple membrane spanning domains that localise NS2 to the ER membrane. 
However, the exact membrane topology and mechanism of translocation remains 
controversial (Santolini et al., 1995). The catalytic activity of the NS2-3 cysteine protease 
resides in the C-terminal half of NS2 and requires the N-terminal one-third of NS3, notably 
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through the zinc binding domain (Grakoui et al., 1993; Hijikata et al., 1993a). The Crystal 
structure of NS2/3 proposes three crucial residues (His143, Cys184 and Glu 163) forming 
the catalytic triad that together form an active site (Lorenz et al., 2006). Subgenomic 
replicons not encoding the NS2 protein replicate efficiently in Huh-7 cells suggesting that 
NS2 is indispensible for RNA replication (Lohmann et al., 1999). However, full length 
NS2 is critical for the assembly of infectious particles in HCVcc, independent of its 
catalytic activity (Jirasko et al., 2008; Jones et al., 2007). There is increasing evidence 
supporting a crucial role for NS2 in factoring the coordination of virus assembly through 
stable interactions with E1, E2, p7, NS2, NS3 and NS5A (Jirasko et al., 2010; Ma et al., 
2011; Popescu et al., 2011; Stapleford & Lindenbach, 2011). The use of chimeric construct 
consisting of NS3-NS5B region from HCV strain JFH1, fused with the structural genes 
from other genotypes, have shown that the position of the intra/inter-genotypic junction 
within NS2 affects infectious particle production (Pietschmann et al., 2006). For most 
chimeras, a junction between the first and second TMD is optimal, indicating that 
interactions between the N-terminus of NS2 and p7 or the structural protein is important 
for virus production (Pietschmann et al., 2006). Additionally, cell culture adaptive 
mutations that enhance virus production have been found within the NS2 coding region 
(Russell et al., 2008; Yi et al., 2007). 
 
 
1.2.6. NS3 and NS4A 
NS3 is a multifunctional 70 kDa protein harbouring a serine-type protease within its N-
terminal, while the two-third of C-terminal features a RNase helicase/NTPase motif. Both 
the NS3 serine protease and the helicase activities require NS4A as a cofactor. NS4A is the 
smallest HCV-encoded protein (6 kDa) and consists of an N-terminal hydrophobic region, 
a central domain and a C-terminal acidic region. The crystal structure of NS3/NS4A 
revealed that the central part of NS4A is mandatory for proper NS3 folding 
(Bartenschlager et al., 1995; Lin et al., 1995; Tai et al., 1996) while its N-terminal 
transmembrane domain (TMD) allows stabilisation and localization of NS3 at the ER 
membrane (Wolk et al., 2000). The C-terminal acidic region of NS4A influences NS5A 
phosphorylation and HCV RNA replication (Lindenbach et al., 2007). Upon association 
with the ER membrane, NS3 serine protease facilitates HCV polyprotein processing in cis 
at the NS3/NS4A and in trans at the NS4A/NS4B, NS4B/NS5A and NS5A/NS5B 
junctions. The catalytic triad is formed by residues His 57, Asp 81 and Ser 139 and 
mutation of any of these amino acids abolishes NS3 mediated cleavage (Bartenschlager et 
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al., 1993; Grakoui et al., 1993). In addition to processing viral proteins, NS3/4A protease 
also cleaves cellular targets, in particular, Cardif and TRIF and thereby blocking the 
antiviral innate immune response triggered by RIG-I and TLR-3 at the early stage of 
infection (Li et al., 2005; Meylan et al., 2005). The NS3 helicase-NTPase has several 
functions, including RNA-stimulated NTPase activity (Kim et al., 1998; Yao et al., 1997), 
RNA binding and unwinding of RNA regions of extensive secondary structure (Serebrov 
& Pyle, 2004). Although the structural data has been determined, the mode of action and 
precise role of the helicase in the virus life cycle remains unclear. Recent studies with 
intergenotypic chimeras have identified compensatory mutations within the NS3 helicase 
domain that rescue the assembly of virus particles of chimeras otherwise defective for 
virion production (Ma et al., 2008; Phan et al., 2009; Yi et al., 2007).  
 
 
1.2.7. NS4B 
HCV RNA replication takes place in specialized membrane derived vesicles called 
membranous web or membrane associated foci (MAF) where all HCV non-structural 
proteins accumulate (Egger et al., 2002; Gosert et al., 2003; Gretton et al., 2005). 
Formations of these membranous webs are induced by NS4B. NS4B is a highly 
hydrophobic 27 kDa integral membrane protein tightly associated with the ER membrane 
(Egger et al., 2002; Hugle et al., 2001). The central portion of NS4B is predicted to 
harbour four TMDs and a N-terminal amphipathic helix that are responsible for its 
association with membrane (Elazar et al., 2004; Hugle et al., 2001; Lundin et al., 2003). 
Disrupting the ability of NS4B to bind to ER leads to loss of non-structural proteins at the 
MAF in addition to abolishing replication of the viral genome (Elazar et al., 2004). Thus, 
these NS4B induced ER membrane alterations likely create an environment suitable for 
viral RNA replication.  
 
 
1.2.8. NS5A 
NS5A is a phosphoprotein that can be found in basally phosphorylated (56 kDa) and 
hyperphosphorylated (58 kDa) form and plays an important role in virus replication and 
regulation of cellular pathways (Macdonald & Harris, 2004). NS5A is divided into three 
domains that are separated by low complexity sequences (LCS) (Lemon et al., 2010).The 
N-terminal region of NS5A contains an amphipathic alpha-helix that mediates membrane 
association and possibly localises the protein to replication complexes. Disruption of this 
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helix structure leads to a loss in membrane binding of NS5A and is lethal for HCV RNA 
replication. (Brass et al., 2002; Elazar et al., 2004; Penin et al., 2004a). Downstream from 
the helix motif resides domain I which contains a zinc binding site that is required for HCV 
RNA replication (Tellinghuisen et al., 2004). The crystal structure of domain I reveals that 
NS5A may dimerise to create a basic groove amenable for RNA binding. Indeed, NS5A is 
able to bind the poly (U/UC) stretch present in 3’UTR of HCV (Huang et al., 2005). 
Moreover, domian I promotes NS5A association with lipid droplets (LDs), an event that is 
crucial for HCVcc assembly (Miyanari et al., 2007). Unlike domain I, domain II and III are 
poorly characterised. It has been noted that many cell culture adaptive mutations enhancing 
replication affect serine residues within NS5A and thus, reduce its hyperphosphorylation. 
This indicates that the phosphorylation state of NS5A modulates the efficiency of HCV 
RNA replication (Appel et al., 2008; Tellinghuisen et al., 2007; Tellinghuisen et al., 2008).  
 
NS5A is able to further interact with several other cellular signalling pathways such as 
mitogenic signalling, apoptosis, phosphatidylinositol 3-kinase-mediated signalling and 
calcium/reactive oxygen signalling pathways, which may be related to HCV pathogenesis 
(Macdonald et al., 2005; Macdonald et al., 2003). 
 
 
1.2.9. NS5B 
NS5B is the RdRp that promotes synthesis of both the positive strand RNA and the 
negative strand intermediate in the absence of other viral or cellular factors in vitro 
(Behrens et al., 1996; Lohmann et al., 1997). A specific interaction between NS5B and the 
3’UTR has been reported (Cheng et al., 1999). The enzyme lacks a proofreading function, 
which contributes to the high genetic variability of HCV (Domingo et al., 1996). NS5B is 
an integral membrane protein with a cytosolic orientation and associates to the ER 
membrane via a highly conserved C-terminal TMD (Ivashkina et al., 2002). The 
membrane association appears to be crucial for NS5B function in cells (Moradpour et al., 
2004). NS5B has the classical ‘fingers, palm, thumb’ polymerase structure (Ago et al., 
1999; Bressanelli et al., 1999; Lesburg et al., 1999; Poch et al., 1989), where the 
interaction between fingers and thumb form a tunnel for binding the RNA template and the 
central palm domain harbours the catalytic GDD motif.  
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NS5B has been shown to interact with cellular components that modulate its polymerase 
activity. For example, interaction with cyclophilin B seems to enhance viral RNA synthesis 
through modulation of the RNA binding capacity of NS5B (Watashi et al., 2005).  
 
Cyclophilin A is also required for HCV RNA replication and directly interacts with NS5A, 
which is speculated to induce a conformation necessary for replicase formation and activity 
(Kaul et al., 2009). Interestingly, drugs targeting cyclophilins are being developed as new 
promising HCV antiviral targets (Table 1.1). For example, cyclophilin A is targeted by the 
cyclosporine analogue DEBIO-025, which has shown potent anti-HCV activity (Kaul et 
al., 2009). 
  
 
1.3. Models to study HCV  
1.3.1. Animal models 
Many features of the HCV infection are similar between human and chimpanzees and for 
more than a decade the chimpanzee was the only animal model available to study the 
course of HCV infection (reviewed in Bukh, 2004). Due to the silent nature of HCV 
disease, acute infections in human usually go unnoticed and the chimpanzee model 
provided the advantage of monitoring the progression of HCV disease from beginning to 
end. Studies in the chimpanzee shed further light on different aspects of the cellular 
immune responses and their role in disease outcome (Jo et al., 2011). Although 
chimpanzees provide a well controlled clinically relevant model for the study of HCV, it is 
extremely limited in its availability, is highly expensive and due to ethical issues has not 
been used for anti-HCV drug discovery.  
 
Many attempts have been made to establish a small animal model for HCV that is widely 
available, affordable and reproducible and one that represents most aspects of human HCV 
infection and disease. Chimeric (xenograft) mice harbouring human hepatocytes 
uPA/SCID (urokinase plaminogen activator/ severe combined immunodeficiency) is 
probably the most relevant small animal model set up so far (Meuleman & Leroux-Roels, 
2008) Inoculation of SCID mice with HCV derived from human serum has shown to 
support prolonged HCV infections with clinically relevant titers (Mercer et al., 2001; 
Meuleman et al., 2005). Most importantly, SCID mice have proven useful in the evaluation 
of efficacy and toxicity of antiviral compounds (Kremsdorf & Brezillon, 2007). 
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More recently an immunocompetent humanized mouse model for HCV was described. 
This model was developed by inoculating mice with a recombinant adenoviral construct 
that induced the expression of the four HCV human receptors in the mouse hepatocytes 
that are sufficient for HCV infection (Dorner et al., 2011). Infection of these mice was 
shown using a bicistronic HCV genome expressing CRE recombinase (Bi-nlsCre-
Jc1FLAG2, abbreviated HCV-CRE), which activates a loxP-flanked luciferase reporter in 
Rosa26-Fluc mice. The mice were infected with the HCV-CRE and displayed high 
luciferase values that peaked at 72 hours postinfection. This system represents the first 
immunocompetent small animal model for studying HCV coreceptor biology in vivo and 
evaluation of passive immunization strategies. 
 
 
1.3.2. Replicons 
Detailed studies on the HCV life cycle were hampered, primarily due to the incapacity of 
HCV serum particles to establish infection in cell culture. Nevertheless a major 
breakthrough came in 1999 with the development of a selectable, subgenomic replicon 
(SGR) system that allowed HCV RNA replication in cell culture (Lohmann et al., 1999). 
The first functional SGR, derived from a genotype 1b strain called Con1, was a bicistronic 
construct. In this system the first cistron encoded neomycin phophotransferase (neor) gene, 
translated under the control of the HCV IRES, resulting in G418 resistance. The second 
cistron encoded non-structural proteins (NS3-NS5B) directed by a heterologous EMCV 
IRES. Upon electroporation of Huh-7 cells with in vitro synthesized SGR RNA and 
selection with G418 resulted in low numbers of surviving cell colonies (Figure 1.6). The 
low frequency of cells supporting SGR RNA replication was partly because replicon RNAs 
had to acquire adaptive mutations for efficient replication in the Huh-7 cells and secondly 
due to limited host cell permissiveness. Adaptive mutations tend to cluster within the non-
structural proteins NS3, NS4B, NS5A and NS5B. Several replication-enhancing mutations 
resulted in loss of NS5A hyperphophorylation (Blight et al., 2000). Introducing adaptive 
mutations into the parental replicon significantly enhanced RNA replication level to 
various extents (Blight et al., 2000; Krieger et al., 2001; Lohmann et al., 2001). 
Furthermore, curing Huh-7 cells supporting viral replication by IFN treatment identified 
cell clones that supported greater levels of RNA replication. For the Huh-7.5 cell clone, 
this phenotype was thought to be due to a defective IFN response in these cells caused by a 
mutation in the RIG-I gene (Sumpter et al., 2005). The aforementioned advancements in 
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the understanding of the SGR system through viral adaptive mutations and highly 
permissive cell clones eventually led to the development of autonomously replicating full-
length replicons harbouring the entire HCV ORF (Blight et al., 2003; Ikeda et al., 2002; 
Pietschmann et al., 2002).  
 
 
1.3.3. HCVpp 
Availability of stable cell lines harbouring autonomously replicating SGR RNAs helped 
define the functional replication unit, as well as the viral and cellular determinants 
involved in replication complex and their subcellular localization. It was however, the 
development of HCV pseudoparticle system (HCVpp) that enabled the study of viral entry 
(Bartosch et al., 2003; Drummer et al., 2003; Hsu et al., 2003) (Figure 1.6). HCVpp are 
engineered viral particles consisting of a retroviral or lentiviral core enveloped by a lipid 
bilayer.  Present within the envelope are HCV E1 and E2 gene products, which confer 
entry of the pseudoparticle into target cells. To quantify the number of infected cells, a 
reporter gene, such as luciferase or green fluorescent protein (GFP), is also included. 
HCVpp harvested from transfected 293T cell supernatant can be used to infect naive Huh-
7 cells, where entry is mediated by HCV glycoproteins and can be blocked by anti-E1 or 
anti-E2 specific antibodies (Bartosch et al., 2003; Hsu et al., 2003; Lavillette et al., 
2005b). Since HCVpp are replication deficient and support only a single infection event, 
the quantification directly reflects the HCVpp capacity to enter the cells. Studies have 
shown HCVpp and HCVcc virions share the same pH-dependent internalisation and fusion 
steps of the entry process (Tscherne et al., 2006; Sharma et al., 2011). More importantly, 
HCVpp representing glycoproteins of all major genotypes have been successfully 
generated (Lavillette et al., 2005b; Owsianka et al., 2005) and have allowed in depth 
studies of virus binding, attachment and internalization and also helped in identifing novel 
HCV receptors.  
 
 
1.3.4. HCVcc 
In 2005, three research groups published reports on the development of a cell culture 
system capable of producing infectious HCV particles (HCVcc) (Lindenbach et al., 2005; 
Wakita et al., 2005; Zhong et al., 2005). Each system relied on the properties of a unique 
genotype 2a isolate, known as JFH1. SGRs derived from JFH1 were previously shown to 
be capable of efficient RNA replication in multiple liver and non-liver specific cell lines 
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without the need for adaptive mutations (Kato et al., 2003; Kato et al., 2005). Later, it was 
demonstrated that RNA transcripts from the full-length JFH1 genome transfected into 
Huh-7 cells produced infectious virus (Wakita et al., 2005) (Figure 1.6). However, virus 
titers released from transfected or infected cells were moderate at best. Higher virus titers 
were shown to be achieved when JFH1 was propagated in the Huh-7.5.1 cell-line (Zhong 
et al., 2005). Also, a chimeric JFH1 clone containing the core to NS2 region of HCV strain 
J6 fused to the JFH1 NS3-NS5B was found to be more infectious than full-length JFH1 
(Lindenbach et al., 2005). The virus release was further improved by altering the fusion 
junction from NS2/NS3 to a crossover point that resides after the first TM segment of NS2 
(Pietschmann et al., 2006). This cross-over point also improved the infectivity of other 
intergenotypic chimeras. Thus, virus release is more efficient when the first TM NS2 
segment is from the same isolate as the core-to-p7 region and the remainder of NS3 is 
homologous to the replicase. It is believed that this enhancement may be related to 
interactions between the N-terminal NS2 region and the structural protein(s) or p7, 
alterations of cleavage at the p7–NS2 site that is processed with delayed kinetics, or effects 
on cleavage at the NS2–NS3 site. Since the development of the J6/JFH1 chimera, viable 
JFH1 chimeras representing all genotypes have been generated (Gottwein et al., 2009).  
 
1.4. HCV Life Cycle 
The HCV life cycle is a highly complex multistep process (Figure 1.4) that begins with the 
viral glycoproteins interacting with several cellular factors, which mediate internalisation 
of the virus into the host via clathrin-mediated endocytosis (Figure 1.5). HCV replication 
occurs in association with cytoplasmic membranes and virion assembly and release are 
believed to occur via the ER membrane following the same secretion pathway as VLDL 
assembly. The following sections will detail the different stages of this process. 
 
1.4.1. Virus Binding and Entry 
1.4.1.1. Attachment factors 
Prior to the interaction of HCV with specific cellular receptors, several attachment factors 
are first involved in bringing the virus into close proximity with the cell surface. These are 
believed to be glycosaminoglycans, low density lipoprotein receptors and C-type lectins 
such as Liver or dendritic cell specific intercellular adhesion molecule 3-grabbing 
nonintegrins (L/DC-SIGN).  
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Low Density Lipoprotein Receptors 
HCV serum particles are suggested to complex with host lipoproteins LDL and VLDL and 
circulate as LVP (Andre et al., 2002). The lipoprotein association is thought to facilitate 
the attachment of HCV to target cells by the LVPs interacting with the LDL receptor 
(Popescu & Dubuisson, 2009). In accordance with this notion, an increased accumulation 
of HCV viral RNA in cells was found to correlate with increased LDL receptor expression 
and LDL entry (Germi et al., 2002; Molina et al., 2007). In addition, HCV RNA 
accumulation in cells is inhibited with antibodies directed against LDL receptor (Agnello 
et al., 1999). Furthermore, HCV infectivity is neutralised in a dose dependent manner by 
antibodies directed against ApoB and ApoE (major protein components of VLDLs) 
(Agnello et al., 1999; Chang et al., 2007). Collectively, these data support the essential role 
of lipoproteins at an early stage of HCV infection. 
 
L/DC-SIGN 
L-SIGN expressed on endothelial cells in liver sinusoids and DC-SIGN expressed on 
dendritic cell subsets have been proposed as tissue-specific capture receptors. L/DC-SIGN 
can bind HCV sE2 with high affinity and an interaction with HCVpp and serum particles 
has also been reported (Gardner et al., 2003; Lozach et al., 2004; Lozach et al., 2003). 
L/DC-SIGN are believed to bind viral envelope glycoproteins via mannose-type 
oligosaccharides without mediating entry, thus serving as capture receptors that 
disseminate viral particles to target organs (Cormier et al., 2004a). 
 
Glycosaminoglycans 
Glycosaminoglycans (GAGs) are long polysaccharides that may be covalently linked to a 
core protein to form proteoglycans. GAGs are negatively-charged structures ubiquitously 
expressed as cell surface molecules and are believed to serve as initial docking site for 
many viruses including several members of the Flaviviridae family (Barth et al., 2003). 
HCV is believed to interact with GAG via positively charged residues within the N-
terminus of E2 glycoprotein (Penin et al., 2001). Although GAGs such as heparin and 
heparin sulphate efficiently binds to intracellular E1E2, no such interaction is detected 
between HCVpp derived envelope glycoproteins (Barth et al., 2003). However, the 
treatment of cells with heparinase (enzyme degrading HS) or virus incubation with 
heparin, a HS analogue, inhibit HCV attachment to cells as well as inhibit HCVpp and 
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HCVcc infectivity (Barth et al., 2006; Basu et al., 2007; Koutsoudakis et al., 2006; 
Morikawa et al., 2007).   
 
1.4.1.2. Specific Receptors 
CD81 
By screening a cDNA library, using soluble E2 (sE2) as a probe, CD81 was identified as 
the first putative HCV receptor (Pileri et al., 1998). CD81 is widely expressed throughout 
the human body and is associated with several cellular functions such as cell-cell adhesion 
and immune cell differentiation (Levy et al., 1998). 
 
CD81 is a 26kDa surface protein and is a member of the tetraspanin family. It consists of a 
small and a large extracellular loop with four TMDs. The large extracellular loop (LEL) 
has been demonstrated to permit binding to the ectodomain of sE2, although the E1/E2 
heterodimer exhibits binding implying that of E1 might modulate the binding process 
(Cocquerel et al., 2003).  As for E2, mutagenesis and alanine substitutions of conserved 
epitopes have revealed several discontinuous regions to be involved in CD81 binding 
(Drummer et al., 2006; Owsianka et al., 2006). 
 
The importance of CD81 in both HCVcc and HCVpp infection has been demonstrated with 
the inhibitory effect of anti-CD81 antibodies, CD81-LEL and by downregulation of CD81 
expression (Bartosch et al., 2003; Cormier et al., 2004b; Lindenbach et al., 2005; Wakita 
et al., 2005; Zhang et al., 2004; Zhong et al., 2005). Inhibition assays using anti-CD81 
revealed that CD81 acts after virion binding to target cells, suggesting that CD81 is not the 
only HCV receptor (Cormier et al., 2004b). Although CD81 is important for HCV entry 
the fact that a wide range of cells expressing CD81 are non-permissive for HCV indicates 
that other liver-specific molecules are involved in facilitating viral entry. 
 
SR-BI 
SR-B1 is a multiligand receptor expressed on liver cells and on steroidogenic tissue. It 
binds to numerous lipoproteins such as HDL, LDL, and VLDL. SR-BI is a 509 amino acid 
long protein with two cytoplasmic domains, two TMDs and a large extracellular loop 
responsible for ligand binding (Acton et al., 1996; Acton et al., 1994). SR-BI was initially 
identified as the major receptor for HDL, facilitating selective cholesterol uptake in the 
liver (Acton et al., 1996).  
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SR-BI as a putative HCV receptor was described by cross-linking sE2 to biotinylated cell-
surface proteins followed by immunoprecipitation using an anti-E2 antibody. This 
interaction was dependent on HVR1 of E2 since deletion of HVR1 was shown to impair 
the interaction between SR-BI and sE2 and reduces HCVpp infectivity. Antibodies against 
SR-BI and knockdown of SR-BI expression inhibits HCVpp and HCVcc infectivity 
confirming the importance of this receptor in HCV entry (Bartosch et al., 2003; Lavillette 
et al., 2005b; Scarselli et al., 2002). However, since anti-E2 or anti-HVR1 antibodies do 
not inhibit the HCV-SR-BI interaction, it has been proposed that lipoproteins attached to 
virion may also interact with the receptor (Maillard et al., 2006). In support of this theory, 
various SR-BI ligands such as VLDL and oxidized LDL exhibit inhibitory effects on HCV 
entry (Maillard et al., 2006; von Hahn et al., 2006). 
 
Interestingly, the major SR-BI ligand HDL facilitates HCVpp and HCVcc entry, although 
no direct interaction between HDL and virus particles has been found. It is hypothesized 
that HDL-mediated enhancement of HCVpp and HCVcc entry relies on the lipid transfer 
function of SR-BI (Dreux et al., 2006). 
 
Tight Junction proteins 
Recently, members of the claudin (CLDN) protein family, involved in the formation of 
tight junctions, have been implicated in the entry of HCV. Evans et al. showed that ectopic 
expression of CLDN-1 in the HCVpp entry resistant non-hepatic cells lines, HEK 293T 
and SW13, rendered them susceptible to HCV infection (Evans et al., 2007). CLDN-1 is a 
cell surface protein with four TMDs, two extracellular loops and intracellular N- and C-
termini. CLDN-1 is most highly expressed in the liver, which may determine the tissue 
tropism of HCV. Residues within the first extracellular loop appear to be critical for 
mediating HCV entry, although no interaction between the HCV glycoproteins and CLDN-
1 has been demonstrated (Evans et al., 2007). Initial studies indicated that CLDN-1 acts at 
a step after virus attachment to cells and its subsequent interaction with CD81 and SR-BI 
but prior to membrane fusion (Evans et al., 2007; Zheng et al., 2007). More recent studies 
have shown an association between CD81 and CLDN-1, implying that these two entry 
factors act in a cooperative manner during HCV entry (Harris et al., 2008; Krieger et al., 
2010). Therefore, it is possible that CLDN-1 may potentiate CD81 association with HCV 
particles by way of E2 interactions. In addition to CLDN-1, CLDN-6 and CLDN-9 are also 
able to mediate HCV entry into target cells (Meertens et al., 2008; Zheng et al., 2007).  
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More recently, another tight junction protein, known as occludin (OCLN), has been 
implicated in HCV cell entry. OCLN is a 60 kDa protein with four TMDs, two 
extracellular loops and N- and C- terminal cytoplasmic domains (Furuse & Tsukita, 2006). 
OCLN-E2 binding in HCVcc infection has been confirmed by co-immunoprecipitation 
assays. Strikingly, HCV infection induces re-localization of tight junction proteins to the 
ER, reducing their expression on HCV infected cells. Knockdown of CLDN-1 and OCLN 
expression on cell surface inhibited HCVpp and HCVcc cell entry (Benedicto et al., 2009; 
Liu et al., 2009; Ploss et al., 2009). 
 
Importantly, expression of CD81, SR-BI, CLDN-1 and OCLN renders murine and hamster 
cells infectable with HCVpp, suggesting that these four receptors complete the set of cell 
surface factors required for HCV entry (Dorner et al., 2011; Ploss et al., 2009). 
 
1.4.1.3. HCV Internalisation 
HCV entry is pH dependent (optimal pH 4.5) and thus requires the formation of vesicles in 
order to be directed to the site of replication. siRNA knockdown of clathrin as well as 
inhibition of clathrin-coated pit assembly using chloropromazine reduced HCV entry 
confirming that HCV utilizes the clathrin-mediated pathway for internalisation. Following 
its interaction with the panel of receptors, HCV gets internalised into clathrin-coated pits, 
which fuse with early endosomes where a drop in pH triggers the fusion process by 
inducing conformational changes in the envelope glycoproteins. Indeed, endosomal 
acidification inhibitors have been shown to significantly reduce both HCVpp and HCVcc 
infectivity (Blanchard et al., 2006; Hsu et al., 2003; Koutsoudakis et al., 2006; Meertens et 
al., 2006). Fusion has further shown to be temperature-dependent and enhanced by 
cholesterol (Lavillette et al., 2006). A very recent study showed that HCV-CD81 binding 
could confer fusion competence upon encountering low pH.  The results from this study 
provide strong evidence that the CD81 receptor may be both necessary and sufficient to 
render E1E2 competent for fusion with acidic intracellular compartments (Sharma et al., 
2011). 
 
 
1.4.2. Genome Translation and RNA replication  
1.4.2.1. Genome Translation 
HCV RNA released into the cytoplasm is immediately translated into the viral polyprotein 
by the host ribosomal machinery via the HCV IRES located within the 5’ UTR (section 
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1.2.1). The viral genome serves as a messenger RNA for synthesis of the HCV polyprotein 
precursor. IRES-mediated translation is initiated by direct binding of a vacant 40S 
ribosomal subunit to the IRES and positioning of the polyprotein start codon into the 40S P 
site (Kieft et al., 2001; Otto & Puglisi, 2004). The IRES can capture the 40S ribosomal 
subunit in the absence of other initiation factors known to be required for ribosome binding 
to an mRNA. Following its formation, the IRES-40S complex then binds to the eukaryotic 
initiation factor 3 (eIF3), followed by recruitment of the eIF2:Met-tRNAi:GTP complex to 
generate a 48S-like complex (Pestova et al., 1998; Ji et al., 2004). Upon hydrolysis of 
GTP, the initiator factors are released and the 60S ribosomal subunit can then attach to the 
48S complex to form a functional IRES-80S complex, which can initiate viral protein 
synthesis. Translation occurs in close association with ER membrane where the 
polyprotein is cleaved co- and post-translationally by viral and cellular proteases into the 
10 mature proteins.  
 
1.4.2.2. RNA Replication 
Like other positive-strand viruses, HCV infection induces rearrangement of intracellular 
membranes to form replication complexes where RNA synthesis takes place. Replication 
complexes (membranous web) are ER-derived membranes that are rich in cholesterol and 
fatty acids. Replication complexes contain positive- and negative-strand viral RNA and the 
HCV non-strutural proteins, as well as cellular components involved in genome replication 
(Egger et al., 2002; Gosert et al., 2003; Waris et al., 2004). Replication complexes are 
enclosed structures where HCV RNA and proteins are resistant to ribonucleases and 
proteases and thus protected from the intracellular environment (Quinkert et al., 2005; 
Waris et al., 2004). Numerous cellular factors have been identified with potential roles in 
HCV RNA replication (Ploss & Rice, 2010). The best characterized of these include the 
DEAD-box RNA helicase DDX3 and GBF1 - a guanine nucleotide exchange factor for 
small GTPases of the ARF family. DDX3 is crucial for virus RNA replication and is 
believed to incorporate into replication complexes to facilitate genome translation (Ariumi 
et al., 2007; Geissler et al., 2012). The presence of GBF1 in the cells is critical for 
replication complex activity, although its exact mechanism of action remains to be 
determined (Gouslain et al., 2010). 
 
Within these active complexes viral RNA is amplified by the NS5B RdRp where 
replication proceeds via synthesis of a negative-strand intermediate that serves as a 
template to generate multiple nascent HCV genomes. Replication complexes are estimated 
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to contain one minus-strand RNA template, up to ten positive-strand RNA copies and 
several hundred non-structural proteins (Quinkert et al., 2005). HCV replication is thought 
to occur rapidly after virus entry as negative-strand templates are detectable at 2-4 hours 
after introduction of RNA into cells (Binder et al., 2007). 
 
 
1.4.3. Assembly and Release 
1.4.3.1. HCV Assembly 
It has been suggested that the core-LD association functions to concentrate core protein 
near the ER-located replication complexes (Boulant et al., 2008; Miyanari et al., 2007). 
This close proximity likely facilitates the formation of genome containing nucleocapsids 
and their subsequent usage towards assembly of virions at ER sites harbouring the E1E2 
proteins. Evidence within recent studies suggests that NS2 provides the link between 
replication complexes and the structural proteins by directly interacting with E1, E2, p7, 
NS3 and NS5A (Jirasko et al., 2010; Ma et al., 2011; Popescu et al., 2011; Stapleford & 
Lindenbach, 2011). Indeed, IF studies have shown that NS2 recruits these factors to 
assembly sites at the LD-ER interface (Boson et al., 2011; Jirasko et al., 2010; Popescu et 
al., 2011). Although no specific interaction has been identified between core and NS2 
(Jirasko et al., 2010; Ma et al., 2011; Stapleford & Lindenbach, 2011), it is possible that 
the NS2-NS5A interaction acts in concert with the core-NS5A interaction (Masaki et al., 
2008) during the assembly process. However, results within very recent studies suggest 
that p7 is involved in recruiting core (Boson et al., 2011) and NS2 (Tedbury et al., 2011) to 
sites adjacent to replication complexes. The exact function of NS2 during assembly 
remains to be determined but one possible role may be to release the viral RNA from the 
replication complexes and allow its encapsidation into nascent HCV particles. Presumably, 
the recruitment of the glycoproteins by NS2 to these cites results in the envelopment of 
these genome containing nucleocapids. In addition to these theories, the results from 
another study suggested that NS2 functions at a late-post assembly maturation step, after 
the interaction of core and NS5A with host cell lipid droplets and the formation of core-
protein containing particles (Yi et al., 2009). 
 
1.4.3.2. HCV Release 
HCV is suggested to utilise the LDL/VLDL assembly and secretion pathway for egress. 
VLDLs are produced in hepatocytes and play an important role in maintaining lipid 
homeostasis in the body. Interestingly, LDs are the intracellular storage compartments for 
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cholesterol and triglyceride ester and VLDLs are responsible for exporting these into the 
extracellular environment. Apolipoprotein B (apoB) and apoE are main components of 
VLDL and microsomal triglyceride transfer protein (MTP) transports triglyceride from 
LDs to the apoB and apoE for VLDL assembly (Gibbons et al., 2004; Shelness & Sellers, 
2001). siRNAs targeting apo B and apo E and an MTP inhibitor are capable of reducing 
the release of infectious virions (Chang et al., 2007; Gastaminza et al., 2008; Huang et al., 
2007). Antibodies against apo B and apo E also inhibit serum derived HCV and anti-apo E 
antibodies inhibit HCVcc infectivity (Chang et al., 2007; Maillard et al., 2006). 
Intracellular virions have a reduced lipoprotein content suggesting that lipoproteins are 
complexed to particles post-envelopement (Gastaminza et al., 2006; Tao et al., 2009). In 
contrast to released virions, the infectivity of intracellular particles are sensitive to low pH 
treatments. Recent evidence suggests that the proton-selective ion-channel activity of p7 
prevents the acidification of intracellular virions during their transit through otherwise 
acidic intracellular compartments (Wozniak et al., 2010). 
 
1.5. HCV envelope glycoprotiens; synthesis, maturation 
and function 
The envelope glycoprotein E1 and E2 have shown to mediate HCV binding to the host cell 
and initiate fusion between the viral envelope and the cellular membrane at the initial stage 
of virus replication. Furthermore, the glycoproteins play an important role in virus particle 
assembly and also in modulating antibody-mediated neutralization response during HCV 
infection. E1E2 are class I trans-membrane proteins, located at the endoplasmic reticulum 
(ER). E1 (~30 kDa) and E2 (~70 kDa) (Dubuisson, 2000) form non-covalent heterodimers 
that are attached to the viral lipid surface and consist of a N-terminal ectodomain and a 
hydrophobic C-terminal domain. The ectodomains are highly modified through N-linked 
glycosylation at the ER (Goffard & Dubuisson, 2003). The development of the HCVpp and 
HCVcc systems has mostly confirmed previous findings however, differences in 
glycoprotein maturation have been observed between these two systems. At the surface of 
HCVpp, functional E1 and E2 have been shown to form noncovalent heterodimers, as with 
their intracellular forms (Op De Beeck et al., 2004). In contrast, it was recently shown that 
in the HCVcc system, virion-associated E1 and E2 form large covalent complexes 
stabilized by disulfide bridges, whereas the intracellular forms of these proteins assemble 
as noncovalent herterodimers (Vieyres et al., 2010). These differences observed in the 
biochemical composition of virion-associated E1E2 may account for the differences 
32 
 
observed in some of the HCV envelope protein functions when the HCVpp and HCVcc 
systems were compared (Russell et al., 2008). 
 
 
 
1.5.1. Synthesis of E1 and E2 Glycoproteins 
HCV polyprotein processing occurs at the ER membrane, where structural proteins are 
cleaved by the ER SP during and immediately after translation. However, a delayed 
cleavage at the E2/P7 and P7/NS2 site results in the production of an uncleaved E2/P7/NS2 
precursor. Although NS2 is progressively released from E2/P7/NS2 precursor, the cleavage 
between E2/P7 remains uncleaved over time resulting in the detection of E2, E2/P7, P7 and 
NS2 (Dubuisson et al., 1994; Dubuisson & Rice, 1996; Lin et al., 1994).  Both E1 and E2 
proteins harbour a single C-terminal TMD that anchors them into the ER membrane while 
the N-terminal ectodomain is oriented towards the ER lumen (Cocquerel et al., 2002). 
Upon E1E2 heterodimerization, these TMDs have shown to favour a single membrane-
spanning topology (Op De Beeck et al., 2000).  Sequence analysis has shown that E1 and 
E2 TMDs are composed of two hydrophobic stretches connected by a short hydrophilic 
segment that contains at least one fully conserved charged residue responsible for their ER 
retention (Cocquerel et al., 2000). The second hydrophobic stretch functions as an ER 
signal sequence for the downstream protein. Before signalase cleavage, the TMDs form a 
hairpin loop allowing E1 and E2 ectodomains to face the ER lumen.  However, after 
cleavage between E1 and E2 the second hydrophobic stretch reorients towards the cytosol, 
forming a complete TMD (Cocquerel et al., 2002). E1E2 TMD is a multifunctional 
sequence that mediates ER retention, serve as ER signal sequence and further play a major 
role in E1E2 heterodimer formation.  
 
 
1.5.2. Folding of E1 and E2 Glycoproteins 
E1 and E2 glycoproteins interact to form noncovalent heterodimers that constitute the 
functional subunit of HCV envelope. However, in heterologous expression systems 
majority of these proteins also form misfolded aggregates stabilized by disulfide bridging 
(Dubuisson et al., 1994).  E1 and E2 ectodomains contain numerous conserved cystein 
residues that form intramolecular disulfide bonds in the oxidizing environment in the ER. 
The overall conformation of E1E2 depends on the formation of these bonds. Kinetic 
studies on disulfide bond formation have revealed that E1 and E2 fold slowly and the 
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correct conformational folding of either protein is dependent on the expression of the other 
(Lavie et al., 2007; Op De Beeck et al., 2001). Presumably the slow folding may increase 
the tendancy of non-productive misfolded aggregate formation. The exact role of 
aggregates is unclear but may play a role in downregulating protein synthesis in order to 
avoid immune surveillance (Deleersnyder et al., 1997). Additionally, several host ER 
chaperones such as calnexin, calreticulin and BiP have been shown to interact with E1 and 
E2, suggesting that HCV exploits cellular factors during protein maturation (Dubuisson & 
Rice, 1996). Interaction of E1E2 with calnexin result in properly folded glycoprotiens, 
whereas calreticulin and BiP have shown to interact with non-productive aggregates 
(Choukhi et al., 1999). 
 
 
1.5.3. Glycosylation of E1 and E2 glycoprotiens 
Both E1 and E2 ectodomains are highly modified by N-linked glycosylation with E1 and 
E2 containing up to five and eleven potential glycosylation sites, respectively.  Sequence 
analyses indicate that most of these sites are fully conserved among genotypes (Goffard & 
Dubuisson, 2003). N-glycosylation occurs by the transfer of an oligosaccharide from a 
lipid intermediate to an Asn-X-Ser/Thr motifs onto the nascent polypeptide. N-
glycosylation starts in the ER, followed by glycan trimming, protein folding and glycan 
modification that continues in the golgi apparatus. Glycans are a signature of protein 
trafficiking. Glycans play an important role in protein folding, E1E2 interaction with 
cellular receptors and modulate sensitivity to neutralising antibodies (Goffard et al., 2005). 
 
 
1.5.4. Functional regions of E1 and E2 Glycoproteins 
The E1E2 heterodimer is essential for HCV entry where E2 is involved in binding to 
cellular receptors CD81 and SRBI. CD81 binding has been mapped to distinct regions on 
E2 while HVR1 is responsible for E2-SRBI binding. Viral attachment to receptors triggers 
a conformational change within the glycoprotein, which may expose the fusion peptide. 
Fusion peptides are divided into two different structural classes, designated as class I and 
class II.  It has been proposed that HCV E2 is a class II fusion protein with a β-sheet 
organisation and an internal fusion peptide (Penin et al., 2004b). Class II fusion proteins 
alter their conformation in response to a cellular trigger such as an acidic milieu, resulting 
in the exposure of the fusion peptide. Indeed, studies based on HCVpp and HCVcc have 
demonstrated that HCV entry occurs via clathrin mediated pathway, which fuses with early 
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endosomes. The low pH in early endosomes triggers the fusion of the viral envelope with 
the endosomal membrane, which leads to the liberation of the HCV genome (Blanchard et 
al., 2006; Meertens et al., 2006). However, acidic pH alone is not sufficient to induce 
fusion, suggesting the involvement of additional but yet unknown factors (Meertens et al., 
2006; Tscherne et al., 2006).  
 
Sequence analyses propose that E1 may contain a putative fusion peptide in its ectodomain 
(Flint & McKeating, 1999; Garry & Dash, 2003), while structural homology with other 
class II fusion proteins suggest that E2 could be the fusion peptide (Yagnik et al., 2000). 
Recently, Krey et al, (2010) proposed a tertiary structure model of sE2 based on the 
disulfide connectivity pattern, CD81 binding data, secondary structure prediction and class 
II fusion protein model (Figure 1.8). This model divides E2 into three domains where 
domain I constitutes the central position and harbours most of the two regions involved in 
CD81 interaction. Domain II is proposed to contain the putative fusion peptide and is 
connected to domain III via the intergenotypic variable region (IgVR) located at its C-
terminal. Upon fusion this flexible linker region may allow the translocation of domain III, 
which also contains some of the residues important for CD81 binding, to the side of fusion 
complex (Krey et al., 2010). 
 
 
1.6. HCV Envelope Glycoproteins and Virus 
Neutralization   
Broadly neutralizing antibodies (nAbs) targeting conserved epitope present attractive 
therapeutic candidates to block infection at an early stage. Using HCV specific antibodies 
combined with antiviral drugs targeting different steps of the viral lifecycle will be 
particularly useful in controlling re-infection of the graft following liver transplantation or 
accidental exposure to HCV (Angus & Patel, 2011). However a deeper understanding of 
the evasion mechanisms and factors leading to viral escape from nAbs resulting in chronic 
infection needs to be addressed for potential therapeutic development (Dilorenzo et al, 
2011). 
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1.6.1. Antibodies to Linear Epitopes 
Being part of the virion particle, the HCV glycoproteins are the natural target for the host 
neutralizing antibody response. HCV infection is specifically neutralized with sera derived 
from HCV infected patients (Bartosch et al., 2003). These antibodies recognise 
conformational epitopes on E2 and generally act by blocking the interaction of E2 with the 
CD81 receptor. However, the glycoproteins account for the large sequence variability 
among HCV genotypes and subtypes. This together with the error prone nature of the RNA 
polymerase and high replication rate of the genome (Neumann et al., 1998) results in the 
production of escape mutants that dominate the quasispecies population during chronic 
infection (Bukh et al., 1995). The E2 glycoprotein contains three HVRs that harbour 
positively selected sites and account for greater variability at the quasispecies level than 
E1. HVR1 is located at the N-terminus of E2 and (amino acids 384-410) is the best 
characterised HCV HVR due to its role in virus entry and its capacity to elicit nAb 
responses. HVR1 mediates sE2 binding to SR-BI (Scarselli et al., 2002) and attenuates sE2 
and HCVcc binding to CD81-LEL (Bankwitz et al., 2010). Virions lacking HVR1 have 
been shown to revert back to WT characteristics through the emergence of compensatory 
mutations elsewhere in E2. Similarly, deletion of HVR1 in the HCVpp system results in a 
40-fold decrease in infectivity (Bartosch et al., 2003c), indicating the defect occurs at the 
entry level. These results were recently confirmed in the HCVcc system (Bankwitz et al., 
2010) where deletion of HVR1 also impaired infectivity but not viral replication. Less is 
known about HVR2 (amino acids 474-482) and HVR3 also known as IgVR (amino acids 
570-580) (Hijikata et al., 1991; McCaffrey et al., 2007; Weiner et al., 1991). According to 
the recent sE2 model by Krey et al, (2010) the HVRs form unstructured domains on E2 
where HVR1 protrude from N-terminal extension, HVR2 from domain II and HVR3 forms 
the linker sequence between domain I and domain III (Krey et al., 2010). HVR1 is highly 
immunogenic and is the main target for the humoral immune response during the natural 
course of infection both in humans (Kato et al., 1993; Scarselli et al., 1995) and in 
chimpanzees (Meunier et al., 2005). However, HVR1 specific antibodies display limited 
cross reactivity and during chronic infection error prone RNA replication produces HVR1 
variability, which results in the accumulation of immune escape variants and thus 
represents a poor vaccine candidate (Farci et al., 1996b; Ray et al., 1999).  Strikingly, 
despite being highly tolerant to amino acid substitution the overall conformation of HVR1 
is well conserved and contains basic residues which, in theory may be required for 
interaction with negatively charged molecules at the cell surface (Penin et al., 2001).  
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The E2 protein contains several discontinuous regions conserved across different 
genotypes that are involved in binding to the CD81 receptor (Owsianka et al., 2006) and 
thus are essential for viral fitness. The neutralizing antibody responses specific to these 
important conserved regions will minimise the likelihood of escape mutants. Mouse 
monoclonal antibody (mAb) AP33 is one such antibody that recognizes a highly conserved 
linear epitope spanning residue 412-423 located immediately downstream of HVR1 
(Owsianka et al., 2006). MAb AP33 has been shown to potently neutralize HCVpp 
incorporating E1E2 from all major genotypes and subtypes (Owsianka et al., 2005) and 
also inhibits HCVcc infectivity (Tarr et al., 2006).  Several other broadly nAbs have also 
been described that recognise this region, including 3/11 (Hsu et al., 2003), HCV-1 and 95-
2 (Broering et al., 2009). In vivo, the prevalence of antibodies reactive to this conserved E2 
region is <2.5 % (Tarr et al., 2007) suggesting a poor ability of this epitope to elicit 
antibody responses. Amino acid substitutions within this epitope have been shown to either 
decrease viral fitness (Owsianka et al., 2006; Tarr et al., 2006) or increase particle 
vulnerability to nAbs (Dhillon et al., 2010; Tao et al., 2009) highlighting the importance of 
epitope conservation in virus entry.  Consequently, a successfull vaccine candidate would 
shift immunodominace towards more conserved neutralising epitopes, rather than non-
specific or highly variable regions.  
 
 
1.6.2. Antibodies to Conformational Epitopes  
To date, there have been numerous reports describing the generation of patient-derived 
mAb targeting either linear or conformational epitopes on E2 (Allander et al., 2000; 
Hadlock et al., 2000; Johansson et al., 2007; Keck et al., 2008; Keck et al., 2004; Keck et 
al., 2007; Mancini et al., 2009; Perotti et al., 2008). Among these, a subset of antibodies 
displayed cross neutralizing activity against different genotypes. Competition assay of 
human mAbs derived from peripheral B-cells of HCV infected patients, the epitopes of 
which are shown in figure 1.7, revealed the presence of three immunogenic domains on E2 
called A, B and C (Allander et al., 2000; Hadlock et al., 2000; Keck et al., 2004; Keck et 
al., 2007). MAbs recognising domain B and C exhibit cross-neutralizing response while 
domain A antibodies demonstrate non-neutralizing characteristics. In particular, the CBH-5 
human mAb harbours cross neutralising activity against all HCV genotypes and alanine 
substitution revealed that it recognises conserved amino acids important for E2-CD81 
binding encompassing residue 523-535 (Owsianka et al., 2008).  
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1.6.3. Antibodies targeting E1 Glycoprotein 
An E1-specific antibody response is reported less frequently, possibly because E1 appears 
to be less immunogenic than E2.  However, E1 does contain neutralizing epitopes and 
studies have shown that E1-specific sera are capable of neutralizing both HCVpp as well as 
HCVcc infectivity (Dreux et al., 2006; Pietschmann et al., 2006). Furthermore, a highly 
conserved E1 epitope has been identified between amino acids 313–327 and mAbs 
targetting to this epitope strongly neutralise genotypes 1a, 1b 4a, 5a and 6a HCVpp as well 
as WT/JFH1 and the chimeric 1a/JFH1 HCVcc (Meunier et al., 2008b). Less is known 
about the role of the E1 glycoprotein and development of E1-specific antibodies will assist 
in delineating the role of this protein in HCV entry. 
 
 
1.7. Mechanism of Immune Escape 
Together with cellular immune response, nAbs play an important role in controlling HCV 
infection. Anti-HCV nAbs targeting the glycoproteins can be detected during the very 
early phase of infection (Lavillette et al., 2005b; Pestka et al., 2007). Despite a strong 
immune response HCV establishes persistent infection in majority of the infected patients. 
Antibodies may mediate neutralisation by either causing aggregation of virus particles, by 
inhibiting virus-host interaction or preventing viral envelope fusion with cellular 
membrane. In any case, neutralization requires the availability of critical epitopes on the 
virion surface and an efficient binding of antibody to these epitopes. HCV utilizes several 
effective nAb escape strategies, which are addressed in the following section. 
 
 
1.7.1. Genetic Diversity within HVR1  
As a response to host immune pressure HCV evolves rapidly with new mutations arising 
regularly resulting in genetic diversity within the infected individual. HCV glycoproteins 
display the highest degree of genetic heterogeneity between genotypes and subtypes 
(Simmonds, 2004) and the constant production of viral variants may result in the 
emergence of more pathogenic strains and the subsequent development of chronic 
infection (Farci & Purcell, 2000). HVR1 is implicated in facilitating E2/SR-BI mediated 
entry where HDL has been shown to influence HCVpp entry (section 1.7.1.2) and 
resistance to nAbs (Bartosch et al., 2005; Scarselli et al., 2002). Intriguingly, positive 
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selection within HVR1 occurs at residues involved in HCV entry without altering the 
overall conformation of the segment, resulting in nAb escape but at the cost of efficient 
cell entry (Brown et al., 2007). In addition to HVR1, other studies have reported mutations 
elsewhere in E2 that function to escape from the humoral immune response (Duan et al., 
2010; Keck et al., 2009). 
  
 
1.7.2. The Glycan Shield 
The HCV envelope proteins are highly glycosylated with up to 5 potential N-linked 
glycosylation in E1 (E1N1-E1N5) and up to 11 potential sites in E2 (E2N1-E2N11).  The 
glycosylation of envelope proteins is essential to ensure correct protein processing, folding 
and fascilitating cellular entry (Goffard et al., 2005).  Particular N-glycans located in close 
proximity to the E2-CD81 binding residues are believed to mask important epitopes from 
nAbs as removal of these glycans enhances the sensitivity of HCVpp and HCVcc to 
neutralization by nAbs and molecules that block CD81 binding (Falkowska et al., 2007; 
Fukushi et al., 2001; Helle et al., 2007; Helle et al., 2010).  
 
 
1.7.3. Interfering Antibodies  
The continuous evolution of HCV may result in the emergence of previously hidden 
glycoprotein epitopes (Zhang et al., 2004). This may elicit antibody responses targeting 
epitopes that are not necessarily involved in virus entry. Indeed, the presence of non-
neutralising anti-E2 antibodies in patient sera has been identified that can compete with 
nAbs targeting the 412-423 conserved epitope (Zhang et al., 2007; Zhang et al., 2009). 
According to these studies a small segment of E2 could be divided into two epitopes where 
non-nAbs binding to epitope II (432-447) may mask the nAbs binding site in epitope I 
(412-419). Accordingly, depletion of interfering antibodies resulted in enhanced 
neutralization. The presence of interfering antibodies may possibly lead to establishment of 
persistent infection despite a strong host immune response during infection.  
 
 
1.7.4. Cell-to-cell transmission 
Recently it has been shown that HCVcc is able to spread from infected cell to the 
neighbouring uninfected cells via direct cell-cell contact without being secreted in the 
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extracellular environment (Timpe et al., 2008; Witteveldt et al., 2009). Numerous viruses 
are reported to utilise the cell-to-cell transmission mode, which enables the viruses to 
circumvent host humoral immune factors such as nAbs and thus enables the rapid spread of 
infection (Mothes et al., 2010). Consequently, it has been shown that HCV is able to 
spread in the presence of polyclonal and monoclonal anti-HCV glycoprotein antibodies 
(Timpe et al., 2008; Witteveldt et al., 2009). It is yet not clear whether the cell-to-cell 
transmission utilises the same entry mechanism as the entry by extracellular virus. 
However, recent studies report that SR-BI and tight junction proteins claudin-1 (CLDN) 
and occludin (OCLN) seem to be required for entry (Brimacombe et al., 2011; Ciesek et 
al., 2011). As for CD81 there is confliciting data as to whether cell-to-cell entry is CD81 
independent or not (Brimacombe et al., 2011; Jones et al., 2010; Timpe et al., 2008; 
Witteveldt et al., 2009). However, the CD81-independent mechanism observed by the first 
3 studies may have been due to an unreliable flow cytometry method for measuring cell-to-
cell transfer that produces false positive results. This was shown by the most recent study 
(Brimacombe et al, 2011), where they modified the flow cytometry method to eliminate 
these false positives. Using the new system they found that CD81 was essential for cell-to-
cell transfer.   Collectively, the available data support a role for cell-to-cell transmission 
which may partially explain how viruses are able to evade the host nAb response during 
chronic infection.   
 
 
1.7.5. Lipoproteins 
HCV serum particles have shown to exhibit highly heterogenous density profiles (ranging 
from <1.06 to >1.20 g/mL) because of the viral particle association with distinct cellular 
components (Nielsen et al., 2006; Thomssen et al., 1993). The high density HCV particles 
which exhibit poor infectivity are shown to be linked with immunoglobulins, whereas 
highly infectious particles are shown to be associated with lipoprotein such as LDL and 
VLDL (Hijikata et al., 1993b). Apart from facilitating the virion entry into host cell via 
LDL receptor, the HCV-lipoprotein association may also protect the virus from the 
humoral immune response possibly by shielding the virus surface glycoproteins from 
circulating nAbs. In support of this, it has been shown that intracellular immature HCVcc 
virions are more sensitive to neutralization with anti-E2 antibodies and less sensitive to 
anti-lipoprotein antibodies compared to the secreted virion (Tao et al., 2009). Furthermore, 
the neutralization sensitivity of extracellular virions with anti-glycoprotein nAbs has been 
shown to increase with HCV particle density, suggesting that the lipoprotein content 
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affects the neutralization efficiency (Grove et al., 2008). Confirming this hypothesis, it has 
been shown that a single mutation in E2 (I414T) (Tao et al., 2009) reduced the HCVcc 
lipoprotein content and thereby enhanced its neutralization efficiency by anti-E2 
antibodies. Thus, lipoproteins may help the virus evade recognition by the host immune 
response by masking the essential epitopes targeted by anti-glycoprotein nAbs. 
 
The high-density lipoproteins (HDL) found in human serum have demonstrated the ability 
to attenuate the antibody-mediated neutralization of HCV by stimulating viral entry at a 
post-binding step (Bartosch et al., 2005; Lavillette et al., 2005a; Voisset et al., 2005). The 
enhancement of HCV entry decreases the time window through which nAbs can bind and 
neutralize the virus (Dreux et al., 2006). This process is facilitated by HVR1 and also 
depends on the expression of SR-BI and its selective lipid-uptake function (Bartosch et al., 
2005; Voisset et al., 2005). ApoC-I was demonstrated to be the HDL component 
responsible for enhancing HCV infection (Meunier et al., 2005). It is believed to be 
recruited from HDL to influence the infectivity of HCV particles at a postbinding stage by 
promoting their membrane fusion properties (Dreux et al., 2007). 
 
Molecules targeting the lipoproteins associated with virus particles or those stimulating 
virus entry could affect HCV infectivity and, as thus, could have implications for future 
therapeutic approaches based on the inhibition of HCV infection. Indeed, HCV-lipid 
interactions may be attractive targets for the development of antiviral drugs, because the 
targeting of essential host cell factors could limit the development of escape mutations 
effective against drugs directly targeting virus components.  
 
 
1.8. Aims 
The aim of this project was divided into two lines of investigation, both of which focused 
on the HCV envelope glycoproteins, namely E1 and E2. The first aim was to investigate 
the importance of a highly conserved region in E2, spanning amino acids 412-423, to the 
viral entry process and antibody-mediated neutralization. This was achieved by analysing 
the viral phenotypes created by four cell culture adapted mutations located within this E2 
region. The second objective was to generate and study the entry properties of infectious 
HCVcc particles harbouring the glycoproteins from a diverse range of genotypes.  
Figure 1.1. Global Variation in Prevalence of Chronic HCV Infection. Extracted 
from Yang and Lewis, (2010). 
Figure 1.2. HCV Subtype Distribution Worldwide. The geographic and subtype 
distribution is shown for the 80849 sequences available online at http://hcv.lanl.gov 
(accessed October 28, 2011).  
Drug Name Phase  of Clinical Trial Mode of Action
I II II
BMS-850032
ACH-1625
GS-9256
ABT-450
IDX320
GS-9451
ACH-2684
MK-6172
TMC435 
BI 201335
Vaniprevir (MK-7009)
Narlaprevir (SCH-900518)
Danoprevir (ITMN-191, RG7227)
Telaprevir
Boceprevir
NS3/4A
protease
inhibitors
INX-184
R7128
IDX184
PSI-7977
PSI-938
NS5B
polymerase
nucleoside
inhibitors
IDX375
ABT-333
GS-9190
Filibuvir (PF868554)
ANA-598
NS5B
polymerase
nonnucleoside
inhibitors
PPI-461
GS-5885
BMS-824393
NS5A
inhibitors
SCY-635
Debio 025
Cyclophilin
inhibitors
I
APPROVED
 
Table 1.1. STAT-C molecules in clinical trials. Adapted from Jazwinski & Muir, 
(2011). 
Type Vaccine
Phase  of 
Clinical Trial Outcome
I II II
Recombinant 
Protein
E1/E2/MF59C 
adjuvant
Induce antibody and E1/E2 
speciﬁc T-cell response
E1 absorbed on 
alum 
Induce both Humoral and 
Cellular immune response
Yeast expressing 
NS3-core protein 
(GI-5005)
Elicit antigen speciﬁc T cell 
response
Core in 
ISCOMATRIX 
adjuvant
Induced humoral response in 
all volunteers 
Peptide 
based 
Vaccine
Core, NS3 and NS4 
peptides with 
poly-L-arginine 
adjuvant (IC41)
Strong T-cell response but 
transient eﬀect on viral load. 
Peptide derived 
from Core protein 
(C35-44)
Induced peptide speciﬁc CD8 
T cell response in some 
patients
HCV  NS3 
formulated with 
inﬂuenza 
virosomes
Result pending
DNA based 
Vaccine
ChonVac-C; NS3-
4a DNA Vaccine 
Transient eﬀect on viral load
CICGB-230: 
core/E1/E2+reco
mbinant core 
protein
Weak cellular and humoral 
response
Recombinant 
Viral 
Vectored 
Vaccine
MVA expressing 
NS3/4/5B 
(TG4040)
Decrease in viral load in some 
patients
Adenovirus 
expressing NS3-5B 
(Ad6, AdCh3)
Highly Immunogenic
I
Table 1.2. HCV vaccine candidates in clinical trials. Adapted from Halliday et al, 
(2011). 
Figure 1.3. The Positive Strand RNA Genome of HCV. It contains 5’ and 3’ non-
coding regions (NCRs) and a single large open reading frame (ORF) that is translated 
into a polyprotein containing the structural and nonstructural (NS) proteins. The 
polyprotein is co-and post-translationally cleaved by both host and viral proteases to 
produced the 10 individual HCV proteins. Extracted from Tellinghuisen et al. (2007). 
Figure 1.4. HCV Lifecycle. Extracellular virus particles enter hepatocytes by 
interacting with cell surface receptors (a), followed by receptor-dependent 
endocytosis. Upon arrival in early endosomes the HCV glycoproteins mediate fusion 
of the viral envelope with the endosome and the viral genome is released into the 
cytoplasm (c). The viral RNA is then translated to generate the large polyprotein that 
is processed into the 10 mature HCV proteins (d). Replication complexes are formed 
through the association of the NS proteins with ER-derived membranes and they 
replicate the genome (e). A portion of the newly synthesized positive-sense RNA is 
packaged into nucleocapsids that then associate with the HCV glycoproteins, leading 
to budding into the ER (f). Maturation of the virions then occurs during their transit 
through the cellular secretory pathway (g). Mature virions are then secreted from the 
cell, completing the life cycle (h). Extracted from Tellinghuisen et al. (2007). 
Figure 1.5. Cell Entry of Lipoprotein Associated HCV. Several cell surface 
molecules are involved in mediating HCV binding and internalization into host cells. 
LDL-R and GAGs may support the initial attachment by interacting with the viral 
glycoprotein and virion-associated lipoproteins, respectively. Virus particles then 
interact with the entry receptors SR-BI and CD81, followed by the tight junction 
proteins claudin-1 (CLDN-1) and occludin (OCLDN). HCV enters the cell by 
clathrin-dependent endocytosis and fusion is mediated by the envelope glycoproteins 
upon acidification of early endosomes. Lipoprotein-mediated HCV cell entry is 
inhibited by natural ligands of lipoprotein receptors such as LDL, VLDL and oxidized 
LDL, whereas HDL indirectly enhances HCV entry in a SR-BI dependent manner. 
Adapted from Burlone et al, (2009).  
Figure 1.6. In vitro systems available for the study of HCV replication, entry and 
infectivity. (A) HCV  replicon system  allows for the study of viral RNA replication 
in cell culture. Bicistronic replicon RNAs, encoding a selectable marker (Neor) under 
control of the HCV IRES in the first cistron and the HCV non-structural (NS3-NS5B) 
proteins under control of a heterologous IRES from encephalomyocarditis selectable 
marker in the second cistron, are electroporated into Huh-7 based cells lines. RNA 
replication results in the production of the selectable marker and allows for selection 
of cell colonies that support active viral RNA replication. (B) HCVpp allows for the 
study of HCV glycoproteins mediated events in the HCV life cycle. Recombinant 
retrovirus expressing HCV envelope glycoproteins on their surface are generated by 
co-transfecting HEK-293T cells with plasmids encoding HCV glycoproteins, 
retroviral core and polymerase proteins and a proviral genome harbouring a reporter 
gene. Following infection of permissive cell lines, the retrovirus genomes express a 
reporter gene allowing for a quantitative measure of cell entry. (C) The HCVcc 
system provide a method to study the entire HCV lifecycle. This system uses either 
JFH1 HCV genomic RNA or chimeras of this genome with heterologous sequence. 
Electroporation of these RNAs into permissive cell lines yield infectious HCV virions 
that can be used to infect naïve cells or animal models. Productive infection can be 
monitored by several methods allowing the detection of intracellular viral RNA or 
protein levels. Extracted from Tellinghuisen et al., (2007). 
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Figure 1.7. Organization of Functional Domains and Conserved epitopes 
recognized by broadly nAbs in E1 and E2. Underlined letters in (a) indicate 
residues critical for E2-CD81 binding. Letters A to F correspond to the antibody 
binding epitope shown in (b). HVR1: Hypervariable region; TMD: Trans-membrane 
domain. 
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Figure 1.8. Model of HCV E2 Glycoprotein 
 
Based on class II fusion proteins, E2 consists of three separate domains and a stem 
region connected to the transmembrane domain. The linear sequence of HCV H77-E2 
ectodomain is represented as a chain of beads (coloured circles) labelled with the 
corresponding amino acid. The pale and bright coloured circles represent residues in 
the background and foreground of the domains, respectively labelled in white and 
black fonts. Disulfide bonds and glycosylation sites are indicated by thick black bars 
and green circles, respectively and numbered sequentially. Unstructured segments are 
in while font on a brown background. Residues that participate in CD81 binding are 
contoured in blue, and those from the putative fusion loop region in red. The four 
glycosylation sites (E2N1, E2N2, E2N4 and E2N6) that modulate CD81 binding are 
indicated by green circles. Adapted from Krey et al, 2010.  
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2.1. Materials 
2.1.1. Chemicals 
Chemical / Reagent Supplier 
2-Amino-2-(hydroxymethyl)-1,3-propanediol (TRIS) BDH 
2-Mercaptoethanol Sigma 
3,3’5,5’-tetramethylbenzidine (TMB) substrate Sigma 
30 % Acrylamide / bis solution 37.5:1 Bio-Rad laboratories 
4’,6-diamidino-2-phenylindole (DAPI) Promega 
5-chloromethylfluorescein diacetate (CMFDA) Invitrogen 
Absolute ethanol Bamford Laboratories, UK
Agarose Melford 
Ammonium persulphate (APS) Bio-Rad Laboratories 
Ampicillin Melford 
Bromophenol Blue  BDH 
Butanol Fisher Scientific 
Chloroform Sigma 
Ethanol Fisher Scientific 
Ethidium Bromide Sigma 
Glucose BDH 
Glycine BDH 
Iodixanol Axis-Shield 
Isopropanol Fisher Scientific 
Methanol Fisher Scientific 
N,N,N’,N’-Tetramethylethylene-diamine (TEMED) Sigma 
Phenol Sigma 
Puromycin Sigma 
Sodium Chloride (NaCl) BDH 
Sodium dodecyl sulphate (SDS) BDH 
Sucrose BDH 
Triton X-100 Sigma 
TRIzol Invitrogen 
Tween-20 Bio-Rad Laboratories 
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2.1.2. Kits 
Kit Source 
Advantage® cDNA polymerase Kit Clonetech 
Luciferase Assay System Promega 
MEGAclear Purification Kit Ambion 
MEGAscript High Yield Transcription Kit Ambion 
QIAamp Viral RNA Kit Qiagen 
Qiagen Plasmid Maxi Kit Qiagen 
QIAprep Spin Miniprep Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QuickChange Site-Directed Mutagenesis Kit Stratagene 
RNeasy Plus Mini Kit Qiagen 
TaqMan Reverse Transcription Kit Applied Biosystems 
SEAP Chemiluminescence Assay kit, Phospha lightTM Applied Biosystems 
 
 
2.1.3. Clones 
Name Details Source 
pcDNA3.1-
E1E2 
Encoding E1E2 gps of diverse HCV 
genotypes representing amino acids residues 
176 to746 (referenced to strain H77) cloned 
downstream from a human CMV promoter.  
Lavillette et 
al. (2005) 
MLV-Gag/Pol Encoding MLV gag and pol genes cloned 
downstream of a human CMV promoter. 
Bartosch et 
al., 2003 
MLV-
Luciferase 
MLV based luciferase transfer construct 
under control of a human CMV promoter. 
Bartosch et 
al., 2003 
pJFH1 Full length JFH1 cDNA downstream of the 
T7 RNA polymerase promoter. 
Wakita et al. 
(2005) 
pJFH1∆E1E2 As JFH1, except carries a deletion in the 
envelope glycoprotein sequences. 
Wakita et al. 
(2005) 
pJFH1GND As JFH1, except carries a mutation in the 
NS5B GDD motif. 
Wakita et al. 
(2005) 
pJFH1N415D As JFH1, except carries a mutation in E2 
(N415D). 
Dhillon et al. 
(2010) 
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pJFH1T416A As JFH1, except carries a mutation in E2 
(T416A). 
Dhillon et al. 
(2010) 
pJFH1N417S As JFH1, except carries a mutation in E2 
(N417S). 
Dhillon et al. 
(2010) 
pJFH1I422L As JFH1, except carries a mutation in E2 
(I422L). 
Dhillon et al. 
(2010) 
pJFH11B12.6 As JFH1, except envelope glycoprotein 
region is replaced by genotype 1 (1B12.6) 
sequence. 
S. Dhillon, 
Unpublished 
pJFH12A2.5 As JFH1, except envelope glycoprotein 
region is replaced by genotype 2 (2A2.5) 
sequence. 
S. Dhillon, 
Unpublished 
pJFH13A1.28 As JFH1, except envelope glycoprotein 
region is replaced by genotype 3 (3A1.28) 
sequence. 
S. Dhillon, 
Unpublished 
pJFH15.15.7 As JFH1, except envelope glycoprotein 
region is replaced by genotype 5 (5.15.7) 
sequence. 
S. Dhillon, 
Unpublished 
pJFH16.5.340 As JFH1, except envelope glycoprotein 
region is replaced by genotype 6(6.5.340) 
sequence. 
S. Dhillon, 
Unpublished 
p4a/JFH1 As JFH1, except core to NS2 region is 
replaced by genotype 4a ED43 sequence. 
M. Iro 
Unpublished 
pAd4a/JFH1 As 4a/JFH1, except contains six cell-culture 
adaptive mutations in E2, NS2, NS3 and 
NS5A. 
 S. Dhillon 
Unpublished 
phCMV E1E2 Encoding JFH1 sequence representing 
amino acids 132-746 cloned downstream of 
a human CMV promoter. 
Witteveldt et 
al., 2009 
phCMV 
E1E2N415D 
As phCMV E1E2, except carries a mutation 
in E2 (N415D), downstream of a human 
CMV promoter. 
Dhillon et al. 
(2010) 
phCMV 
E1E2T416A 
As phCMV E1E2, except carries a mutation 
in E2 (T416A), downstream of a human 
CMV promoter. 
Dhillon et al. 
(2010) 
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phCMV 
E1E2N417S 
As phCMV E1E2, except carries a mutation 
in E2 (N417S), downstream of a human 
CMV promoter. 
Dhillon et al. 
(2010) 
phCMV 
E1E2I422L 
As phCMV E1E2, except carries a mutation 
in E2 (I422L), downstream of a human 
CMV promoter. 
Dhillon et al. 
(2010) 
 
 
2.1.4. Cell lines 
Cells Description Source 
Huh7  Human Hepatoma cell line Jean Dubuisson (CNRS, 
Institut de Biologie de Lille, 
Lille, France) 
Huh-7 J20  Human Hepatoma reporter 
cell line 
Arvind Patel (Centre for 
Virus Research, Glasgow, 
UK) 
HEK-293T Human Embryonic Kidney 
cell line 
American Type Culture 
Collection 
 
 
2.1.5. Antibodies 
2.1.5.1. Primary Antibodies 
Antibody Name Type  Raised in Source 
Anti-core C7-50 Monoclonal Mouse Bioreagents 
Anti-NS5A  9E10 Monoclonal Mouse  Lindenbach 
et al. (2005) 
Anti-NS5A  Anti-NS5A Polyclonal Sheep Macdonald et 
al. (2003) 
Anti-E2 AP33 Monoclonal Mouse Clayton et al. 
(2002) 
Anit-E2 D3.7 Monoclonal Mouse Dhillon et al. 
(2010) 
Anti-E2 3/11 Monoclonal Rat Flint et al. 
(1999) 
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Anti-E2 CBH-4B Monoclonal Human Keck et al. 
(2003) 
Anti-E2 CBH-5 Monoclonal Human Keck et al. 
(2003) 
Anti-E2 HC-11 Monoclonal Human Keck et al. 
(2008) 
Anti-HCV IgG7 Purified 
polyclonal IgG 
Human Haberstroh et 
al. (2008) 
Anti-HCV IgG17 Purified 
polyclonal IgG 
Human Haberstroh et 
al. (2008) 
Anti-HCV IgG19 Purified 
polyclonal IgG 
Human Haberstroh et 
al. (2008) 
Anti-Tubulin Anti-Tubulin Monoclonal Mouse Sigma 
Anti-CD81 Anti-CD81 Monoclonal Mouse BD 
Biosciences 
Anti-SR-BI CLA-1 Monoclonal Human BD 
Biosciences 
Anti-SR-BI Anti-SR-BI Polyclonal sera Rat Zeisel et al. 
(2007) 
Anti-MLV gag CRL-1912 Monoclonal Rat American 
Type Culture 
Collection 
 
 
2.1.5.2. Secondary Antibodies 
Antibody Source 
FITC-conjugated donkey anti-mouse IgG Invitrogen 
FITC-conjugated goat anti-human IgG Invitrogen 
FITC-conjugated goat anti-rabbit IgG Invitrogen 
TRITC-conjugated goat anti-mouse IgG Invitrogen 
TRITC-conjugated donkey anti-sheep IgG Invitrogen 
Cy5-conjugated donkey anti-rabbit IgG Invitrogen 
PE-conjugated anti-mouse IgG BD Biosciences 
PE-conjugated anti-mouse IgG 2a specific BD Biosciences 
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Anti-streptavidin-HRP conjugate Sigma 
Anti-mouse-HRP conjugate Sigma 
Anti-rabbit-HRP conjugate Sigma 
Anti-human-HRP conjugate Sigma 
 
 
2.1.6. Solutions 
2.1.6.1. Bacterial Expression 
Solution Components 
Lysogeny Broth (LB)*  170 mM NaCl, 10 g/l Bactopeptone, 5 g/l 
yeast extract 
LB-agar*  LB plus 1.5 % (w/v) agar 
Yeast tryptose broth (YTB)*  85 mM NaCl, 16 g/l Bactopeptone, 10 g/l 
yeast extract 
* Prepared in-house by the media department 
 
 
2.1.6.2. DNA Manipulation  
Solution Components 
DNA loading dye 30 % glycerol, 0.25 % bromophenol blue, 
0.25 % xylene blue 
TBE (10x) 8.9 M Tris-borate, 8.9 M boric acid, 0.02 
M EDTA (pH 8.0) 
 
 
2.1.6.3. SDS-PAGE 
Solution Components 
Running Gel Buffer  40 mM Tris, 185 mM Glycine, 0.1 % SDS 
Resolving Gel Buffer 0.5 M Tris-HCl pH 8.9, 0.4 % SDS 
Stacking Gel Buffer 0.5 M Tris-HCl pH 6.9, 0.4 % SDS 
Sample loading buffer 2X (Reducing) 100 mM Tris-HCl pH 6.9, 2 % SDS, 10 % 
glycerol, 5 % β-mercaptoethanol, 1 µg/ml 
bromophenol blue 
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2.1.6.4. Western Blot Analysis 
Solution Components 
Towbin Buffer 25 mM Tris-HCL (pH 8.0), 192 mM 
glycine, 20 % (v/v) methanol 
PBSA* 170 mM NaCl, 3.4 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, 
25 mM Tris-HCl (pH 7.2) 
PBST PBSA, plus 0.05 % (v/v) Tween-20 
*Prepared in-house by the media department 
 
 
2.1.6.5. Cell Lysis  
Solution Components 
Cell Lysis Buffer (LB2) 20 mM Tris-HCl pH 7.4, 20 mM 
iodoacetamide, 150 mM NaCl, 1 mM 
EDTA, 0.5 % Triton X-100 
 
 
2.1.6.6. Tissue Culture 
Solution Components 
Trypsin solution 0.25 % (w/v) Difco trypsin dissolved in PBSA, 
0.002 % (w/v) phenol red 
Versene 0.6 mM EDTA in PBSA, 0.002 % (w/v) phenol red 
 
 
2.1.7. Oligonucleotide Synthesis 
Oligonucleotides were purchased from Sigma. 
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2.2. Methods 
2.2.1. Basic Technique 
2.2.1.1. Tissue culture 
All components of cell culture media were supplied by Invitrogen. Huh7 and HEK-293T 
cells were grown in DMEMcomplete (Dulbecco’s modified Eagle’s medium [DMEM] 
supplemented with 10 % fetal calf serum [FCS] (heat inactivated at 56oC for 30 min), 100 
U/ml penicillin, 100 μg/ml streptomycin, 0.1 mM non-essential amino acids and 2 mM 
glutamine) and maintained at 37 oC in an atmosphere of 5 % CO2. Huh-7 J20 cells were 
cultured in DMEMcomplete in the presence of puromycin at a concentration of 2µg/ml. This 
Huh-7 reporter cell-line stably expresses a fusion protein composed of the enhanced green 
fluorescence protein and secreted alkaline phosphatase linked by an octapeptide spacer and 
the HCV NS4A/4B cleavage site that acts as a substrate for the viral serine protease 
NS3/4A. The role of EGFP is to retain the entire fusion protein within the cell. During 
HCV replication the NS3/4A protease releases SEAP from the fusion protein, thus 
enabling its N-terminal signal peptide to direct its secretion into the extracellular culture 
medium. During infection the SEAP levels directly reflect the levels of intracellular HCV 
RNA replication (Iro et al., 2009). Cell lines were typically grown in 80 cm2 or 175 cm2 
tissue culture flasks (Nunc). At reaching about 90 % confluency cells were washed gently 
with PBSA followed by their removal with trypsin (Sigma) diluted 1:100 in versene (TV). 
Cells were then resuspended in 10 ml of DMEMcomplete before re-seeding or use in 
experiments. 
 
2.2.1.2. Indirect Immunofluorescence  
Immunofluorescence (IF) was used to visualise the intracellular expression of HCV 
proteins following electroporation or infection. Cells seeded onto coverslips in a 24-well 
plate were first washed with PBSA and then fixed in 100 % methanol at -20oC for a 
minimum of 2 h. Subsequently cells were washed 3 times with PBSA, blocked for 10 min 
in blocking buffer (PBSA containing 2 % FCS) and incubated at room temperature (RT) 
for 1 h with primary antibody diluted at appropriate concentration in the blocking buffer. 
Cells were then washed 3 times with PBSA and stained with secondary antibody 
conjugated with FITC, TRITC, or Cy5 for 1 h at room temperature. Finally cells were 
washed 3 times with PBSA and then dH2O and the coverslips were mounted on a glass 
slide. Mounting media used contained DAPI (Biochemika) for nuclei staining. The cells 
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were examined with a Zeiss Laser Scanning LSM510 META inverted confocal microscope 
(Carl Zeiss Ltd., UK). The images were analyzed using LSM510 software. 
 
2.2.1.3. ELISA 
Cells were lysed directly in LB2 and the lysates were clarified by briefly spinning at 
13,000 r.p.m. for 1 min. ELISA was performed to determine the reactivity of the 
intracellular HCV E2 glycoproteins to different anti-E2 antibodies or to the soluble CD81-
LEL (hCD81-LEL). Immulon 2HB flat bottom plates were either coated with Galanthus 
nivalis (GNA) lectin (5 µg/ml) or hCD81-LEL (5 µg/ml). 100 µl of capture agent diluted 
in PBSA was added to each well and incubated overnight at 4 oC under gentle shaking. 
Plates were washed 3 times in PBST and blocked for 2 h at RT in 200 µl PBST with 2 % 
dried milk. Plates were washed as above. 100 µl of neat and 3-fold serially diluted cell 
lysate in PBST was captured onto the GNA and hCD81-LEL coated plates and incubated 
overnight at 4 oC. Cell lysate from naive uninfected cells diluted in PBST served as 
negative control. Plates were washed as above and incubated for 1 h at RT with 100 
µl/well anti-E2 specific antibodies diluted at appropriate concentration in PBST. Plates 
were washed as above and incubated for 1 h at RT with 100 µl/well of appropriate anti-
species HRP conjugated secondary antibody. Following incubation plates were washed 6 
times in PBST and binding was realised by addition of 100 µl/well TMB substrate. 
Reactions were stopped with 0.5M H2SO4 and absorbance value was measured at 450 nm. 
 
2.2.1.4. SDS-PAGE 
2.2.1.4a. Preparation of cell extract for SDS-PAGE analysis 
For SDS-PAGE cells were either lysed directly in 1x sample loading buffer (reducing) or 
LB2. Cells lysed in sample buffer were homogenised by passing through a 22-gauge 
needle. Following lysis in LB2, the lysates were spun briefly (13,000 r.p.m. for 1 min) to 
remove nuclei and the clarified lysates were mixed 1:1 with 2 x sample loading buffer. All 
samples were denatured by boiling at 100 ºC for 5 min before use. 
 
2.2.1.4b. SDS-PAGE analysis 
Resolving gels were prepared using acrylamide solution at a final concentration of 10-14 
% in 1 x resolving gel buffer. Stacking gels were prepared using acrylamide at a final 
concentration of 5 % in 1 x stacking gel buffer. Polymerisation of gels was initiated by the 
addition of APS (to 0.1 %) and TEMED (to 0.08 %). A 10-tooth Teflon comb was 
typically used to form wells in the stacking gel. Denatured proteins were loaded onto the 
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gel alongside a protein marker (Amersham) for size determination. Fractionation was 
performed at 100 V in gel running buffer. Upon separation gels were removed from the 
apparatus and transferred onto nitrocellulose membrane. 
 
2.2.1.5. Western Immunoblotting 
Proteins separated on polyacrylamide gels were transferred to HybondTM-ECLTM 
nitrocellulose membranes using a BioRad transblot semi-dry blotting device. Transfer was 
carried out at 25 V for 15 min. Following transfer membranes were incubated for 1 h at RT 
or overnight at 4 oC in PBST containing 5 % dried milk powder to block non-specific 
binding of antibody. Membranes were washed 3 times in PBST and probed with the 
appropriate antibody (diluted in PBST) for 1 h at RT. The membranes were washed as 
above and incubated with the appropriate HRP conjugated secondary antibody (diluted in 
PBST) for 1 h at RT. Finally, the membranes were washed as above and bound antibody 
was detected using Enhanced Chemiluminescence Reagents I and II (ECL I & II) 
(Amersham) in equal ratio. Bands were visualized by autoradiography using Kodak X-
OMAT film and a Konica SRX-101-A film processor. 
 
2.2.1.6. Flow Cytometry 
Flow cytometry was used for counting and sorting of cells resuspended in a stream of fluid. 
Cells of interest were washed in PBSA and either trypsinised for 5 min or de-attached from 
the surface using cell dissociation buffer (Sigma). Cells were then washed in PBSA, 
pelleted at 1000 rpm for 5 min, resuspended in PBSA and counted using a 
haemocytometer. When necessary cells were fixed in 2 % paraformaldehyde (PFA) for 15 
min at RT. Cells were then washed once in PBSA followed by a wash in PBSA + 2 % FCS 
+ 0.01 % sodium azide (FPBSA). Subsequent steps, including blocking, washes and 
incubation with antibodies, were carried out in this buffer. When necessary fixed cells 
were permeabilised using FPBSA + 0.1 % saponin and subsequent steps were carried out 
in this buffer.  Prior to staining cells were blocked at RT for 30 min. Following incubations 
cells were pelleted and 2x105 cells were incubated for 45 min at RT in 100 µl primary 
antibody or an irrelevant IgG control diluted in FPBSA (+/- 0.01 % saponin). Unbound 
antibody was removed by washing and the cells were further incubated for 45 min at RT 
with fluorescently conjugated secondary antibody. Finally cells were washed, resuspended 
in FPBSA and analysed on BD FACSCalibur using CellQuest Pro software (BD 
Biosciences).  
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35 cycles 
2.2.2. Molecular Cloning 
2.2.2.1. PCR Amplification 
PCRs were performed in a GeneAmp PCR machine (Applied Biosystems). PCR 
amplification was used to introduce point mutations, generate cDNA from total RNA, 
amplify cDNA for sequencing and fuse PCR products together to produce JFH1 chimeric 
constructs. 
 
2.2.2.1a. PCR amplification of cDNA 
For direct sequencing, viral cDNA generated from total cellular RNA was amplified using 
Advantage cDNA polyermase kit (Clonetech). Each reaction mix had a final volume of 50 
µl and consisted of 1x reaction buffer, 5 µl cDNA, 1 µl each of 10 µM forward and reverse 
primer, 1 µl 10 mM dNTPs and 1 µl DNA polymerase. Each reaction was amplified at  
 
1 min  95 oC 
30 sec   94 °C  
3 min   68 °C    
3 min  68 oC 
∞  15 oC 
 
Following amplification the entire reaction was subjected to agarose gel electrophoresis 
(section 2.2.2.3.) and the band of interest purified by gel extraction (section 2.2.2.4.) using 
QIAquick gel extraction kit (Qiagen). 
 
2.2.2.1b. Fusion PCR (to generate E1E2/JFH1 Chimeric viruses) 
Fusion PCR was performed in three stages using the Herculase II fusion DNA polymerase 
(Agilent Technologies). Primers were designed to generate fragments with overlapping 
overhangs and additional primers to fuse the fragments together (Appendix A). In the first 
PCR step pUC JFH1 and pcDNA3.1-E1E2 were used as templates to generate three PCR 
fragments with overlapping overhangs. Reaction mix consisted of 30 ng DNA template, 1 
µl each of 10 µM forward and reverse primers, 1x reaction buffer, 1 µl dNTPs and 0.5 µl 
herculase polymerase in a total of 30 µl volume. For each fragment PCR programme 
consisted of: 
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2 min  94 oC 
15 sec   94 °C ⎫ 
20 sec   56 °C ⎬ 10 cycles 
60 sec   72 °C ⎭ 
∞    4 oC 
The PCR product was separated on 1 % agarose gel (section 2.2.2.3.) and the gel purified 
(2.2.2.4.) fragments were fused together in a second PCR step. An equal amount of each 
fragment was mixed in the absence of primers with 1x reaction buffer, 1 µl dNTPs and 0.5 
µl herculase polymerase in a total of 30 µl volume. The PCR program consisted of: 
 
2 min  94 oC 
15 sec   94 °C ⎫ 
20 sec   56 °C ⎬ 10 cycles 
60 sec   72 °C ⎭ 
∞    4 oC 
2 µl of the fusion product was subsequently amplified in the presence of 1µl each of the 10 
µM forward and reverse primers, 1x reaction buffer, 1 µl dNTPs and 0.5 µl herculase 
polymerase in a total of 30 µl volume. The PCR program consisted of: 
 
2 min  94 oC 
15 sec   94 °C ⎫ 
20 sec   65 °C ⎬ 10 cycles 
2,30 min  72 °C ⎭ 
3 min  72 oC 
∞    4 oC 
 
The final PCR product was run on 1 % agarose gel (section 2.2.2.3.) and the gel purified 
(section 2.2.2.4.) fragment was digested with either FspAI/NotI or KpnI/AgeI restriction 
enzyme. Finally, the digested fragments were cloned into pJFH1 backbone digested with 
the appropriate restriction enzyme (section 4.2). The proper incorporation of inserts into 
the pJFH1 template was verified by nucleotide sequencing (Appendix B). 
 
2.2.2.1c. Site Directed Mutagenesis 
Mutagenesis reactions were performed using the QuickChange II XL Site-Directed 
Mutagenesis kit (Stratagene). Forward and reverse primers (Appendix C) were designed 
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(according to the manufacturer’s instructions) with the desired mutation(s) incorporated in 
the middle of the primer sequence of length between 25 and 45 bases. PCR mix consisted 
of 50 ng pUCJFH1 DNA template, 1x reaction buffer, 1.25 µl each of 10 µM forward and 
reverse mutagenic primers, 1 µl dNTPs, 3 µl Quick solution (added to improve linear 
amplification) and 1 µl pfuUltra HF DNA polymerase in a total of 50 µl reaction. The PCR 
program consisted of 
 
1 min  95 oC 
50 sec   95 °C ⎫ 
50 sec   60 °C ⎬ 18 cycles 
12 min  68 °C ⎭ 
7 min  68 oC 
∞    4 oC 
 
Following amplification, each reaction was chilled on ice for 2 min followed by the 
addition of DpnI (10 units) to digest the non-mutated dam-methylated parental DNA. The 
reactions were gently mixed by pipetting and then centrifuged at 13,000 r.p.m. for 1 min, 
followed by incubation at 37 ºC for 1 h. 2 µl of the DpnI-treated DNA was then 
transformed into 45 μl of XL10-Gold Ultracompetent cells mixed with 2 µl of β-ME 
according to the manufacturer’s instructions. 
 
2.2.2.1d. RT-qPCR 
RT-qPCR was a two-step protocol. The first step involved reverse transcription of viral and 
cellular RNA in a GeneAmp PCR machine (Applied Biosystems) using the TaqMan 
Reverse Transcription Reagents Kit. Each reaction contained 1 µl purified cellular RNA 
mixed with 1x RT buffer, 4.4 µl MgCl2, 4.0 µl dNTPs, 1 µl random hexamers, 0.4 µl 
RNase inhibitor, 0.5 µl multiscribe reverse transcriptase in a total volume of 20 µl.  
Reaction cycle consisted of  
 
10 min  25 oC 
60 min  37 °C   
5 min   95 °C  
∞    4 oC 
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40 cycles 
The second step involved either relative or absolute quantification of RNA where each 
sample was analysed in triplicate as a singleplex reaction. For relative quantification of 
HCV RNA, cDNA obtained from first step was amplified using both HCV -specific and 
GAPDH-specific primers (Applied Biosystems) in the presence of FAMTM (HCV-specific) 
and VIC® (GAPDH-specific) labelled probes. The JFH1 probe and primer sequences are 
located in the 5’ UTR of the viral genome (Witteveldt et al., 2009). To determine mRNA 
transcript of SR-BI and CD81 genes, cDNA obtained from first step was amplified using 
TaqMan probes (ABI) specific for SR-BI (Hs00969819) and CD81 (Hs00174717). Each 
sample was normalised to the endogenous GAPDH control gene. The Real-Time PCR 
reaction mix for each sample contained  
 
JFH1 RNA Reaction Mix    Volume (µl) 
18 μm Forward Primer (Final 900 nm)  1.0  
18 μm Reverse Primer (Final 900 nm)  1.0  
5 μm FAM JFH1 Probe (250 nm)   1.0  
TaqMan Fast Universal Mix (2x)   10.0 
dH2O       5.0  
cDNA       2.0  
 
GAPDH, SR-BI and CD81    Volume (µl) 
RNA Reaction Mix     
Probe       1.0 
TaqMan Fast Universal Mix (2 x)   10.0 
dH2O                7.0 
cDNA       2.0 
 
The amplification was performed on an Applied Biosystems 7500 Fast Real-Time PCR 
System using Fast Universal PCR conditions and the data analysed using Applied 
Biosystems software (SDS version 1.3.1), according to the manufacturer’s instructions. 
 
20 sec  95 oC 
3 sec   95 °C  
30 sec   60 °C    
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In order to determine the absolute quantification of purified HCV RNA, in vitro-
transcribed JFH1 genomic RNA of known concentration was used as a standard. Serially 
diluted standard cDNA and the undiluted sample cDNA obtained in first step was 
amplified and analysed using the same fast universal conditions as for relative 
quantification using HCV- specific primer and FAM probe. 
 
2.2.2.2. Restriction Enzyme Digestion 
Restriction enzyme digests were performed at 37 °C for at least 1 h unless otherwise 
specified by the manufacturer. Reactions were typically carried out in 50 µl volume using 
10 units of each enzyme per μg DNA. All reactions were performed using the appropriate 
enzyme buffers and BSA if necessary. 
 
2.2.2.3. Agarose Gel  Electrophoresis 
This method was used to isolate and purify DNA fragments amplified by PCR or DNA 
fragments produced by restriction enzyme digestion.  Typically, larger fragments (>500 
bp) were separated on 1 % agarose gel and smaller fragments (<500 bp) on 2 % agarose 
gel. The agarose gels were prepared in 1x TBE containing 1 µg/ml ethidium bromide. 
DNA fragments to be loaded on the gel were first mixed with 0.1 volume of 10x DNA 
loading dye and gels were typically run at 100 V in 0.5 x TBE buffer. DNA fragments 
were run alongside 1 kb or 100 bp DNA ladders (NEB). To excise digested DNA 
fragments and PCR product, fragments were visualised using long wave UV light followed 
by purification using the QIAQuick gel extraction kit (Qiagen) (section 2.2.2.4.). 
 
2.2.2.4. Purification of DNA from Agarose Gels 
Excised gel slices containing digested DNA fragments were dissolved in buffer QG 
(solubilisation buffer) at a ratio of 1:3 and incubated at 50 oC. Dissolved DNA fragment 
was then mixed with 1 gel volume of isopropanol to increase DNA yield. DNA in the gel 
solution was then bound to a QIAquick spin column by centrifugation at 13, 000 r.p.m. for 
1 min. The column was washed once with 750 µl buffer PE (washing buffer) and 
centrifugation was repeated at 13, 000 r.p.m. for 1 min. DNA was eluted from the column 
by addition of 30-50 µl of buffer EB (elution buffer) followed by further centrifugation  at 
13, 000 r.p.m. for 1 min. 
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2.2.2.5. DNA fragment Ligation 
Gel purified DNA fragments following restriction enzyme digestion were ligated for 16 h 
at 16 °C in 10 µl reactions containing 1x ligase buffer and 2 units of T4 DNA ligase. 
Following ligation, 2 µl DNA was used for electroporation into competent E. coli bacteria 
(section 2.2.2.7.). 
 
2.2.2.6. Preparation of electrocompetent bacterial cells  
NEB DH5α competent E. coli culture was grown overnight on a shaker at 37 oC. 10 ml of 
the overnight culture was added to 1 L pre warmed LB and incubated at 37 °C to an OD600 
reached around 0.8. The culture was chilled on ice for 30 min followed by centrifugation at 
4000 rpm for 10 min at 4 °C. The formed pellet was resuspended in 1 L ice-cold deionised 
molecular biology grade water (dH2O). Cells were re-centrifuged as before and 
resuspended in 500 ml ice-cold dH2O with 10 % glycerol. Again cells were centrifuged as 
before and resuspended in 2-3 ml ice-cold dH2O with 10 % glycerol. The suspension was 
aliquoted into 70 μl aliquots and stored for up to 6 months at -70 °C. 
 
2.2.2.7. Transformation of Electrocompetent E. coli Cells 
2 µl of plasmid or ligated DNA was added to 70 μl electrocompetent E. coli in a pre-
chilled 1 mm gap cuvette (Apollo) and electroporated (1.8 kV, 25 μF, 200 Ω) using a 
BioRad GenePulser Xcell. Electroporated cells were then resuspended in 0.5 ml YTB and 
incubated at 37 °C with shaking at 180 rpm for 1 h before being plated out on LB-agar 
plates with ampicillin (100 μg/ml). Plates were then incubated overnight at 37 °C.  
 
2.2.2.8. Small Scale Plasmid Preparation (Minipreps)  
Single colonies were picked from a freshly streaked selective agar plate to inoculate 5 ml 
cultures of LB with ampicillin (100 μg/ml), followed by overnight incubation at 37 ºC with 
vigorous shaking at 180 r.p.m. 1.5 ml of cultures was then centrifuged at 13,000 r.p.m. for 
5 min and the bacterial pellets were resuspended in 250 μl buffer P1 (cell resuspension 
buffer). The cells were then lysed by mixing equal volume of buffer P2, vortexed briefly 
and then incubated at RT for 5 min. 350 μl of buffer N3 (precipitation buffer) was added to 
the cells and the samples were vortexed briefly, followed by centrifugation at 13, 000 
r.p.m. for 10 min in order to pellet cellular debris. The supernatants were then applied to 
the QIAprep spin columns, followed by centrifugation at 13, 000 r.p.m. for 1 min. The spin 
columns containing the bound DNA were washed once with 750 μl buffer PE (washing 
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buffer) and centrifugation was repeated at 13, 000 r.p.m. for 1 min. DNA was eluted from 
the column by addition of 30-50 µl of buffer EB (elution buffer) followed by further 
centrifugation  at 13, 000 r.p.m. for 1 min. 
 
2.2.2.9. Large Scale Plasmid Preparation from Transformed Bacteria 
A single colony was picked from a freshly streaked selective agar plate to inoculate a 5 ml 
starter culture of LB with ampicillin (100 μg/ml). Following 8 h incubation, the starter 
culture was diluted 1:500 into 200 ml of LB with ampicillin as above and cultured 
overnight at 37 ºC with vigorous shaking (180 r.p.m.). A large scale DNA preparation was 
then made from the bacterial pellet harvested by centrifugation at 3000 r.p.m. for 10 min at 
4 ºC, using the Qiagen HiSpeed plasmid Maxi kit. The pellet was resuspended in 10 ml 
buffer P1 (cell resuspension buffer) by pipetting. 10 ml of buffer P2 (Lysis buffer) was 
added to the suspension and mixed by vigorously inverting the tube few times. The 
suspension was incubated at RT for 5 min before adding 10 ml of buffer P3 (precipitation 
buffer) and further mixing by inversion. The lysate was then poured into the barrel of the 
QIAfilter cartridge and incubated at RT for 10 min. During the incubation period a high 
speed maxi tip was equilibrated using 10 ml buffer QBT and the column was allowed to 
empty by gravity flow, followed by filtering the lysate into the equilibrated tip and again 
allowing the column to empty by gravity. Once the lysate had filtered through and plasmid 
DNA had bound, the column was washed with 60 ml buffer QC (wash buffer) and allowed 
to empty by gravity. Plasmid DNA was then eluted by adding 15 ml of buffer QF (elution 
buffer) and the DNA was precipitated by adding 10.5 ml isopropanol to the eluate followed 
by incubation at RT for 5 min. The eluate/isopropanol mixture was then transferred into 
the 30 ml syringe attached to the QIAprecipitator maxi module and the mixture was 
filtered by inserting the plunger using constant pressure. The DNA was then washed by 
adding 2 ml 70 % ethanol to the syringe and filtered as above. The plasmid DNA bound to 
membrane was allowed to dry by pressing air through the QIAprecipitator quickly and 
forcefully by inserting the plunger a couple of times. In the final step the QIAprecipitator 
was attached to a 5 ml syringe and the plasmid DNA eluted by adding 1 ml of buffer TE 
(elution buffer) to the syringe and eluting DNA by inserting the plunger.  
 
2.2.2.10. DNA Quantification 
DNA aliquots were diluted 1:50 in dH2O and the OD260 measured using a BioPhotometer 
(Eppendorf). 
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2.2.2.11. Nucleotide Sequencing 
Sequencing of plasmid and amplified cDNA was performed by GATC biotech, Germany. 
A minimum of 30 µl of DNA (100 ng/µl) and primers (10 µM) were required for each 
reaction. Completed sequences were analyzed using Chromas (ABI) and NCBI alignment 
software. 
 
 
2.2.3. HCVcc Based Work 
HCVcc based work was performed using JFH1WT, JFH1∆E1E2, JFH1GND, JFH1 containing 
E2 point mutations and intergenotypic chimeric JFH1 viruses. 
 
2.2.3.1. Generating E1E2/JFH1 chimeras 
E1E2/JFH1 chimeras were designed as described in section 2.2.2.1b. Primers used for PCR 
amplification and for sequencing the final product are listed in Appendix A and B. 
 
2.2.3.2. Introducing E2 Mutations into pJFH1  
All single mutations were introduced individually into pUC-JFH1 by site-directed 
mutagenesis using primers listed in Appendix C. Several colonies from each agar plate 
were selected and plasmids extracted using mini-preps were sequenced using sequencing 
primers NA17 and NA24 (Appendix D). Positive clones were then restriction digested with 
BsaBI and BsiWI and the desired fragments ligated into the parental pJFH1 vector 
backbone digested with the same enzymes. The ligation mix was then transformed into 
competent DH5α cells and plasmid maxi-prep was prepared. To verify the presence of 
desired mutations and to confirm the correct ligation of the fragments, the plasmids were 
sequenced again using the same primers as above. Following sequencing the correct 
plasmids were linearised and used to prepare in vitro transcribed viral RNA.   
 
2.2.3.3. Introducing Cell Culture Identified Mutations into 4a/JFH1     
vector 
A total of six mutations selected during long term passaging of 4a/JFH1 infected cells were 
introduced into the parental 4a/JFH1 plasmid by site directed mutagenesis (SDM). 
Mutations I690M, T827A and T889I were introduced into the same plasmid by three 
separate SDM reactions. To do this, an SDM reaction was first used to introduce the 
I690M mutation using the appropriate primers. Bacterial colonies obtained from the 
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transformation of this reaction were used to generate minipreps of plasmid DNA. 
Sequencing was then performed on each miniprep using primers to confirm the presence of 
the desired mutation and the absence of any unwanted PCR mutations between the BglII 
(nt 3123) and BsrGI (nt 7793) restriction enzymes sites. A correct plasmid was then used 
in a second SDM reaction to introduce the T827A reaction using the same method as 
above. A third SDM was then performed on the plasmid containing the I690M and T827A 
changes to then finally introduce the T8891 mutation. In parallel, mutations M956L, 
A1271V and Y2289H were incorporated into the 4a/JFH1 using the same method 
described above for introducing the I690M, T827A and T889I mutations. The two clones 
each containing the three respective mutations were digested with BglII and BsrGI and 
subsequently ligated together. Proper ligation of the two fragments and presence of 
mutations was confirmed by nucleotide sequencing (Appendix D) prior to linearizing the 
plasmid and preparing in vitro transcribed viral RNA. 
 
2.2.3.4. Preparation of template DNA for In Vitro Transcription  
Briefly, 50 µg of plasmid DNA was linearised by XbaI digestion in a 200 µl reaction in a 
1.5 ml RNase free tube (Ambion). The linearised template was then treated with Mung 
Bean Nuclease for 30 min at 30 oC to allow complete removal of the sticky ends generated 
by XbaI. To clean the template of proteins, Proteinase K (final concentration 100 μg/ml) 
and SDS (final concentration 0.5 %) were added and the mixture incubated for 30 min at 
50 °C. The linearised DNA was then recovered using the phenol/ chloroform purification. 
200 μl of neutral phenol-chloroform (25 parts saturated neutral phenol: 24 parts 
chloroform: 1 part isoamylalcholol) was added and the mixture was vigorously vortexed. 
The solution was then centrifuged at 13,000 r.p.m. for 2 min to separate the aqueous layer 
from organic layer.  The aqueous layer was placed in a fresh RNase-free tube and mixed 
with 0.1 volumes of 5 M NH4OAc and 3 volumes 100 % ethanol. The sample was stored at 
-20 °C for a minimum of 30 min before being centrifuged at 13,000 r.p.m. for 15 min to 
pellet the precipitated DNA. The supernatant was carefully removed, pellet washed with 70 
% ethanol, centrifuged again at 13,000 r.p.m. for 15 min and the washed pellet allowed to 
dry at RT before being resuspended in 30 μl nuclease-free dH2O.  
 
2.2.3.5. In Vitro Transcription  
RNA transcripts were generated using the T7 Megascript Kit (Ambion) according to the 
manufacturer’s instructions using 1 µg of linearised DNA template. The reaction mixture 
was incubated at 37 oC overnight followed by DNase-I treatment for 15 min at 37 oC and 
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the RNA purified using the MEGAclear kit (Ambion) according to remove nucleotides, 
proteins and salt from the RNA. 1 μl of purified RNA was mixed with 49 μl H2O and the 
RNA concentration was measured by reading the OD260 using a BioPhotometer 
(Eppendorf). Typically, this kit yielded RNA concentrations of 70-100 μg. 
 
2.2.3.6. RNA Electroporation of Huh-7 cells  
Cells at 60-80 % confluency were trypsinised, washed in DMEMcomplete and counted using 
a haemocytometer. For each electroporation, aliquots of 4 x 106 cells were washed 2 times 
in PBSA and pelleted by centrifugation at 1000 r.p.m. for 5 min. The pellet was then 
resuspended in 400 μl PBSA and added to a 4 mm gap cuvette (Apollo) along with 10 μg 
of in vitro transcribed viral RNA. Electroporation was performed using a BioRad 
GenePulser Xcell (250 V, 950 μF), following the manufacturer’s instructions. The 
transfected cells were then allowed to rest for 10 min prior to being resuspended in the 
appropriate amount of DMEMcomplete and seeded into the appropriate tissue culture flask or 
plate. Typically electroporated cells were resuspended in 15 ml DMEMcomplete and plated in 
90 mm culture dish.  
 
2.2.3.7. Generation of HCVcc Virus 
Huh-7 cells electroporated with in vitro transcribed RNA were transferred to category 3 
containment laboratory and the virus was harvested at 24 h, 48 h, 72 h and 96 h post 
electroporation by filtering the culture media through a 0.45 µm pore-sized membrane. 
 
2.2.3.8. Measuring HCVcc Infectivity 
Virus infectivity was determined using either the 50 % Tissue Culture Infectious Dose 
(TCID50) assay as described by Lindenbach et al. (2005) or the focus forming unit (FFU) 
assay, as described by Zhong et al. (2005). Naive Huh-7 cells were seeded at 1 x 103 cells/ 
per well in 200 μl DMEMcomplete in a flat bottomed 96-well plate (Nunc). Six wells per 
dilution were used with the TCID50 method and three wells per dilution with the FFU 
method. Cells were allowed to settle at 37 oC for 24 h before being inoculated with 200 μl 
of serial 5-fold or 10-fold dilutions of harvested culture medium. 48 h post-infection the 
medium was removed, cells washed with PBSA and fixed with ice-cold methanol at -20 °C 
for a minimum of 2 h. The cells were then washed three times in PBSA and probed with 
anti-NS5A mAb 9E10 diluted 1:20,000 in PBST and incubated for 1 h at RT. Cells were 
washed again as above and incubated for 1 h at RT with FITC conjugated secondary 
antibody diluted 1:500 in PBST. The cells were then washed 3 times in PBSA before being 
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overlaid with 100 μl of dH2O, followed by visualization under a fluorescent microscope 
(Nikon Eclipse TS100).  
 
Infectivity of cell-associated virus was determined using previously established methods 
(Gastaminza et al., 2006; Shavinskya et al., 2008). Electroporated cells seeded into a 90 
mm tissue culture dish were washed once in PBSA at 48 h post incubation. The cells were 
then removed from the culture dish using a cell scraper in the presence of 10 ml PBSA 
followed by centrifugation at 1000 r.p.m. for 5 min. The pellet was then resuspended in 1 
ml DMEMcomplete, and freeze-thawed rapidly three times using dry ice/ethanol and a 37 oC 
water bath. Finally, the samples were centrifuged at 4000 r.p.m. for 5 min to remove cell 
debris, and the infectivity was determined using the TCID50 method.  
 
2.2.3.9. Preparation of cells for HCVcc replication and protein 
Expression Analysis 
The viral replication was visualised by either IF and western immunoblotting or 
determined by RT-qPCR. For IF analysis, a few drops of electroporated cells were seeded 
onto coverslips in a 24 well plate and incubated for 48 h at 37 oC before being fixed, 
stained and visualised. For IF analysis following infection, naive Huh-7 target cells were 
seeded onto coverslips and 24 h later infected with 200 µl harvested culture media. At 48 h 
post infection cells were fixed, stained and visualised as before. For western 
immunoblotting, electroporated cells seeded onto 90 mm culture dishes were washed once 
in PBSA at 72 h post incubation and lysed either directly in sample loading buffer or in 
LB2 and analysed as described in section 2.2.1.5. To quantify virus replication by RT-
qPCR cells were typically washed in PBSA before being lysed in RLT buffer (RNeasy Kit) 
and total RNA was extracted according to the manufacturer’s instructions. Briefly 1 
volume of 70 % ethanol was added to the lysate and mixed thoroughly by pipetting. 
Samples were then transferred to an RNAeasy spin column and centrifuged at 10, 000 
r.p.m. for 30 sec. 700 µl buffer RW1 (wash buffer) was added to the spin column and the 
centrifugation was repeated at 10, 000 r.p.m. for 30 sec. Spin column was then washed 
twice with 500 µl buffer RPE (wash buffer with ethanol) and centrifuged at 10, 000 r.p.m. 
for 2 min. At this point the spin column was placed into a fresh collection tube and the 
RNA was eluted by adding 30-50 µl RNase-free water and spinning the sample at 10, 000 
r.p.m. for 1 min. Following electroporation, cells were seeded onto 90 mm culture dishes 
and incubated at 37 oC. At 4 h post-incubation cells were washed trypsinised and 
resuspended in DMEMcomplete. Next, the resuspended cells were divided equally into three 
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25 cm2 flasks and at appropriate time-points the cell-lysates (for RT-qPCR) and culture 
supernatant (for TCID50) were harvested. To determine virus replication kinetics after 
infection, 53,000 naïve Huh-7 cells were seeded into three 6-well culture dishes. For each 
virus, cells were infected at the indicated multiplicity of infection (m.o.i.) for 6 h in a total 
volume of 900 µl before supplementing the cells with 2 ml of fresh DMEMcomplete. At 24, 
48 and 72 h cell lysates and culture supernatants were harvested.  
 
2.2.3.10. Passaging of HCVcc infected cells 
Cells infected with JFH1WT were passaged every 3-5 days at the time of subconfluency. At 
each passage cell culture supernatants were harvested and infectivity determined by 
TCID50. The cells were washed, trypsinised, resuspended in fresh DMEMcomplete and 
seeded onto coverslips for viral protein expression analysis by IF. Cells electroporated with 
4a/JFH1 viral RNA or infected with adapted 4a/JFH1 virus were passaged as described 
above. However, in addition to analysing the infectivity of the culture supernatant and the 
intracellular viral protein expression by IF, 1 ml of cell resuspension was pelleted and 
lysed in RLT to generate cDNA for sequencing or to determine RNA replication by RT-
qPCR. 
 
2.2.3.11. Iodixanol gradient 
Huh-7 cells were electroporated in duplicate with the relevant viral RNAs and seeded into 
90 mm culture dishes in 15 ml DMEMcomplete. The culture medium from each dish was 
harvested, pooled and purified through 20 % (w/v) sucrose cushions in PBS(A) by 
ultracentrifugation at 25,000 r.p.m. for 4 h at 4oC using a Sorvall Discovery 90SE 
ultracentrifuge. Viral pellets were then re-suspended overnight in 500 μl PBSA. Linear 
iodixanol gradients were prepared according to a pre-established protocol described by 
Lindenbach et al., 2005. Equal volumes of 10-40 % Optiprep (Iodixanol; Axis-Shield) 
solutions in PBS were layered in 5 % increments and incubated at 4oC for 16 h. Next, the 
concentrated virus was layered on top of the gradients and equilibrium was reached by 
ultracentrifugation at 36, 000 rpm for 16 h at 4oC using a using a Sorvall Discovery 90SE 
ultracentrifuge. Following centrifugation 1 ml fractions were harvested from the top of the 
tube and 1/10 of each fraction was weighed to calculate fraction density. 100 μl aliquots of 
each fraction were diluted 10 times in DMEMcomplete before the infectivity was determined 
by FFU assay. 
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2.2.3.12. Determining Virus Neutralisation 
HCVcc inhibition assays were performed using either Huh-7 or HuhJ-20 cells and 
infectivity levels were determined by FFU or secreted alkaline phosphatase (SEAP) 
reporter assay, respectively. With FFU, Huh-7 cells were seeded at 3x103 cells/ per well in 
200 μl DMEMcomplete in a 96-well plate and were allowed to settle at 37 oC for 24 before 
infection. For HCVcc inhibition with anti-E2 antibody, 100 FFU of virus was pre-
incubated for 1 h at 37 oC with the appropriate antibody or control antibody diluted in 
DMEMcomplete prior to infecting the cells with the antibody/virus mixture. To treat the 
target cells by anti-receptor antibodies, target cells were incubated with the appropriate 
antibody diluted in DMEMcomplete for 1 h at 37 oC. Next the antibody was removed and 
cells were infected with 100 FFU of virus per well. The infectivity was determined by 
staining cells with anti-NS5A mAb 9E10. 
  
To measure HCVcc neutralisation by SEAP reporter assay, naive Huh-7 J20 cells were 
seeded as above in 96 well plate. The next day cells were inoculated with 100 µl of virus at 
an m.o.i of 0.5 and incubated for 3 h after which the inoculum was replaced with fresh 
medium and cells incubated at 37 oC. At 72 h post incubation 90 µl of culture medium was 
lysed in 10 µl of 10x concentrated LB2 to inactivate the virus and the SEAP activity was 
measured using SEAP Chemiluminescence Assay kit, Phospha lightTM (ABI) following 
manufacturer’s instructions (section 2.2.3.13.).  
 
2.2.3.13. SEAP Assay 
In a 96-well plate 30 µl of lysed cell medium was mixed 1:1 with 1x dilution buffer and 
incubated at 65 oC for 30 min. The plates were then cooled on ice to reach room 
temperature. 50 µl of the cooled reaction was then mixed with 50 µl assay buffer in a black 
96-well microplate. Before measuring the luminescence, 50 µl of reaction buffer was 
added to the plate. Reaction buffer was prepared by diluting 1,2 dioxetane phosphate 
(CSPD) substrate 1:20 with reaction buffer diluents. The SEAP acitivity was measured by 
using a Hidex Chameleon plate reader and expressed as relative light units (RLU)  
 
2.2.3.14. Analysing Effect of HDL on HCVcc Infectivity 
JFH1WT and JFH1 E2 mutant virus inoculum was used to infect naive Huh-7 cells at an 
m.o.i. of 1.0.  At 3 h post incubation cells were washed 3 times in PBSA and supplemented 
with cell culture medium containing 3 % lipoprotein-deficient fetal calf serum. Released 
virus in the culture medium was harvested at 6 days post-infection. To test the effect of 
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HDL on virus infectivity, naive Huh-7 J20 cells were seeded in a 96-well plate and 
incubated overnight. The following day cells were treated with cell culture medium 
containing 3 % lipoprotein-deficient fetal calf serum for 3 h at 37 oC prior to infection with 
virus in the presence or absence of HDL (20 µg/ml). At 72 h post-infection the SEAP 
activity was measured to determine infectivity. 
 
2.2.3.15. RNA Interference 
The expression of CD81 and SR-BI protein was down-regulated by reverse transfecting 
gene specific siRNA into naive Huh-7 cells. Two siRNAs targeting two different regions 
of CD81 (14501 and 146379) and SR-BI (s2650 and s2649) were obtained from Ambion. 
Each siRNA, supplied as a 5 nmol stock, was diluted in dH2O to obtain a stock 
concentration of 100 µM. Transfections were performed in 24-well plates in triplicates. For 
each well, 100 µl Optimem-I was mixed with 1 µl lipofectamine RNAiMAX reagent 
(Invitrogen) and 0.5 µl each of the two siRNAs targeting either CD81 or SR-BI gene or 1 
µl scrambled siRNA . The plates containing the siRNA and lipofectamine mix were then 
incubated for 20 min at RT. Following incubation the wells were seeded with 1x104 
cells/well in 900 µl DMEMcomplete, giving a total volume of 1 ml/well and a final 
concentration of 100 nM of siRNAs. At 48 h post-incubation the viability of cells and 
mRNA expression levels were determined by ELISA and RT-qPCR, respectively. To 
determine the level of cells surface expressed CD81 and SR-BI protein, FACS analysis 
was performed using anti-CD81 and anti-CLA-I antibody, respectively. In parallel, siRNA 
treated cells were infected at 48 h post-incubation with JFH1WT, JFH1N415D, JFH1T416A, 
JFH1N417S and JFH1I422L virus for 4 h before being supplemented with fresh DMEMcomplete. 
At 24 h post infection the intracellular HCV RNA levels were measured by qRT-PCR. 
2.2.3.16. Cell Viability Assay 
Cell viability of Huh-7 cells following reverse transfection with siRNAs was determined 
using the colorimetric WST-1 assay (Roche) according to the manufacturer’s instructions. 
siRNA reverse transfected cells were seeded in a 96-well plate in a total volume of 180 µl. 
At 48 h post-incubation 20 µl (1/10 dilution) of WST-1 was added to the cell medium and 
the cells were incubated for 3-4 h at 37 oC. Following incubation the cell metabolism was 
measured by ELISA. 
 
2.2.3.17. Cell-to-Cell Transmission Assay 
The cell-to-cell transmission efficiency of JFH1WT and gt4a/JFH1 virus was tested using 
the previously established co-culture assay (Brimacombe et al., 2010) (Appendix 6). This 
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study showed this system to be more reliable than the previously reported HCV cell-to-cell 
transfer techniques. This assay requires donor and target cells to be cultured together at 
high levels of confluency to maximize the occurrence of viral spread. To generate the 
donor cells, Huh-7 cells were transfected with in vitro transcribed HCV RNA and 
incubated at 37oC. At 72 h post-incubation these donor cells were labelled with CMFDA 
dye by incubating the cells at 37oC with 5 µM of CMFDA dye for 30 min. In parallel, 9 x 
104 naive Huh-7 cells (Target cells) were seeded in a 24-well cell culture plate and allowed 
to rest for 1 h at 37oC in the presence of 100 µg nAb AP33 or no antibody control (PBSA). 
Upon CMFDA labelling, donor cells were trypsinized, washed and counted and equal 
amount of cells were then mixed with the target cells and incubated for 48 h. The additions 
of nAb AP33 in the test samples prevented cell free virus from infecting the target cells. At 
48 h post co-culture incubation the cell medium was harvested to test the level of 
neutralization of infection with AP33 nAb. This was done by infecting naive Huh-7 J20 
cells followed by measuring SEAP activity at 48 h post-infection. In parallel, the level of 
cell-to-cell transfer from donor to target cells was determined by performing FACS 
analysis on the co-cultured cells to quantify NS5A positive cells in the presence or absence 
of nAb AP33. 
 
 
2.2.4. HCVpp Based Work 
HCVpp assay was used to compare infectivity and neutralisation profile of AP33 mutants. 
pJFH1 containing the individual AP33 mutations were digested with BsiWI and BsaBI 
restriction enzymes that have recognition sites located at the N-terminus of E1 and C-
terminus of E2, respectively. The resulting fragments containing the mutations were 
ligated into phCMV vector digested with the same restriction enzymes. The proper 
incorporation of inserts into phCMV template was confirmed by sequence analysis using 
primers NA15, NA17 and NA19 (Appendix D). 
 
2.2.4.1. Generation of HCVpp (Transfection of DNA) 
HCVpp were generated as decribed previously (Bartosch et al., 2003; Hsu et al., 2003; 
Owsianka et al., 2005). Typically one million HEK-293T cells were seeded into a 90mm 
tissue culture dish in 20 ml DMEMcomplete 24 h before transfection.  The following day the 
cells were co-transfected with three different plasmids expressing (i) replication deficient 
MLV gag/pol core (8 µg), (ii) HCV E1E2 glycoprotein (3 µg) and (iii) luciferase reporter 
gene (8 µg) using the Sigma Calcium Phosphate Transfection Kit. The plasmid DNA were 
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mixed with molecular biology grade water and 40 μl 2.5 M CaCl2 in a total volume of 200 
μl in a sterile eppendorf. In a second 1.5 ml eppendorf tube, 200 μl of 2 x HEPES-Buffered 
saline (HeBS), pH 7.05 was added. To prepare the precipitate, the HeBS solution 
containing sodium phosphate was gently bubbled using a sterile pasteur pipette while the 
DNA/CaCl2 solution was gently added dropwise. The precipitate was then incubated for 20 
min at RT before being gently distributed over the cells. At 24 h post transfection the 
medium was replaced with 5 ml fresh DMEMcomplete replenished with 10 mM Hepes. At 48 
h post-transfection the culture media containing HCVpp was harvested by filtering through 
a 0.45 µm pore-sized membrane. The transfected cells were washed once in PBSA and 
later lysed in 500 µl 1 x lysis buffer (Promega) for ELISA assay or lysed directly in sample 
buffer for WB. Lysed cells were centrifuged 1000 r.p.m. for 10 min and the clarified 
supernatant was stored at -2 0oC and used in ELISA assay. 
 
2.2.4.2. Luciferase Infection assay 
Target cells (Huh-7) were seeded 24 h before infection at a concentration of 2.5 x104 cells 
per well of a 24 well tissue culture plate in a total volume of 1 ml. To infect, cells were 
incubated for 3 h with 200 µl harvested HCVpp culture media, after which the media was 
replaced with fresh DMEMcomplete and cells were incubated for 48 h. Infection was assessed 
with a luminometer using Luciferase Assay System (Promega) according to the 
manufacturer’s instructions. Briefly, cells were washed with excess PBSA and cell lysates 
were prepared by adding 100 µl of 1 x lysis buffer to each well and the mix incubated on 
gentle shaking for 5 min at RT. Meanwhile, luciferase assay reagent was prepared by 
dissolving 17.1 mg lyophilized luciferase assay substrate into 1 ml luciferase assay buffer. 
Cell lysate was then mixed with equal amount of luciferase assay reagent in 1.5 ml 
eppendorf and luminescence measured immediately.  
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3. Characterisation of E2 Cell Culture Adaptive 
Mutations 
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3.1. Introduction 
The first groups to establish the HCVcc system described the ability of JFH1 and J6/JFH1 
to persistently infect Huh-7 cells and the derived sublines Huh-7.5 and Huh-7.5.1 cells 
(Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al., 2005). Since then numerous 
studies have documented that the long-term culturing of infected cells results in the virus 
acquiring cell culture adaptive mutations throughout the genome, some of which enhance 
infectivity. An interesting observation from these studies is that nonsynonymous mutations 
frequently arise within the E2 glycoprotein. Furthermore, these mutations tend to cluster 
within the highly conserved region spanning amino acids 412-423 (QLINTNGSWHIN). 
Given its high level of conservation, it is possible that this region is crucial for the 
structural integrity of the glycoproteins. In line with this theory, a comprehensive 
mutagenesis study reported that several of the residues within this region were crucial for 
HCVpp infectivity (Owsianka et al., 2006). This site also harbours one of the critical E2 
residues, at position W420, required for CD81 binding (Owsianka et al., 2006). This region 
is also of great interest with regards to immunotherapy and vaccine development as several 
broadly neutralising mAbs bind to this epitope. These include mouse mAb AP33, rat mAb 
3/11 and human mAbs e137, HCV1, 95-2, AR3A, AR3B, AR3C and AR3D (Broering et 
al., 2009; Flint et al., 1999; Law et al., 2008; Owsianka et al., 2005; Perotti et al., 2008). 
Of these, mAbs AP33, 3/11 and e137 are known to block binding of E2 to CD81. The in 
house generated mAb AP33 has been extensively characterized. AP33 has been shown to 
potently neutralize HCVpp bearing glycoproteins representative of the major HCV 
genotypes (Owsianka et al., 2005). The development of the HCVcc system has now 
afforded us the opportunity to examine the importance of the conserved 412-423 region in 
E2 for virus infection and AP33-mediated neutralization using authentic HCV virions. 
Alanine substitution of these residues is not a suitable approach for such HCVcc studies as 
these mutations could affect different stages of the viral lifecycle other than cell binding 
and entry, such as RNA replication, virus assembly and egress. In contrast, cell culture 
adaptive mutations in this site of E2 are valuable for such studies as they have been shown 
not to alter virus replication levels. 
 
In this study, an asparagine-to-aspartic acid mutation at residue 415 (N415D) in HCV 
strain JFH1 E2 was first identified following the long-term passaging of infected Huh-7 
cells. Alongside N415D, three adjacent cell culture adaptive mutations (T416A, N417S  
70 
 
and I422L) reported previously (Bungyoku et al., 2009; Kaul et al., 2007; Russell et al., 
2008) were then characterized, to gain further insight into the function of this E2 region in 
viral infection and antibody mediated neutralization.  
 
 
3.2. Identification of a Cell Culture Adaptive Mutation in 
E2 
With the aim of generating our own cell culture adapted virus, naïve Huh-7 cells were 
infected at a low m.o.i. with the JFH1WT virus harvested from cells electroporated with 
viral RNA and serially passaged over a period of 6 weeks (9 passages). The infectious 
virus yields in the culture supernatants increased up to cell passage (cp) 6 at which time the 
titers peaked at 1 x 105 TCID50/ml (Figure 3.1A). The infectivity then decreased in the 
subsequent passages and then settled at 1 x 104 TCID50/ml at cp 8 and 9. Interestingly, no 
correlation was found between the number of HCV infected cells and the levels of virus 
released at each cell passage (Figure 3.1B). Furthermore, virus infection between cp 5 and 
6 induced clear cytopathic effects (CPE) as characterized by rounded cells floating in the 
culture medium. Zhong and colleagues reported similar observations during the adaptation 
of JFH1 in serially passaged cells (Zhong et al., 2006). This study also showed that the 
adapted virus obtained from the late cell passages could achieve superior viral titers 
following its infection of naïve cells. To determine if our late passaged virus displayed a 
similar phenotype, naïve Huh-7 cells were infected with virus collected from cp 9. At 3 
days post-infection, the viral titers were approximately 100-fold higher than those recorded 
at cp 9, indicating that this virus had acquired infectivity enhancing mutations. As this high 
tittered virus was generated after one supernatant passage, this preparation will now be 
referred to as supernatant passage 1 (sp1) virus. To identify the mutation(s) responsible for 
this changed phenotype, RNA harvested from sp1 infected cells was RT-PCR amplified, 
and the population was sequenced over the core to NS5B region. In total 3 nonsynonymous 
mutations were detected in NS5A (A2322G), NS4A (C1678S), and E2 (N415D). The latter 
mutation is located within the highly conserved region between residues 412-423. 
Interestingly, three other studies also reported adaptive E2 mutations within this epitope, at 
positions T416 (Bungyoku et al., 2009), N417 (Russell et al., 2008) and I422 (Kaul et al., 
2007) (Figure 3.1C). These were generated in Huh-7.5 cells using the chimeric J6/JFH1 
(T416A) or the JFH1WT (N417S and I422L) HCVcc. To study what effect these 
aforementioned mutations have on virus infectivity, receptor affinity and antibody-
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mediated neutralization, each mutation was first introduced separately into the parental 
genome by site directed mutagenesis as described in materials and methods. These four 
viruses were then characterized alongside the JFH1WT. 
 
 
3.3. Effects of E2 Mutations on Virus Infection  
First, the effect of these E2 mutations on viral RNA replication and infectious particle 
release was determined following electroporation of the in vitro transcribed RNAs into 
Huh-7 cells. In contrast to JFH1GND, which served as a negative control, both the JFH1WT 
and the four E2 mutant virus RNAs were capable of releasing similar levels of infectious 
particles into the medium (Figure 3.2A) and showed comparable levels of intracellular 
replication at all the time points tested (Figure 3.2B). To further determine the effect of the 
introduced mutations on virus assembly, the intracellular versus extracellular infectivity in 
Huh-7 cells was titrated at 72 h post electroporation. Again no major difference was 
noticeable in the infectivity of intra- and extracellular virus (Figure 3.2 C). Concomitantly 
this data suggest that each individual mutation has no major impact on virus replication, 
virus assembly or virus release following electroporation with the viral RNA. 
 
Next, a short term infection kinetics experiment was performed. Extracellular virus 
collected at 72 h post-electroporation was used to inoculate naïve Huh-7 cells at an m.o.i of 
0.1 and 1.0. At each m.o.i tested, no major differences were observed in the infectivity and 
intracellular RNA replication of each mutant compared to JFH1WT throughout the time 
course (Figure 3.3A-D). Interestingly, the JFH1sp1 virus, which was included for 
comparison, produced infectious titers ~1 log greater than JFH1WT and the E2 mutants. 
Furthermore, the intracellular RNA replication levels of JFH1sp1 were greatly reduced 
compared to the other viruses, particularly at the 24 and 48 h time points. These results 
suggest that more JFH1sp1 virus particles are produced per intracellular RNA molecule. 
The contrasting phenotype of JFH1sp1 next to JFH1N415D is likely due to the mutations in 
the non-structural regions of the genome. Next, the specific infectivity (defined as 
infectious titer relative to the HCV RNA titer) of JFH1N415D, JFH1T416A, JFH1N417S and 
JFH1I422L was determined using a pre-established protocol (Zhong et al., 2006). To do this, 
naïve Huh-7 cells were inoculated at an m.o.i. of 1.0 and at 72 h post-incubation, the level 
of virus infectivity and HCV RNA in the culture medium was determined by TCID50 and 
RT-qPCR. Interestingly, compared to JFH1WT, the specific infectivity of each mutant were 
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much lower, with values 5.7-, 21.1-, 4.3- and 2.2-fold less for JFH1N415D, JFH1T416A, 
JFH1N417S and JFH1I422L, respectively (Fig. 3.3E). This result indicates that the E2 mutant 
viruses release fewer non-infectious particles than JFH1WT, which could be explained by 
these mutants being more efficient at packaging the viral genome during virus assembly. 
 
3.4. E2 Mutations Alter Sensitivity to Neutralizing  
Antibodies 
Next it was determined whether these single changes alter the affinity of E2 to the broadly 
neutralizing mAbs AP33 and 3/11. Both these mAbs recognize distinct but overlapping 
epitopes within the highly conserved region of E2 spanning residues 412 to 423 
(QLINTNGSWHIN), where these four mutations are located. To test the binding 
efficiency of E2 with AP33, cells were fixed and probed for IF analyses at 48 h post 
electroporation. While a clear E2-AP33 interaction was visible for JFH1WT, JFH1T416A and 
JFH1I422L, AP33 binding to E2 from JFH1N415D and JFH1N417S appeared to be completely 
abrogated in IF imaging (Figure 3.4A). The conformational sensitive anti-E2 human mAb 
CBH-5 was used as a control antibody. Immunoblotting of infected cell lysates confirmed 
the IF data, showing no binding of mAb AP33 to E2 from JFH1N415D and JFH1N417S mutant 
viruses. Immunoblotting with the anti-NS5A mAb 9E10 and the anti-E2 mAb D3.7 
confirmed that there was a similar level of viral protein expression in each infected cell 
lysate (Figure 3.4B). 
 
Next the reactivity of mAb AP33 or 3/11 to the glycoproteins of each E2 mutant virus was 
quantified by ELISA. The levels of JFH1WT and mutant E2 in Huh-7 cells electroporated 
with appropriate viral RNAs was first normalized by measuring binding to the 
conformation sensitive anti-E2 human mAb CBH-4B (Appendix 1A). Notably, the various 
E2s also bound to the mouse mAb D3.7, which recognizes a linear epitope in E2, with 
comparable efficiency (Appendix 1B). Consistent with IF and immunoblotting data, AP33 
showed very weak binding to the E2 from JFH1N415D and JFH1N417S captured onto GNA 
ELISA (Figure 3.5B and Appendix 2). Similar binding efficiency in ELISA was observed 
when probing GNA captured E2 with mAb 3/11 (Figure 3.6B and Appendix 3). 
Furthermore, the efficiency of these anti-E2 antibodies to block infection of JFH1WT and 
E2 mutant viruses was also tested. Virus harvested at 72 h post-electroporation was 
incubated with mAb AP33 or 3/11 prior to infecting target cells. It was found that 
JFH1T416A and JFH1I422L were highly sensitive to neutralization by both mAbs, whereas 
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JFH1N415D and JFH1N417S were completely resistant (Figure 3.5A and 3.6A). Together, the 
neutralization and ELISA data show that the JFH1N415D and JFH1N417S mutations disrupt 
the binding of mAbs AP33 and 3/11 to E2. This data is further supported by the IF and 
immunobloting results shown in figure 3.4A and 3.4B. However, while the reactivity of the 
intracellular glycoproteins from JFH1T416A and JFH1I422L was unaltered for both mAbs, the 
virions were more sensitive to neutralization by these antibodies. This is indicated by the 
IC50 values ranging between 25- and 12.5-fold lower for mAb AP33 and 11- and 6- fold 
lower for mAb 3/11 (Table 3.1).  
 
A range of polyclonal anti-HCV IgGs purified from HCV-infected patients that inhibit 
infection after virus attachment to the cell have been reported previously (Haberstroh et al., 
2008). The sensitivity of JFH1WT and the E2 mutant viruses to neutralization by three of 
these IgG preparations was tested. Virus harvested at 72 h post-electroporation was 
incubated with different amounts of patient IgGs; IgG7, IgG17 or IgG19 prior to infecting 
target cells. The degree of inhibition of the JFH1WT virus afforded by these IgGs was in 
accordance with the previous published data (Haberstroh et al., 2008). However, the 
mutant viruses were more sensitive to neutralization, with IC50 values 18- to 60-fold lower 
for IgG17, 9- to 20-fold lower for IgG19 and >25 fold lower for IgG7 (Figure 3.7C, D and 
E and Table 3.1). As expected, antibodies purified from an uninfected individual had no 
effect on virus infectivity at the highest concentration tested for each IgG (20 μg/ml) 
(Figure 3.7F). Next the efficiency of neutralization of all viruses was tested using the 
conformation-sensitive anti-E2 hmAbs, CBH-5 and HC-11. Both of these hmAbs 
recognize discontinuous overlapping epitopes within the domain B of E2 and like CBH-5, 
HC-11 also inhibits viral entry into cells by blocking the E2-CD81 interaction (Keck et al., 
2008). With both the antibodies it was found that each mutant virus was more sensitive to 
neutralization compared to JFH1WT, with the IC50 values ranging from 12- to 30- fold 
lower for CBH-5 and strikingly 3 to 4 log lower for HC-11 (Figure 3.7A and B; Table 3.1). 
Together, these findings indicate that these E2 mutations enhance the exposure of 
neutralizing epitopes on the virion glycoproteins. 
 
 
3.5. E2 Mutations Alter Virus-Receptor Interactions 
Grove and colleagues reported that the E2 cell culture adaptive mutation G451R altered the 
affinity of virions to CD81 and SRB1. A similar phenotype was also observed for delta 
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HVR1 virions (Bankwitz et al., 2010). To establish whether the N415D, T416A, N417S 
and I422L mutations altered the affinity of glycoproteins for the virus receptor CD81, a 
competition assay using the hCD81-LEL was performed. This protein has been shown to 
interact with the E2 glycoprotein and inhibit HCV infection (Bartosch et al., 2003). 
Viruses were incubated with various concentrations of hCD81-LEL for 1 h prior to 
infecting target cells. All four mutant viruses showed increased sensitivity to neutralization 
by hCD81-LEL (Figure 3.8A). To investigate if this was due to a change in the binding of 
the E2 mutant glycoproteins to CD81, their reactivity to hCD81-LEL was determined by 
ELISA. The viral glycoproteins used in this assay were obtained from cell lysates 
harvested at 72 h post-electroporation. Interestingly, despite the similar inhibition pattern 
of each E2 mutant virus by hCD81-LEL, their intracellular glycoproteins showed 
dissimilar levels of binding to hCD81-LEL by ELISA. Mutations N415D, T416A and 
N417S enhanced hCD81-LEL binding in a dose-dependent fashion (Appendix 4), by 38%, 
106% and 64%, respectively (Figure 3.8B). In contrast, the I422L mutation bound hCD81-
LEL with comparable affinity to JFH1WT E2 (Figure 3.8B and Appendix 4). A potential 
explanation for this difference between hCD81-LEL neutralization and binding is that each 
E2 mutation causes a local change to occur during the virion assembly process leading to a 
better exposure of the CD81-binding region and therefore enhanced neutralization. Given 
the increased sensitivity of the E2 mutant viruses to neutralization by the soluble form of 
CD81, one would expect these viruses to be less prone to inhibition by antibodies blocking 
this receptor. To test this, naïve cells were incubated with anti-CD81 mAb prior to 
infection with each virus. Surprisingly, no differences in inhibition were observed for the 
E2 mutant viruses compared to JFH1WT (Figure 3.8C). This may be explained by the high 
affinity of the anti-CD81 mAb simply masking any interaction differences that exist 
between the JFH1WT and E2 mutant virions with cellular CD81.  
 
Having established that these mutations influence the HCV-CD81 interaction, it was next 
investigated whether these mutations have an effect on SR-BI-dependent entry. Naïve cells 
were pre-incubated with different concentrations of a neutralizing anti-SRBI rat serum 
(Zeisel et al., 2007) prior to infection with each virus. Interestingly, all mutants were less 
sensitive than JFH1WT to neutralization by this antiserum with IC50 values 5- to 28-fold 
higher (Figure 3.9A and Table 3.1). It has been shown that HDL, which is a SR-BI ligand, 
enhances HCV entry through a process that requires the lipid transfer function of SR-BI 
(Bartosch et al., 2005; Voisset et al., 2005). To follow up on this observation, the effect of 
HDL on mutant virus infection was tested. Naïve Huh-7 J20 cells were pre-incubated with 
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lipoprotein-deficient fetal calf serum, prior to infection in the presence or absence of HDL. 
As shown in Figure 3.9B, while the infectivity of JFH1WT was significantly enhanced, the 
E2 mutants appeared insensitive to HDL treatment. Together, these data suggest that each 
adaptive mutation alters HDL/SR-BI-mediated uptake of the virus during entry. One 
explanation for these results is that these E2 mutant viruses have a reduced SRB1 
dependency for viral entry. To test this, two siRNAs targeting different regions of SR-BI 
mRNA were transfected into Huh-7 cells to silence its expression. At the time of infection, 
these cells expressed 99% less SR-BI mRNA whilst maintaining 80% of the control cell 
viability (Figure 3.10A). The knockdown of cell-surface expressed SR-BI was also 
confirmed by FACS analysis (Figure 3.10C). Under these conditions, the infectivity of all 
viruses was inhibited by 94%-98%, showing the E2 mutant viruses still require sufficient 
expression of SR-BI for infection (Figure 3.10B). Similarly, efficient knock down of CD81 
(Figure 3.11A and C) reduced the infectivity of all viruses (Figure 3.11B). These results 
indicate that despite the E2 mutations modulating the interactions of the virus with CD81 
and SRB1, the expression of these receptors on the cell surface is still necessary for the 
mutant virions to infect target cells. 
 
 
3.6. Bouyant Density of Infectious JFH1N415D Virions  
Numerous reports have shown that both serum- and cell-culture-derived HCV is tightly 
associated with LDL and VLDL. In vivo, these associations protect HCV from the humoral 
immune response by shielding the glycoproteins from circulating nAbs (Bartenschlager et 
al., 2011). In line with this, low-density HCVcc shows reduced sensitivity to neutralization 
by HCV patient IgG (Grove et al., 2008). Thus, particle density can be used as an indirect 
measure of lipoprotein interaction. Previously, it was shown that the G451R mutation 
altered the relationship between buoyant density and infectivity, with high density mutant 
virus demonstrating greater infectivity than WT (Grove et al., 2008; Zhong et al., 2006). 
To investigate whether cell culture adaptive mutations within the conserved 412-423 E2 
region caused similar alterations to infectious virion density, iodixanol density gradient 
ultracentrifugation was performed on JFH1N415D alongside JFH1WT. Iodixanol was 
employed to form the gradients as it has been proven to preserve HCV-LDL/VLDL 
associations (Nielsen et al., 2006). Consistent with previous reports (Gastaminza et al., 
2006) the buoyant density of JFH1WT was distributed over a broad range with the peak 
infectivity between fractions 5 and 7 (1.06-1.11 g/ml) (Figure 3.12). In contrast, the peak 
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infectivity of JFH1N415D was located between fractions 6 and 8 resulting in a rightward 
shift in the mean density of the virus. These results may suggest that the mutant virions 
contain less lipoproteins. 
 
 
3.7. Infectivity and Neutralization Profiling in HCVpp 
System 
Next, the effect of these E2 mutations on virus infectivity and neutralization was tested in 
the HCVpp system. To do this, HCVpps carrying the JFH1 glycoproteins with and without 
the E2 mutations were generated (see materials and methods). In contrast to the JFH1 
HCVcc results, a notable reduction was observed in the infectivity of HCVpp carrying the 
same mutations (Figure 3.13A). Nevertheless, neutralization assays using mAbs AP33 
(Figure 3.14A) and CBH-5 (Figure 3.14B) showed IC50 values very similar to those 
obtained in the HCVcc system (Table 3.1).  These data further support the hypothesis that 
the mutations located between residues 412-423 of E2 may alter its conformation on the 
virus particle. E2 GNA-capture ELISA confirmed that the WT and the mutant E2 were 
expressed in comparable quantities (Appendix 5), and the mutations had no affect on the 
E2 incorporation into HCVpps as shown by immunoblot performed on pelleted supernatant 
from HCVpp infected cells (Figure 3.13B). Thus, the reasons for the lower infectivity of 
mutant HCVpps are not clear. Other studies have demonstrated differences in some HCV 
envelope protein functions when the HCVpp and HCVcc systems were compared (Grove 
et al., 2008; Johansson et al., 2007; Sainz et al., 2009). It is conceivable that the former 
being a surrogate system may not always mimic the authentic virus in terms of 
glycoprotein presentation and function. Furthermore, HCVpp purely measure virus entry, 
excluding complications such as virus spread and RNA replication that exist within the 
HCVcc system when measuring virus infectivity. Therefore, direct comparisons in 
infectivity between these two systems are not always appropriate.  
 
 
3.8. Discussion 
In this section a number of key residues were identified in a conserved region of the E2 
glycoprotein that determines the viral glycoprotein interaction(s) with cellular receptors 
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and nAbs. This region, located between amino acids 412-423, carries residues that are 
critical for recognition of two broadly nAbs used in this study, mAbs AP33 and 3/11. Two 
of the four JFH1 E2 mutations (N415D and N417S) described in this study abrogated E2 
reactivity to, and virus neutralization by, mAbs AP33 and 3/11, while T416A and I422L 
displayed enhanced neutralization sensitivity. 
 
The AP33 escape mutant N415D arose spontaneously during cell culture passaging. In the 
HCVpp system, alanine replacement of the residue N415 in the HCV genotype 1a H77 E2 
drastically reduced mAb AP33 and 3/11 binding and completely abrogated infectivity 
(Owsianka et al., 2006; Tarr et al., 2006). In addition Gal-Tanamy and colleagues 
described an AP33 escape mutant, N415Y, selected in genotype 1a/2a chimeric HCVcc 
following repetitive rounds of antibody neutralization and amplification in cell culture 
(Gal-Tanamy et al., 2008). The N415Y mutation alone severely attenuated mAb AP33 and 
3/11 recognition and neutralization, but it did not enhance sensitivity to neutralization by 
other human anti-E2 mAbs. Furthermore the N415Y substantially reduced viral fitness, 
while having no major effect on CD81 binding. In contrast the N415D mutation showed 
enhanced affinity to hCD81-LEL, maintained viral fitness and displayed enhanced 
sensitivity to other human anti E2 mAbs. Interestingly, a recent study identified the N415D 
as a compensatory mutation that restored the infectivity of Jc1 virus lacking the HVR1 
region (McCaffrey et al., 2011). However, it remains to be determined whether this 
mutation rescues infectious particle assembly or entry of the JFH1ΔHVR1 virus. 
 
Bungyoku and colleagues previously showed that the E2 T416A mutation in a chimeric 
J6/JFH1 HCVcc background does not alter virus infectivity in Huh-7.5 cells (Bungyoku et 
al., 2009).  In accordance with these data, no significant affect to JFH1T416A infectivity was 
observed in the present study. It was previously shown that the T416A mutation in the 
genotype 1a HCVpp system moderately reduced mAb AP33 and 3/11 recognition (Tarr et 
al., 2006), enhanced CD81-binding, and abrogated virus infectivity (Owsianka et al., 
2006). In contrast, the present study found that this same mutation in HCVcc enhanced E2 
reactivity to mAbs AP33 and 3/11 and did not alter virus infectivity. Together, the different 
infection system, viral isolates and/or cell lines used in each study likely account for these 
inconsistencies.  
 
Russell and colleagues identified the N417S mutation during cell culture passaging of 
JFH1 virus in Huh-7.5 cells (Russell et al., 2008). This single mutation did not alter 
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HCVcc infectivity but reduced HCVpp infectivity by 90% (Russell et al., 2008). These 
results are consistent with the HCVcc and HCVpp infectivity data obtained for this 
mutation in the present study. The reasons for the lower infectivity of N417S mutant in 
HCVpps are not clear. Several studies have demonstrated functional differences between 
HCVpp and HCVcc. It is conceivable that the former being a surrogate system maynot 
always mimic the authentic virus in terms of glycoprotein presentation and function. 
Furthermore, HCVpp purely measure virus entry, excluding complications such as virus 
spread and RNA replication that exist within the HCVcc system when measuring virus 
infectivity. Therefore, direct comparisons in infectivity between these two systems are not 
always appropriate. This point is further strengthened by the observation that the G451R 
adaptive mutation, which enhances HCVcc infection, renders HCVpps noninfectious 
(Grove et al., 2008). Previous reports have also shown that alanine replacement of the 
residue N417 in the HCV genotype 1a H77 E2 reduced HCVpp infectivity by ~90% 
(Owsianka et al., 2006). Furthermore, this mutation reduced the E2 binding of mAbs AP33 
and 3/11 by ~60% and 40%, respectively (Tarr et al., 2006). In line with these results, the 
N417S mutation in this study was found substantially reduce AP33 and 3/11 binding, 
rendering JFH1N417S HCVcc resistant to neutralization by either antibody and highlighting 
the contribution of N417 to their binding sites on E2. 
 
The I422L mutation was first isolated alongside other structural and nonstructural 
mutations after several rounds of JFH1 passaging in Huh-7.5 cells and was shown not to 
alter virus infectivity (Kaul et al., 2007), which is in agreement with the present findings in 
Huh-7 cells. Consistent with previous findings for I422A in the genotype 1a HCVpp 
system (Tarr et al., 2006), this mutation did not affect E2 recognition by mAbs AP33 and 
3/11, confirming that I422 is not a critical contact residue in E2 for either antibody.  
 
In the present study substitutions N415D, T416A and N417S resulted in increased E2-
CD81 binding, whereas the I422L mutation caused no alteration to CD81 binding. 
However, each mutant virus exhibited a similar heightened sensitivity to neutralization by 
hCD81-LEL, suggesting an increased affinity of the mutated glycoproteins for CD81. One 
theory that may explain these discrepancies is that each mutation causes structural 
alterations to the virion glycoproteins that result in the enhanced exposure of the CD81 
binding epitope. The heightened inhibition of these mutants by a range of human anti-HCV 
glycoprotein antibodies (and by the anti-E2 rodent mAbs AP33 and 3/11 in the case of 
mutants T416A and I422L) supports this theory. Under these circumstances, the 
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differences in E2-CD81 binding observed by ELISA may be simply be masked by an 
improved ratio of virion E2 to hCD81-LEL in the neutralization assay.  
 
The reduced sensitivity of these mutants to inhibition by the anti-SR-BI antibody was an 
unexpected result. In keeping with these observations, we found that all the mutants 
studied here were insensitive to HDL-mediated enhancement of virus infection. The exact 
mechanism by which the HDL-SR-BI association facilitates HCV entry is currently 
unknown. Although no interaction between HDL and HCVpp particles has been 
demonstrated in culture medium, the possibility of an association occurring at a post-
binding stage cannot be discounted (Voisset et al., 2005). More importantly, the binding of 
HDL to HCVcc virions has yet to be investigated. Also, it has been postulated that the lipid 
transfer events resulting from HDL-SR-BI binding, known to be essential for regulating 
the properties of cells membranes, may affect the fusion efficiency of the HCV envelope 
with cell membranes (Voisset et al., 2005). SR-BI was first identified as a putative HCV 
receptor based on its ability to bind soluble, truncated E2 (sE2) via HVR1 (Scarselli et al., 
2002). However, sE2 may not fully mimic E2 structures on the HCV virion (Clayton et al., 
2002) and an interaction between SR-BI and the E1E2 heterodimers has yet to be 
confirmed. In addition, the initial binding of serum HCV to SR-BI was found not to be 
mediated by HVR-1 or indeed other regions of the E2 glycoprotein. Instead, the 
association of VLDL to virus particles appeared to play a critical role in the primary 
interaction with SR-BI (Maillard et al., 2006). Thus, there is much uncertainty as to how 
HCV utilizes this receptor during virus entry. In the absence of definitive assays that can 
measure an interaction between SR-BI with full-length E1E2 or indeed HCVcc virions, it 
is difficult to decipher the effects caused by these E2 mutations to the entry process via this 
receptor. However, the siRNA knockdown experiment shows that SR-BI is not dispensable 
for the mutant virus entry.   
 
The heightened sensitivity observed to several anti-HCV envelope glycoprotein nAbs 
could be due to several reasons. The mutant viruses secrete fewer non infectious particles 
and thereby may increase the ratio of nAbs to infectious virus compared to JFH1WT. 
However all mutants display similar level of neutralization profile with different nAbs 
while a dissimilarity exists in specific infectivity of mutants. Therefore increased specific 
infectivity is unlikely to be the cause of enhanced neutralization sensitivity. The HCV 
envelope glycoproteins are highly N-glycosylated. These N-linked glycans are believed to 
mask the important antibody binding epitopes on the virion surface and removal of some of 
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these glycans have shown to enhance HCVpp and HCVcc antibody-mediated 
neutralization (Falkowska et al., 2007; Helle et al., 2007; Helle et al., 2010). The residue 
N417 is part of an N-linked glycosylation site, the removal of which from genotype 1a E2 
(N417Q) has been shown to increase the sensitivity of HCVpp to antibody neutralization 
and to increase CD81 binding (Helle et al., 2007; Owsianka et al., 2006). The latter 
observations are also in keeping with our findings. Our data show that the molecular 
weight of the genotype 2a E2 N417S mutant is identical to the WT glycoprotein; however, 
it would be inappropriate to conclude on this basis that this site is not used for 
glycosylation. This is because the N417S change potentially creates a new N-glycosylation 
site over positions 415-417 (i.e. a change from NTN to NTS), which, if utilized, will not 
alter the migration of the mutant E2 in SDS-PAGE. Therefore, it is unlikely that the effect 
of the N417S mutation on the exposure of the virion glycoproteins is due to a glycan loss. 
 
The most likely explanation is that these mutations may induce global conformational 
changes on to the E2 glycoprotein and as a result the antibody binding epitopes on the 
virion surface may be more exposed. Gradient density data performed on JFH1N415D 
suggest that this could be likely due to reduced lipoprotein content associated with viral 
particle. In line with this theory, the E2 cell culture adaptive mutation I414T reduced the 
lipoprotein content of HCVcc virions that were more sensitivity to neutralization by anti-
E2 antibodies (Tao et al., 2009). The authors speculated that the reduced lipoprotein 
content of the virions could result in the increased exposure of the glycoproteins, making 
them more accessible for binding by anti-E2 nAbs. Further experiments are necessary to 
determine if the E2 mutant virions examined in the present study have less lipoproteins. 
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Figure 3.1. Cell Culture Adaptive Mutations Located in the E2 Glycoprotein 
 
(A) Identification of a spontaneous mutation within E2. Huh-7 cells were infected 
with the JFH1WT virus at an m.o.i of 0.05 and serially passaged nine times. At each 
cell passage (CP) virus released into the medium was titrated by TCID50 assay. 
Similarly, virus generated at CP 9 was used to infect naïve Huh-7 cells and the 
resulting infectious yield in the medium was measured as represented by the black bar 
(SP). (B) Percentage of NS5A positive cells were counted between CP 2-9. The 
passages where cytopathic effects (CPE) were observed are indicated. (C) The 
location of spontaneous mutations within the E2 glycoprotein residue 412-423 
identified here and in other studies. The arrows denote amino acid substitution.  
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Figure 3.2. Replication Levels of E2 Mutants 
 
Huh-7 cells were electroporated with JFH1WT and E2 mutant virus RNAs. At 24, 48 
and 72 h post-incubation the released infectious virus in the medium (A) and the 
intracellular RNA (B) were quantified by TCID50 and RT-qPCR, respectively. Means 
and error ranges of two independent experiments are given. (C) Huh-7 cells were 
electroporated with viral RNA and at 72 h post-incubation the intracellular (IC) and 
extracellular (EC) virions were harvested and their infectivity quantified by TCID50.  
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Viruses HCV RNA 
copies GE/ml 
Infectious titer 
TCID/ml 
Specific 
Infectivity 
WT 1.1 x 107 2.3 x 104 1:485 
N415D 8.2 x 106 9.6 x 104 1:85 
T416A 2.4 x 106 1.0 x 105 1:23 
N417S 1.1 x 107 1.0 x 105 1:114 
I422L 2.2 x 107 1.0 x 105 1:221 
 
E
Figure 3.3. Infection Kinetics of E2 Mutant Viruses 
 
Huh-7 cells were infected at an m.o.i of 0.1 (A and B) and 1.0 (C and D) with JFH1WT 
and E2 mutant viruses harvested at 72 h post-electroporation. Virus from passage 9 
(sp1), which was used to originally identify the N415D mutation (refer to Fig 1A) was 
also included in the experiment. At 24, 48 and 72 h post-infection virus released in the 
medium (A and C) and intracellular RNA (B and D) was measured by TCID50 and 
RT-qPCR, respectively. Means and error ranges of two independent experiments are 
given. (E) Specific infectivity’s of E2 mutants. Huh-7 cells were infected at an m.o.i 
of 1.0 with the viruses harvested at 72 h post-electroporation. At 72 h post-infection, 
the levels of extracellular infectivity and HCV RNA were quantified by TCID50 and 
RT-qPCR, respectively.  
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Figure 3.4. Intracellular Viral Protein Expression of E2 Mutants 
 
(A) Huh-7 cells were electroporated with JFH1WT and E2 mutant viral RNAs. At 48 h 
post-incubation cells were fixed and probed with anti E2 antibodies CBH-5 and 
AP33. (B) Cell lysates harvested at 72 h post-electroporation were subjected to 
immunoblotting using antibodies against E2 (D3.7 and AP33), NS5A (9E10) and 
tubulin. 
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Figure 3.5. E2 Mutant Binding and Neutralization by mAb AP33  
 
(A) JFH1WT and E2 mutant viruses were pre-incubated for 1 h with different 
concentrations of mAb AP33 before infecting Huh-7 J20 target cells. The level of 
virus inhibition was assayed by quantifying the SEAP activity in the medium. Percent 
neutralization was calculated by quantifying viral infectivity in the presence of mAb 
AP33 relative to infection in the absence of antibody. Error bars represent variability 
of the assay. (B) The levels of JFH1WT or mutant E2 in Huh-7 cells electroporated 
with appropriate viral RNAs were first normalized by measuring their binding to 
CBH-4B (Appendix 1). Normalised lysates were then tested for their reactivity to 
mAb AP33 by GNA capture ELISA and the data is presented as an average of two 
independent experiments (Appendix 2). Reactivity is expressed as percentage of 
binding relative to the JFH1WT.  
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Figure 3.6. E2 Mutant Binding and Neutralization by mAb 3/11 
 
(A) JFH1WT and E2 mutant viruses were pre-incubated for 1 h with different dilution 
of mAb 3/11 before infecting Huh-7 J20 cells. The level of virus inhibition was 
assayed by quantifying the SEAP activity in the medium. Percent neutralization was 
calculated by quantifying viral infectivity in the presence of mAb 3/11 relative to 
infection in the absence of antibody. Error bars represent variability of the assay. (B) 
The levels of JFH1WT or mutant E2 in Huh-7 cells electroporated with appropriate 
viral RNAs were first normalized by measuring their binding to CBH-4B (Appendix 
1). Normalised lysates were then tested for their reactivity to mAb 3/11 by GNA 
capture ELISA and the data is presented as an average of two independent 
experiments (Appendix 3). Reactivity is expressed as percentage of binding relative to 
the JFH1WT.  
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Figure 3.7. Neutralization of E2 Mutant Viruses by Human Anti-Envelope 
Antibodies 
 
JFH1WT and E2 mutant viruses were incubated for 1 h with different amounts of 
human mAbs (A) CBH-5 or (B) HC-11, the HCV-infected patient derived IgGs (C) 
IgG17, (D) IgG19 or (E) IgG 7 or control IgG (F) purified from an uninfected 
individual prior to infecting Huh-7 J20 target cells. The level of virus inhibition was 
measured by quantifying the SEAP activity in the medium. Percent neutralization (A-
E) or percent infectivity (F) was calculated by quantifying viral infectivity in the 
presence of anti-HCV E2 specific antibodies or control IgG relative to infection in the 
absence of antibodies. Error bars represent variability of the assays. 
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Figure 3.8. Effect of E2 Mutations on CD81 Binding 
 
(A) JFH1WT and JFH1 E2 mutant viruses harvested at 72 h post-electroporation were 
incubated with different dilutions of hCD81-LEL for 1 h prior to infecting target cells. 
At 2 days post-infection, virus infectivity was determined by FFU assay. Percent 
neutralisation was calculated by quantifying viral infectivity in the presence of 
hCD81-LEL relative to standard infection. (B) The levels of JFH1WT or mutant E2 in 
Huh-7 cells electroporated with appropriate viral RNAs were first normalized by 
measuring their binding to CBH-4B (Appendix 1). Lysates containing equivalent E2 
levels were assessed for binding to hCD81-LEL by ELISA and the data presented as 
average of two independent experiments (Appendix 4), each performed in triplicate. 
Reactivity is expressed as percentage of binding relative to the JFH1WT. (C) Naïve 
Huh-7 cells were pre-incubated for 1 h with different concentration of anti-CD81 
antibody before infection. Cells were then infected with JFH1WT or mutant viruses for 
48 h and the infectivity levels determined by FFU assay. Percent neutralization was 
calculated by quantifying viral infectivity in the presence of inhibitory antibodies 
relative to standard infection. Error bars indicate variability of the assays. 
AN
eu
tra
lis
at
io
n 
(%
)
10 100 1000
-40
-20
0
20
40
60
80
100
 anti-SRBI serum (reciprocal dilution)
0.0
0.5
1.0
1.5
2.0
2.5
R
el
at
iv
e 
In
fe
ct
iv
ity
B
W
T
N
41
5D
T4
16
A
N
41
7S
I4
22
L
WT 
N415D 
T416A 
N417S 
I422L 
Figure 3.9. E2 Mutants Have an Altered Dependence on SR-BI  
 
(A) Naïve Huh-7 cells were pre-incubated for 1 h with different dilution of anti SRBI 
serum before infection. Cells were then infected with JFH1WT or mutant viruses for 48 
h and the infectivity levels determined by FFU assay. The data are expressed as 
percent neutralization relative to infection with the control rat serum. Error bars 
indicate variability of the assays. (B) Huh7-J20 cells were infected with JFH1WT or 
mutant viruses in the presence (gray bars) or absence of HDL (black bars) and virus 
infectivity determined by SEAP assay as described in Methods. Error bars represent 
variability of the assays. 
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Figure 3.10. Effect of SR-BI Gene Silencing on E2 Mutant Virus Infection
 
Huh-7 cells were transfected with control siRNAs or siRNAs targeting SR-BI gene. 
(A) At 48 h post-transfection, the cell viability (grey bar) and mRNA expression 
levels (black bar) of SR-BI were measured by ELISA and RT-qPCR, respectively. (C) 
The expression of SR-BI on the surface of Huh-7 cells transfected with control 
siRNAs (left panel) or receptor-specific siRNAs (right panel) was determined by 
FACS. Solid and broken lines represent cells stained with anti-SR-BI antibody and 
IgG subtype control, respectively. (B) In parallel, the control siRNA-transfected Huh-
7 cells (black bars) or the SR-BI knockout cells (grey bars) were infected with 
JFH1WT or mutant viruses and the intracellular HCV RNA levels measured by qRT-
PCR to quantify infectivity. Error bars represent variability of the assays. 
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Figure 3.11. Effect of CD81 Gene Silencing on E2 Mutant Virus Infection 
 
Huh-7 cells were transfected with control siRNAs or siRNAs targeting CD81 gene. 
(A) At 48 h post-transfection, the cell viability (grey bar) and mRNA expression 
levels (black bar) of CD81 were measured by ELISA and RT-qPCR, respectively. (C) 
The expression of CD81 on the surface of Huh-7 cells transfected with control 
siRNAs (left panel) or receptor-specific siRNAs (right panel) was determined by 
FACS. Solid and broken lines represent cells stained with anti-CD81 antibody and 
IgG subtype control, respectively. (B) In parallel, the control siRNA-transfected Huh-
7 cells (black bars) or the CD81 knockout cells (grey bars) were infected with JFH1WT 
or mutant viruses and the intracellular HCV RNA levels measured by qRT-PCR to 
quantify infectivity. Error bars represent variability of the assays. 
WT 
N415D 
1.0
1
1.0
3
1.0
5
1.0
7
1.0
8
1.1
0
1.1
1
1.1
2
1.1
4
1.1
6
1.1
8
Density (g/ml)
0
10
20
30
40
%
 In
fe
ct
iv
ity
50
Figure 3.12. Buoyant Density of JFH1N415D 
 
Concentrated culture medium from JFH1WT and JFH1N415D electroporated cells was 
fractionated using 10-40% iodixanol density-gradient centrifugation. For each 
fraction, the amount of infectivity was determined by FFU assay. The average density 
measured at each fraction is plotted on the X-axis. 
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Figure 3.13. E2 Mutants Characterization in the HCVpp System 
 
(A) HCVpp bearing JFH1WT E2 or mutant JFH1 E2 was generated in HEK-293T cells 
co-transfected with HIV gag-pol and luciferase reporter gene. At 48 h post-incubation 
the medium containing HCVpp was harvested and used to infect naïve Huh-7 cells. At 
48 h post-infection the luciferase activity in the cell lysates was measured and the 
values are expressed as percentage infectivity relative to the JFH1WT E2 levels. Means 
and error range represents average of two independent experiments. (B) HCVpp 
harvested at 48 h post transfection was pelleted through a 20 % sucrose cushion, lysed 
and used for immunoblotting to detect virion E2 using an anti-E2 mAb D3.7 and 
MLV gag proteins using a gag-specific mAb.  
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Figure 3.14. Further Characterization of E2 Mutant in the HCVpp System 
 
HCVpp bearing JFH1WT E2 or JFH1 mutant E2 were first normalised with respect to 
their infectivity (luciferase reading) values and then mixed with mAbs AP33 (A) or 
CBH-5 (B) 1 h prior to infecting Huh-7 cells. Virus infectivity was measured 3 d post-
infection by quantifying luciferase activity. Percent neutralization was calculated by 
quantifying viral infectivity in the presence of anti-E2 specific mAbs relative to 
infection in the absence of mAbs. Error bars represent variability of the assays.  
Table 3.1. IC50 values (μg/ml) of hCD81-LEL and inhibitory antibodies for each 
virus.  
Inhibitors WT N415D T416A N417S I422L 
hCD81-
LEL 
>50 4.4 3.4 3.7 3 
anti-CD81 0.12 0.1 0.13 0.07 0.13 
anti-SR-BI 1:560 1:40 1:25 <1:20 1:100 
IgG7 >20 0.39 0.96 0.81 0.9 
IgG17 12.11 0.2 0.3 0.66 0.3 
IgG19 22 1.1 1.3 1.4 2.5 
CBH-5 0.6 0.02 0.02 0.05 0.035 
AP33 1.5 NN 0.06 NN 0.12 
HC11 7.0 0.001 0.0003 0.004 0.002 
3/11 44.9 NN 4.1 NN 7.12 
AP33  
(HCVpp) 
1.0 NN 0.01 NN 0.02 
CBH-5 
(HCVpp) 
2.3 0.01 0.016 0.03 0.036 
 
NN = Non-neutralizable 
ND = Not done 
Anti-SR-BI IC50 values are represented as serum dilutions 
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4.1. Introduction 
Until recently, studies on the HCV lifecycle have been limited due to the lack of a robust 
cell culture system for propagating the virus. Before HCVcc was available, the HCVpp 
system was the primary model used for characterizing the early HCV infection steps, 
involving virus binding and utilisation of cellular receptors for entry into host cells. The 
HCVpp system has been an invaluable tool for dissecting the role of the HCV E1E2 
glycoproteins in viral entry and furthermore in measuring the neutralizing capacity of anti-
E1E2 antibodies to prevent infection of target cells (Bartosch et al., 2003; Drummer et al., 
2003; Hsu et al., 2003). HCV exhibits high genetic variability, particularly in the E1 and 
E2 glycoprotein region of the HCV genome. Infectious HCVpp bearing the envelope 
glycoproteins of all HCV genotypes have been generated (Broering et al., 2009; Lavillette 
et al., 2005b; Law et al., 2008). Studies using HCVpp of different genotypes have 
confirmed that all viruses require the expression of cell surface receptors CD81, SR-BI 
(Lavillette et al., 2005b) and tight junction proteins CLDN-1 (Evans et al., 2007; Fofana et 
al., 2010; Meertens et al., 2008) and OCLN (Ploss et al., 2009) for entry. In addition, the 
HCVpp from all genotypes can be neutralized by patient serum and a panel of anti-E1E2 
antibodies (Johansson et al., 2007; Keck et al., 2009; Keck et al., 2007; Lavillette et al., 
2005b; Law et al., 2008; Owsianka et al., 2005; Perotti et al., 2008). HCVcc is a more 
desirable system to study the different aspects of virus entry and antibody-mediated 
neutralization given that it produces authentic infectious virus particles. The HCVcc 
system is based on the genotype 2a HCV strain JFH1, cloned from an individual with 
fulminant hepatitis. The key limitation with this system is that the JFH1 clone only 
represents one of the seven HCV genotypes. Therefore, comparative studies on the effect 
of genetic variability on different stages of the life cycle, as well as the, development and 
evaluation of anti-viral strategies is not possible with this system.  
 
With the aim of studying HCVcc entry from different HCV genotypes, 5 chimeric 
genomes were constructed by substituting the JFH1 E1E2 sequences with those from 
different patient isolates that represented genotypes 1, 2, 3, 5 and 6. While all chimeric 
genomes could replicate efficiently post-electroporation, none were able to assemble and 
release infectious virus particles. In addition, work was continued on a previously 
generated chimeric clone harbouring the JFH1 NS3-NS5B fused to the core-NS2 region of 
a genotype 4 isolate, ED43. The ED43/JFH1 viral RNA replicated efficiently post-
electroporation, but was unable to produce sufficient infectious virus titers for 
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experimental purposes. The long-term culture of cells replicating ED43/JFH1 substantially 
improved the infectivity of this virus due to the selection of several cell-culture adaptive 
mutations in various regions of the genome. Introducing these mutations into the original 
ED43/JFH1 genome dramatically improved infectious virus production to levels 
comparable to JFH1WT, post-electroporation. The cell-culture adapted ED43/JFH1 was 
then characterized alongside WT virus to compare its CD81 receptor dependency during 
virus entry, the ability of several anti-E2 nAbs to inhibit its infection and the ability of this 
virus to spread via cell-to-cell transfer. 
 
 
4.2. Generation of E1E2/JFH1 Chimeric Genomes 
Full length E1E2 sequences extracted from patients infected with diverse HCV genotypes 
and subtypes were cloned into the pcDNA3.1 V5-DTOPO mammalian expression vector. 
Due to the absence of unique enzyme recognition sites around the region of interest within 
the pcDNA3.1 vector, it was not feasible to use the simple digestion and ligation method 
for cloning. Therefore, an overlap extension strategy was applied to generate the chimeric 
viruses. Primers were first designed to generate three fragments with overlapping 
overhangs (Figure 4.1). Two fragments in pUC JFH1 (fragment 1 and 3) and one fragment 
(fragment 2) in the pcDNA3.1 was then PCR amplified and fused together. Subsequently, 
the fusion product was amplified by PCR (Figure 4.2). The sequences of fragments 1 and 3 
contain unique FspAI and NotI enzyme recognition sites located in the JFH1 core and NS2 
genes, respectively. For constructing the 2a2.5, 3A1.28 and 6.5.340 clones, the amplified 
fusion product was digested with FspAI and NotI. The 1B12.6 and 5.15.7 fusion product 
sequences contained additional FspAI and NotI restriction sites. Therefore, these products 
were digested with the AgeI and KpnI enzymes, which have unique cutting sites located in 
the JFH1 5’UTR and NS2, respectively. Each digested fragment was then subcloned into 
the pJFH1 backbone cleaved with the appropriate restriction enzymes. The proper 
incorporation of inserts into the pJFH1 template was verified by diagnostic digestion and 
further confirmed by sequence analysis. 
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4.3. Charactersiation of E1E2/JFH1 Chimeras 
All the chosen E1E2 sequences were fully functional in the HCVpp system (Owsianka et 
al., 2005), except 2A2.5 (Dr Ania Owsianka, personnal communication). To determine the 
viability of the generated E1E2/JFH1 chimeras in the HCVcc system, Huh-7 cells were 
first electroporated with JFH1WT and the E1E2/JFH1 chimeric in vitro transcribed viral 
RNAs. JFH1∆E1E2 was included as a replication competent but non-infectious virus control 
(Wakita et al., 2005) and JFH1GND, as the replication-deficient control. At 72 h post-
incubation, the protein expression and virus release levels of each chimera was then tested. 
To do this, cells were fixed for IF analysis and lysed for immunoblotting, whereas the cell 
medium was titrated for infectivity and lysed for qRT-PCR assay. All E1E2 chimeras were 
replication competent, like JFH1WT, as seen by the intracellular expression of E2 and 
NS5A protein by IF (Figure 4.3A) and core protein by immunoblotting (Figure 4.3B). As 
expected no E2 protein expression was observed for JFH1∆E1E2 and JFH1GND was 
completely incapable of replication. However, apart from JFH1WT, none of the clones 
tested were capable of producing extracellular or intracellular infectious particles. 
Concomitantly, the relative extracellular HCV RNA levels for all chimeras were lower 
than the levels of JFH1∆E1E2 virus (Figure 4.3B).  
 
To further establish if functional clones could be selected for during long term passaging, 
electroporated cells were passaged serially every 5-6 days for a total of 4 months. At every 
passage cells were tested by IF for NS5A expression and the cell medium was titrated for 
infectious particles. Although positive cells supporting replication could be detected up to 
passage number 4, none of the viruses were able to release infectious particles into the 
medium. Collectively these results suggest that replacing the E1E2 proteins in JFH1 may 
not be suffice to generate fully functional chimeric clones. It is possible that the presence 
of the foreign glycoprotein sequences may prevent proper E2/p7 and p7/NS2 cleavage 
during the processing of the HCV polyprotein, which in turn prevents virion assembly 
occurring. It would be interesting to test if supplying the JFH1 glycoproteins into the cells 
replicating the E1/E2 chimeric genomes could rescue their infectivity. Indeed, such an 
approach proved effective for virus harboring a defective NS2 protein (Yi et al., 2009). 
Recently published papers on chimeric viruses viable in the HCVcc system demonstrate 
that cloning the entire structural region from core-p7 together with the homologoues NS2 
protein is necessary to obtain infectious chimeric viruses (Gottwein et al., 2009; 
Pietschmann et al., 2006; Scheel et al., 2008). Some studies have gone a step further and 
have pinned down the exact NS2 junction essential to generate fully viable JFH1 based 
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chimeric viruses (Pietschmann et al., 2006; Scheel et al., 2008). Due to lack of access to 
the rest of the genome from these clones it was not possible to apply the aforementioned 
strategy to generate chimeras incorporating the core-NS2 region in the JFH1 backbone 
from these particular genotypes.  
 
 
4.4. Generation of an Infectious Genotype 4a/JFH1 
Chimeric virus 
Sequences obtained from the genotype 4a reference strain, ED43 (Chamberlain et al., 
1997) were used to generate a genotype 4a/JFH1 chimera by replacing the core to NS2 
region of JFH1 with the analogous region of ED43 (Figure 4.4A). The cloning procedure 
used to generate this chimeric virus was performed by Dr Michaela Iro at the MRC 
Virology Unit. Preliminary studies indicated that post-electroporation, this chimeric 
genome was replication competent but generated very low quantities of infectious virus. 
The following section extended the characterization of this previously generated chimera.  
 
Following electroporation, the 4a/JFH1 viral RNA was replication competent, as seen by 
the intracellular expression of NS5A at 72 h post-incubation (Figure 4.5A). However, its 
ability to produce infectious virus particles was greatly reduced (6.81 TCID50/ml) as 
compared to JFH1WT (4.64 x 105 TCID50/ml) (Figure 4.5A). Previous studies have reported 
that for efficient virus production, certain chimeras depend on several cell-culture adaptive 
mutations that are selected during long-term culture (Gottwein et al., 2007; Gottwein et al., 
2009; Scheel et al., 2008; Yi et al., 2007). In an attempt to adapt the 4a/JFH1 chimera and 
improve its infectivity, Huh-7 cells electroporated with viral RNA were subjected to 
several cell passages (P1, P2, P3 etc.) and supernatant passages (I1PX and I2PX) (Figure 
4.4B). The first supernatant passage or infection is noted I1 with the corresponding 
passages and the second infection I2. The level of replication was determined at each 
passage by staining cells for NS5A as well as measuring the levels of infectivity in the 
culture medium by limiting dilution assay. As depicted in figure 4.5A, the long-term 
passaging of 4a/JFH1 resulted in a ~100-fold increase in virus production. Based on the 
previous studies, the large increase in 4a/JFH1 infectivity was likely due to the selection of 
cell culture adaptive mutations. To identify the mutation(s) responsible for this changed 
phenotype, RNA harvested from I2P3 and I2P5 was RT-PCR amplified, and the population 
was sequenced over the core to NS5A region. In total, six nonsynonymous mutations were 
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detected at both passages, three of which were clustered within the NS2 region and one 
each within the E2, NS3 and NS5A proteins (Figure 4.5B). All the six changes were 
introduced into the parental 4a/JFH1 genome and the viability of the resulting virus, 
designated Ad4a/JFH1, was tested in Huh-7 cells.  
 
 
4.5. Replication Properties of Ad4a/JFH1  
The intracellular RNA and virus infectivity of JFH1WT and Ad4a/JFH1 was measured from 
electroporated cells at 24, 48 and 72 h post-incubation. In parallel, cells were lysed at 72 h 
post-electroporation for immunoblotting against the viral core and E2 proteins. The 
Ad4a/JFH1 displayed virus production level 32-, 7- and 6-fold lower than JFH1WT at 24, 
48 and 72 h, respectively (Figure 4.6A). In contrast, the intracellular HCV RNA levels 
observed for Ad4a/JFH1 were very similar to WT at each time point (Figure 4.6B). In line 
with this, similar levels of intracellular core and E2 protein expression were observed for 
Ad4a/JFH1 and JFH1WT, at 72 h post-electroporation (Figure 4.6C). Next, the infectivity 
and replication efficiency of Ad4a/JFH1 virus particles released from electroporated cells 
was determined. To do this, naive Huh-7 cells were inoculated at an equal multiplicity of 
infection (m.o.i) with virus obtained at 72 h post-electroporation. The released virus 
production in the medium and the level of intracellular replication were determined at 24, 
48 and 72 h post-infection. As determined by the TCID50 assay, the infectivity titers of 
Ad4a/JFH1 were lower than JFH1WT at each time point with values 2-, 3- and 20-fold 
lower at 24 and 48 and 72 h, respectively (Figure 4.7A). Also, the intracellular RNA levels 
of Ad4a/JFH1 were 9-, 3- and 2-fold lower at 24, 48 and 72 h compared to JFH1WT (Figure 
4.7B). It is interesting to note that at the 24 h timepoint Ad4a/JFH1 virus production is 
similar to JFH1WT, yet its intracellular RNA levels are much lower. This could indicate that 
Ad4a/JFH1 is more efficient than JFH1WT at producing virions at early timepoints 
following infection. A useful future experiment would be to test the specific infectivity of 
Ad4a/JFH1 virions at these early time points in order to gain better insight into this 
phenotype. Nevertheless, it is fair to say that overall these data suggest Ad4/JFH1 has 
lower replication levels compared to JFH1WT. 
 
 
87 
 
4.6. Ad4a/JFH1 has Reduced CD81 Binding  
To test the dependency of the Ad4a/JFH1 virus for the CD81 receptor, a competition assay 
using the hCD81-LEL was performed. To do this, virus was incubated with hCD81-LEL 
prior to infecting naive Huh-7 cells with virus harvested at 72 h post electroporation. The 
Ada/JFH1 virus showed a slightly decreased sensitivity to neutralization by hCD81-LEL 
with an IC50 value 2-fold higher than JFH1WT (Figure 4.8A). Next, the ability of a 
neutralizing CD81 antibody to inhibit Ad4a/JFH1 infection was tested. Naive Huh-7 cells 
were incubated with CD81 MAb prior to infection with virus harvested at 72 h post 
electroporation. As shown in figure 4.8B the Ad4a/JFH1 virus was more effectively 
neutralized compared to JFH1WT with an IC50 value 2-fold lower. Together, these results 
indicate that the E2-CD81 interaction is slightly lower for Ad4a/JFH1 than JFH1WT. 
 
 
4.7. Ad4a/JFH1 demonstrates an increased sensitivity to 
anti-E2 nAbs 
Next the efficiency of several broadly neutralizing anti-E2 MAbs to block Ad4a/JFH1 
infection was evaluated. Virus harvested at 72 h post-electroporation was incubated with 
Mab AP33, 3/11, CBH-5 or HC-11 prior to infecting target cells. All these antibodies have 
shown to possess broad cross-reactive activity and are thought to inhibit virus infection by 
blocking the E2-CD81 interaction (Keck et al., 2009; Keck et al., 2004; Keck et al., 2007; 
Owsianka et al., 2005; Owsianka et al., 2008; Tarr et al., 2006). The Ad4a/JFH1 chimeric 
virus found to be more sensitive to neutralization by all these antibodies compared to 
JFH1WT with IC50 values 6-, 8-, >8-, and 14-fold lower for AP33, 3/11, CBH-5 and HC11, 
respectively (Figure 4.9). These data indicate that the glycoproteins presented on the 
surface of Ad4a/JFH1 have altered affinities for nAbs targeting conserved linear and 
conformational epitopes on E2.  
 
 
4.8.  Cell-to-Cell Transmission of Ad4a/JFH1 
It has been recently demonstrated that JFH1 as well as a number of intergenotypic and 
intragenotypic chimerics viruses are able to transmit via cell-to-cell, in addition to the cell-
free route (Brimacombe et al., 2011; Timpe et al., 2008; Witteveldt et al., 2009). The cell-
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to-cell transfer efficiency of Ad4a/JFH1 was tested alongside JFH1WT using a previously 
described infectious co-culture assay (Appendix 6) (Brimacombe et al., 2011). To do this, 
Huh-7 cells were electroporated with viral RNA and then labelled with CMFDA diffusion 
dye at 72 h post-incubation. These cells, known as donor cells, were then trypsinized and 
co-cultured with an equal ratio of naïve Huh-7 cells (target cells) in the presence of high 
concentrations of Mab AP33. At 48 h post-incubation, the JFH1WT extracellular infectious 
virus had been efficiently neutralized by AP33 (Figure 4.10A). Nevertheless, FACS 
analysis performed on the cultured cells revealed only a moderate reduction in the number 
of NS5A positive target cells in the presence of AP33 (33.4%) compared to the no 
antibody control (54.3%). This indicates that the majority of JFH1WT virus spreads via cell-
to-cell transmission in cultured cells (Figure 4.10B). The majority of the Ad4a/JFH1 virus 
was also neutralized by MAb AP33 (Figure 4.10A). However, in great contrast to the 
JFH1WT, there were far fewer NS5A positive target cells in the presence of nAb (2.9%) 
compared to the no nAb control (23.5%) (Figure 4.10B). This suggests that this chimeric 
virus is poor at cell-to-cell transfer and relies on cell-free transmission as its predominant 
mode of spread.  
 
 
4.9.  Discussion 
The data from this section indicate that viable intergentoypic HCVcc chimeras cannot be 
generated by replacing the envelope glycoprotein coding sequences of JFH1 with those 
from other genotypes. The E1E2 chimeric genomes could replicate efficiently, however no 
infectious virus production could be detected following electroporation or after several cell 
passages. The process of passaging electroporated cells for long time periods was 
performed in the hope that spontaneous mutations would arise in the viral genomes and 
permit infectious virus production. While this lengthy process failed to adapt the E1E2 
chimeric genomes, it was successful in improving the infectivity of the previously 
constructed 4a/JFH1 chimera. This viral genome was created by replacing the core-NS2 
genes of JFH1 with those from the ED43 sequence and was based on the strategy used by 
Lindenbach and colleagues to generate the highly infectious J6/JFH1 intragenotypic 
chimera (Lindenbach et al., 2005). However, unlike J6/JFH1, the 4a/JFH1 chimera 
required the selection of several nonsynonymous mutations before efficient growth could 
be achieved. Ad4a/JFH1 harbouring the six mutations identified in this study could 
assemble and release moderate quantities of infectious virus over 3 days following 
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electroporation, albeit at lower levels to JFH1WT. As the RNA replication of Ad4a/JFH1 
was comparable to JFH1WT within these cells, this indicates that the lower viral titers of 
this chimera is likely caused by a defect during infectious virus assembly and/or release. In 
contrast, in the infection experiment it was found that Ad4a/JFH1 had lower virus release 
and intracellular RNA replication kinetics. This could be explained by the Ad4a/JFH1 
virions being slower at binding and/or entering target cells via the normal infection route. 
Furthermore, the cell-to-cell transfer assay found that Ad4a/JFH1 was poor at spreading 
via this mode of transmission, which would almost certainly contribute to the reduced 
infection kinetics of this virus. Interestingly, it was found that Ad4a/JFH1 virions had a 
reduced affinity for the CD81 receptor. This may be one reason that might account for the 
lower spreading capacity of this virus as this receptor is required for virus entry via the 
normal infection route as well as cell-to-cell transfer. However, future experiments are 
necessary to determine if the poor cell-to-cell transfer of Ad4a/JFH1 is primarily 
responsible for its poor infection kinetics. One way to confirm this theory would be to 
infect sparsely seeded target cells to limit the cell-to-cell spread of the virus and thereby 
ensuring that the infectious progeny measured in the culture medium would be derived 
from virus spreading mainly via cell-free infection. The Ad4a/JFH1 virions showed a 
heightened sensitivity to neutralization by the four nAbs AP33, 3/11, CBH-5 and HC-11, 
as indicated by the lower IC50 values. Therefore, it is possible that the glycoprotein 
sequence of this particular genotype has a stronger binding affinity for the nAbs compared 
to the JFH1WT sequence. Alternatively, the Ad4a/JFH1 glycoprotein conformation on the 
virion surface may differ somewhat to JFH1WT, such that the neutralizing epitopes are 
more accessible to these nAbs. Further studies will be necessary to distinguish between 
these two possibilities. 
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Figure 4.1. Cloning E1E2/JFH1 Chimeras 
 
Schematic representation of the full length JFH1 plasmid (pUC JFH1) and the 
plasmid that encodes E1E2 of diverse genotypes (pcDNA3.1). To generate each 
chimeric virus two fragments in pUC JFH1 (frag 1 and 3) and one fragment in 
pcDNA3.1 (frag 2) were first PCR amplified and then fused together. The overlapping 
sequence in each fragment is represented by white shading. The location of sense 
(FW) and antisense (RV) primers for each fragment is indicated for each plasmid.  
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Figure 4.2. Illustration of the Fusion PCR Procedure  
 
The 3 fragments were PCR amplified (step 1), fused together to form a fusion product 
(step 2), which was subsequently amplified by PCR (step 3). The nucleotide position 
of fragment 1 and 3 as well as the restriction enzyme used within pUC JFH1 are 
indicated in bold. White shading represents the overlapping sequence in each 
fragment. Black arrows represents the primer location used to PCR amplify the fusion 
product. 
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Figure 4.3. Replication Properties of E1E2/JFH1 Chimeric Genomes. 
 
(A) Huh-7 cells electroporated with the indicated viral RNAs were fixed at 72 h post-
incubation and analysed by confocal microscopy for the intracellular expression of E2 
and NS5A using antibodies AP33 and anti-sheep NS5A, respectively. Bar, 20 µm. (B) 
Huh-7 cells electroporated with viral RNAs as shown were subjected to Western 
immunoblotting at 72 h post-incubation using anti-core mAb C7-50 and an anti-
tubulin mAb. The infectious virus titers (intra- and extracellular) and the genomic 
HCV RNA levels from these samples were assayed by TCID50 and RT-qPCR, 
respectively.  
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Figure 4.4. Organisation of the 4a/JFH1 Genome and its Long-Term Passaging 
in Cell-Culture. 
 
(A) Diagram of the 4a/JFH1 chimeric genome design. (B) Schematic representation of 
the successive rounds of infection performed on 4a/JFH1 to improve its infectivity. 
Huh-7 cells electroporated with 4a/JFH1 viral RNA were subjected to several cell 
passages (P1, P2, P3 etc.) and cell-free passages (I1PX and I2PX). The first cell-free 
passage or infection is noted I1 with the corresponding passages and the second 
infection I2.  
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Figure 4.5. Passaging of 4a/JFH1 Chimeric Virus and Identification of Cell 
Culture Adaptive Mutations 
 
(A) Huh-7 cells electroporated with 4a/JFH1 virus were subjected to several cell 
passages (P0, P1, and so on) and cell free passages (I1 and I2). At 72 h post- incubation 
cells were fixed and probed with anti-NS5A mAb, 9E10. Bar, 20 µm. At 72 h post- 
incubation virus released in the medium was titered using TCID50 assay. (B) Cellular 
RNA from 2nd infection at P3 and P5 were used to amplify and sequence the viral 
genome and six mutations were identified.  
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Figure 4.6. Characterisation of Ad4a/JFH1 Chimera.  
 
(A) Infectious virus production and (B) intracellular HCV RNA replication of 
Ad4a/JFH1 at 24, 48 and 72 h post-electroporation into Huh-7 cells, as determined by 
TCID50 and RT-qPCR, respectively. Means and error ranges from two independent 
experiments are given. (C) Huh-7 cells electroporated with indicated viral RNAs were 
subjected to western immunoblotting at 72 h post-incubation using anti-E2 mAb 
D3.7, anti-core mAb C7-50 and an anti-tubulin mAb. 
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Figure 4.7. Infection Kinetics of Ad4a/JFH1. 
 
Naïve Huh-7 cells were infected with JFH1WT and Ad4a/JFH1 at an m.o.i. of 0.2 
using virus harvetsetd at 72 h post-electroporation. The infectious virus released into 
the medium (A) and the intracellular viral RNA (B) were quantified at 24, 48 and 72 h 
post-infection by TCID50 and RT-qPCR, respectively. Error bars indicate variability 
of the assays. 
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Figure 4.8. Inhibition of Ad4a/JFH1 Infection Using Soluble CD81 Molecule and 
Anti-CD81 Antibody 
 
(A) Virus collected at 72 h post-electroporation was incubated with different amount 
of hCD81-LEL for 1 h prior to infecting Huh-7 J20 target cells. (B) Huh-7 J20 cells 
were preincubated for 1 h with different dilutions of anti-CD81 antibody prior to 
infection with virus. The extracellular SEAP activity was measured 3 days post- 
infection. The level of virus inhibition is expressed as percentage, normalized to the 
no-antibody control. Error bars indicate variability of the assays.  
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Figure 4.9. Inhibition of Ad4a/JFH1 Infection Using Anti-E2 Neutralising 
Antibodies 
 
JFH1WT and Ad4a/JFH1 were incubated for 1 h with different dilutions of mouse 
mAb AP33 (A), rat mAb 3/11 (B) or human mAbs CBH-5 (C) and HC-11 (D) prior to 
infection of Huh-7 J20 cells using virus harvested at 72 h post-electroporation. The 
extracellular SEAP activity was measured 3 days post-infection. The level of virus 
inhibition is expressed as percentage, normalized to the no-antibody control. Error 
bars indicate variability of the assays.  
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Figure 4.10. Cell-to-Cell Transmission of Ad4a/JFH1  
 
(A) Percentage neutralization of extracellular virus in the co-culture medium in the 
presence of 100 μg of mAb AP33. Huh7-J20 cells were infected in triplicate with the 
medium obtained from the co-cultured cells at 48 h post-incubation. The SEAP 
activity present in the cell medium was then determined at 48 h post-infection and the 
percentage neutralization calculated. Values are relative to no nAb control. Means and 
error ranges from duplicate infections are shown. (B) Quantification of HCV 
transmission to co-cultured recipient cells by flow cytometry. (i) Bar graph plotting 
the percentage of infected target cells of all NS5A positive cells recorded for JFH1WT 
and Ad4a/JFH1 in the absence and presence of nAb. Means and error ranges from 
duplicate co-culture assays are shown. (ii) Dot plots representing one measurement 
from each of the duplicate co-culture assays. The lower left quadrant of each dot plot 
represents non-CMFDA labelled, uninfected cells, while the upper left quadrant 
shows uninfected CMFDA labelled cells. The upper right quadrant represents the 
CMFDA labelled donor cell population and the infected recipient target cells are 
shown in the lower right quadrant. The percentage of infected target cells of all NS5A 
positive cells is shown in the lower right quadrant of each dot plot. 
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5.1   Characterisation of E2 Cell Culture Adaptive 
 Mutations 
5.1.1. Summary 
The two main studies described in the results section were each based on the adaptive 
properties of JFH1 that enables persistent viral infection to be established in cell culture. 
The adapted viruses from each section provided useful insights into the viral entry process 
as well as antibody-mediated inhibition of infection by broadly nAbs. The major findings 
from each of these sections are discussed separately below. 
 
 
5.1.2. Characterization of E2 Cell Culture Adaptive Mutations 
5.1.2.1. Viral Evolution during Persistent Infection 
Cell culture adaptation that greatly enhance replication and infectivity of HCV during long 
term cell culture in vitro have been reported by several groups. As shown in Table 5.1, 
adaptive mutations appear to arise most frequently in E2, NS2 and NS5A. The use of 
different cell lines, different viruses and different methods of establishing persistent 
infection may explain the varied locations and number of adaptive mutations observed in 
these studies. Adapted variants have been generated from the serial passage of 
electroporated cells (Russell et al., 2008; Zhong et al., 2006) and infected cells (Bungyoku 
et al., 2009) as well as additional passaging of the infected cell supernatants on naïve cells 
(Delgrange et al., 2007; Kaul et al., 2007; Pokrovskii et al., 2011). Regardless of the 
process employed, these genetic studies have established that adaptive mutation(s) 
significantly enhance viral spread. However, the mechanism exploited by virus to achieve 
this efficiency seems to differ depending on where the mutation is located.  
 
Zhong and colleagues were the first group to identify cell culture adaptations in JFH1 
during persistent infection (Zhong et al., 2006). In this study, the expansion kinetics and 
specific infectivity of virus taken from the day 183 (D183) time point in experiment 1 was 
superior to WT virus, which was due to the selection of the four mutations K74T, G451R, 
M1051T and C2219R. However, the E2 mutation G451R was primarily responsible for 
this phenotype. The infectivity of virus taken from the day 160 (D160) time point from 
experiment 2 was also higher than the WT virus. This virus contained a different set of 
mutations at positions V22A, K74Q, V388P, I414T and L644I. In a later report, the I414T 
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change was found to be the main mutation responsible for the improved infectivity of the 
D160 virus by improving virus secretion (Tao et al., 2009). In contrast to the above 
studies, Delgrange and colleagues reported only a single mutation in E2 (N534K) after 
performing successive infections on naïve cells (Delgrange et al., 2007). Nevertheless, the 
presence of this mutation alone greatly increased virus infectivity. Another study improved 
the infectivity of J6/JFH1 after 27 cell passages post-infection with the WT virus 
(Bungyoku et al., 2009). The adapted virus contained the eight mutations T396A, N534H, 
A712V, Y852H, W879R, F2281L and M2876L. Interestingly, no individual mutation was 
capable of increasing virus infectivity. In a study by Russell and colleagues the effects of 
cell culture adaptive mutations in E2 (N417S), p7 (N765D), NS2 (Q1012R) and NS5A 
(L2175V) were characterized. The presence of all mutations significantly increased 
infectious virus production, for which the p7 and NS2 mutations were partly responsible 
for (Russell et al., 2008). Kaul and colleagues passaged JFH1 in two separate experiments, 
both of which generated adaptive viruses that were more efficient at assembling of 
infectious particles than the WT (Kaul et al., 2007). Similar to the study by Zhong and 
colleagues (Zhong et al., 2006), the viral genomes in each experiment were mutated at 
different positions. Interestingly, the enhanced infectivity’s of both adapted viruses were 
primarily due to one mutation; V2440L in NS5A for experiment 1 and N765D in p7 for 
experiment 2. Pokrovskii and collegues isolated 7 cell culture adaptive mutations following 
their passaging experiment of J6/JFH1 (Pokrovskii et al., 2011). The increased infectivity 
of the adapted J6/JFH1 virus was explained by an improvement in infectious particle 
stability. This adaptive phenotype was conferred by the mutations core K78E, NS2 
W879R, and NS4B V1761L.  
 
5.1.2.2. Cellular Evolution during Persistent Infection 
The exact reason for the emergence of the cell culture adaptive mutations in the above 
studies is unknown. However, Zhong and colleagues reported that during persistent 
infection cells that are resistant to HCV infection rapidly emerge and dominate the cell 
population (Zhong et al., 2006). Examination of cell lines obtained from these populations 
identified two different mechanisms that explain such resistance to HCV infection: 
1) Reduced CD81 cell surface expression that prevents virus entry. 
2) A defect operating downstream of viral entry that prevents viral RNA replication. 
 
Therefore, it seems that during persistent infection a complex virus-host relationship exists, 
which exerts selective pressure on both parties. It is likely that the death of permissive cells 
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caused by HCV infection is responsible for the outgrowth and dominance of these resistant 
cells. Therefore, the adaptive mutations selected throughout the genome may function to 
enhance viral fitness within this environment. In line with this theory, the G451R mutation 
allowed more efficient production of infectious virus particles and the entry properties of 
this mutant appeared to be less dependent upon CD81 molecules on the cell surface. Such 
properties would give this virus a selective advantage during the late period of persistent 
infection when resistant cells emerge. It is possible that the N415D mutation identified in 
the current study arose as a response to similar selective pressure. When passaging JFH1 
infected cells in the current study, maximum number of NS5A positive cells were observed 
at cp 4, which was followed by maximum cell death visible at cp 5 and cp 6. This phase 
was followed by a drop in total number of NS5A positive cells as observed by IF, but an 
increase in the released infectivity was detected by TCID50. Although cell surface CD81 
expression was never investigated in the present study, the increased affinity of the adapted 
virus to CD81 may assist viral spread in cells presenting less CD81 during persistent 
infection. Similar circumstances may also account for the emergence of E2 cell culture 
adaptive mutations in the majority of the studies summarized in table 5.1. 
 
Persistent infections in other virus cell culture systems have also reported co-evolution of 
both viruses and cells. Persistent infection with rotavirus and foot-and-mouth disease virus 
(FMDV) are good examples of these. During maintenance of persistent rotavirus infections 
of MA104 cells, mutations were selected in both viruses and cells. After an initial period of 
cell crisis the cultures stabilized and produced substantial titers of infectious virus for 12 
months of continuous passage. The passaged viruses grew better than WT virus in cured 
cells, and the cured cells were less permissive for growth of WT virus than the parental 
cells. These observations suggest that cells manifesting resistance to viral replication are 
selected for their capacity to survive increasing viral titers. In addition mutant viruses were 
selected that exhibit a greater capacity to infect the resistant cells by bypassing the cellular 
block to viral replication. Therefore, it seems that for rotavirus persistent infections to 
survive in cell culture, an equilibrium must be reached between viral cytopathicity and 
cellular resistance in which ongoing viral replication is not sufficient to completely lyse the 
culture (Mrukowicz et al., 1998). Virus and cells also evolve during the serial passage of 
cloned BHK-21 cells persistently infected with foot-and-mouth disease virus. The 
passaged cells become constitutively resistant to the parental FMDV, whereas the late 
passaged virus partly overcome the cellular block and were more cytolytic than WT virus 
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for BHK-21 cells. The results suggest that coevolution of BHK-21 cells and FMDV 
contributes to the maintenance of persistence in cell culture (De la Torre et a.l, 1988). 
 
5.1.2.3. E2 Cell Culture Adaptive Mutations 
The two E2 cell culture adaptive mutations G451R and I414T have been well 
characterized. The presence of each mutation alone in the JFH1 genome improves virus 
spread as well as increasing the specific infectivity of secreted particles. The mechanism 
responsible for the enhanced infectivity of G451R was not determined whereas I414T was 
found to specifically increase the virus release stage of the lifecycle. In contrast, the 
JFH1N415D, -T416A, -N417S and -I422L E2 mutants described in this study, displayed no 
alteration to virus assembly/release or virus spread. Nevertheless, these four mutant viruses 
did share a number of phenotypic similarities to JFH1G451R and JFH1I414T such as: 
-Altered CD81 and SRB1 receptor dependencies 
-Heightened sensitivity to nAbs targeting HCV envelope glycoproteins 
-Increased buoyant density of infectious virions  
 
It is likely that the above characteristics are closely linked to one another. The shift in 
sedimentation rate of infectious virions does indicate reduced lipoprotein content. This 
could result in the virion glycoproteins being more exposed, which would explain the 
increased sensitivities of these mutants to anti-envelope antibodies as well as soluble CD81 
molecule. In line with this theory, immature intracellular JFH1WT virions, which 
presumably have a lower lipoprotein content than released virions (based on density 
gradient analyses), are more sensitive to neutralization by anti-E2 antibodies and less 
sensitive to anti-ApoE and anti-ApoC1 antibodies than released virions. The I414T 
extracellular virions also shared similar inhibition profiles to intracellular JFH1WT virions 
using the anti-E2, anti-ApoE and anti-ApoC1 antibodies. It is interesting to speculate that 
these single amino acid changes in E2 may function to reduce the lipoprotein content of 
virions to better expose the E2-CD81 binding sites in order to enhance this virus-receptor 
interaction and maintain viral spread during persistent infection. The reduced lipoprotein 
content theory may also explain why these E2 mutants have an altered SRB1 dependency 
for virus infection. If the association of VLDL to virus particles does indeed play a critical 
role in the primary interaction with SR-BI, then virus containing less lipoproteins may 
have an altered requirement for this receptor (Maillard et al., 2006). However, the altered 
SR-BI dependency is unlikely to improve HCVcc viral persistence during long term cell 
culture and may occur only as an indirect effect of the reduced lipoprotein content to 
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expose CD81 binding residues. In line with this, Zhong and colleagues found that the HCV 
resistant cells that emerge during persistent JFH1 infection had similar SR-BI expression 
levels as the parental cells (Zhong et al., 2006). 
 
On the other hand, the HCVpp results obtained in this study are at odds with the 
lipoprotein hypothesis. As described in the introduction, HCVcc assembles in an ER-
derived compartment in association with very low density lipoproteins (Gastaminza et al., 
2008; Huang et al., 2007) whereas HCVpp are assembled in a post-Golgi compartment and 
are not associated with lipoproteins (Meunier et al., 2008a; Sandrin et al., 2005). Tao and 
colleagues reported that the I414T mutation did not alter the sensitivity of HCVpp to anti-
E2 nAbs, in contrast to the HCVcc findings (Tao et al., 2009). These results should make 
sense as if the I414T change functions to delipidate virus particles and increase 
glycoprotein exposure, no such effect should occur to HCVpp which lack lipoproteins. In 
contrast, the present study found that HCVpp harbouring the four E2 mutations showed 
identical anti-E2 neutralization profiles as the HCVcc viruses. This suggests that their 
HCVcc phenotype may not be entirely lipoprotein related. Instead, these mutations may 
simply exert global conformational changes to the E2 glycoprotein that result in increased 
exposure of antibody binding epitopes presented on the virus particle. However, it still 
remains to be determined whether HCV virions associate with the low density lipoproteins 
present in the culture medium following their secretion from producer cells. Such 
information would aid in our understanding of the effect that these E2 mutations have on 
the virion glycoprotein conformation. Although the exact mechanism through which these 
E2 mutations enhance the exposure of the virion glycoproteins is not fully understood, 
their phenotypes have provided valuable information with regard to the antibody mediated 
neutralization of HCV.  
 
The entry properties of the E2 mutant viruses also raise interesting questions regarding the 
current model for HCV entry (Figure 1.5), particularly regarding the SR-B1 receptor. As 
mentioned previously, HCV interacts with SR-B1 via the virion-associated lipoproteins as 
well as the HVR1 of E2. Indeed, delipidated virions as well as those lacking HVR1 have 
been shown to be less dependent on SR-B1 for entry (Grove et al., 2008; Tao et al., 2009). 
However, given that the E2 mutants in this study appear not to be delipidated and contain 
HVR1 suggests that the integrity of the conserved E2 sequence between residues 412-423 
is also necessary for HCV-SR-B1 binding. It is possible that the glycoprotein 
conformational changes inflicted by these E2 mutations may have somehow reduced 
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HVR1-SR-B1 binding. The reduced SR-B1 dependence may explain why these E2 
mutations reduce HCVpp but not HCVcc entry. In the HCVcc system, the virion 
lipoprotein-SR-B1 interaction of these E2 mutants is likely to still be functional, whereas it 
is seemingly lacking in the HCVpp system. Therefore, the HCVpp mutant virions may 
only be able to associate with SR-B1 via a weak E2 interaction, which could explain their 
impaired entry kinetics. Together, the entry properties of the E2 mutants analysed in this 
study allow certain revisions to be made to the current HCV entry model proposed in Fig. 
1.5. Firstly, the attachment of HCV to cells via LDLR, GAGs and SR-B1 via its 
lipoproteins is not essential for virus entry as HCVpps can still infect cells. Furthermore, 
viruses can enter cells with no SR-B1-lipoprotein association and an impaired E2-SR-B1 
interaction. It is possible that the enhanced E2-CD81 interaction compensates for the 
reduced E2-SR-B1 interaction. Clearly, these E2 mutations are extremely useful tools to 
dissect the complex entry pathway used by HCV at both the early and late stages of the 
process.  
 
5.1.2.4. In vivo Significance of E2 Mutations 
The four E2 mutations N415D, T416A, N417A and I422L were chosen for analysis due to 
their location within the conserved E2 region that is the epitope for nAb AP33. Two of 
these mutations (N415D and N417S) made virus resistant to AP33 inhibition. The 
selection of AP33 neutralization resistance viruses was recently described by propagating 
JFH1WT (Dhillon et al., 2010) and chimeric H77/JFH1 (Gal-Tanamy et al., 2008) in the 
presence of inhibitory concentrations of antibody. For each virus, mutations that permitted 
AP33 resistance occurred within residues critical for AP33-E2 binding. In the experiment 
using JFH1WT, mutation G418D was responsible for the AP33 escape. Interestingly, 
characterization of this JFH1G418D found that it had an identical phenotype to the 
JFH1N415D, JFH1T416A, JFH1N417S and JFH1I422L in terms of virus infectivity, receptor 
utilization and sensitivity to human anti-envelope antibodies. In the study using H77/JFH1, 
mutation N415Y permitted AP33 escape however; the phenotypic properties of this virus 
were much different to the above JFH1 E2 mutants. The ability of H77/JFH1N415Y virus to 
spread over multiple rounds of infection was markedly reduced. The lower specific 
infectivity of the H77/JFH1N415Y suggested that its defects occur at the viral entry part of 
the lifecycle. Indeed, antibody binding studies suggested that this escape mutation may 
inflict global conformational changes to E2. Given the phenotypes of AP33 resistant 
mutants, it is fair to speculate that if escape variants to such antibodies do occur in vivo 
then their presence would be short-lived due to either reduced viral fitness or enhanced 
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inactivation by other circulating nAbs. Therefore, the existence of such variants in vivo is 
likely to be short-lived, which explains the low occurrence of T414, D415, Y415, A416, 
S417, L422 and the complete absence of D418 from 1311 HCV patient sequences (Tables 
5.2 and 5.3) analysed within the Los Alamos National Laboratory sequence database 
(Derek Gatherer, Personnal Communication). 
 
 
5.1.3. Creation and Characterisation of JFH1 chimeras  
5.1.3.1. Generation of Intra- and Intergenotypic JFH1 Chimeric Viruses 
With the development of HCVcc in 2005 (Lindenbach et al., 2005; Wakita et al., 2005; 
Zhong et al., 2005), it became possible for the first time to analyse full lifecycle of HCV 
infection and to develop and test antiviral drugs in a more authentic system. However, as 
JFH1 only represents one of the seven HCV genotypes it became desirable to generate 
recombinant viruses to represent all the genotypes. Since then several HCV groups have 
been successful in generating constructs using JFH1 clone as the backbone. The fully 
viable chimeric clones consist of 5’ and 3’ NCR, including NS3-NS5B region of JFH1 and 
the C-NS2 region replaced by genomes of different genotypes. These recombinant 
constructs have been useful in delineating the details in HCV entry and further highlighted 
the role of structural and non-structural proteins in the assembly process of HCV infection.  
JFH1 replicates to high levels in cell culture without the requirement of adaptive mutations 
(Wakita et al., 2005; Zhong et al., 2005). Likewise the J6/JFH1 chimera (2a/2a) has also 
shown to replicate and produce infectious particle without the need of cell culture 
adaptation (Gottwein et al., 2009; Lindenbach et al., 2005). The J6/JFH1 clone was 
generated by replacing C-NS2 region of JFH1 with the corresponding sequence of J6. 
Subsequently, all the chimeric constructs shown to be viable in cell culture have been 
generated using the same methodology (Gottwein et al., 2007; Gottwein et al., 2009; 
Jensen et al., 2008; Pietschmann et al., 2006; Scheel et al., 2008; Yi et al., 2007). 
Interestingly, naturally occurring intra- and intergenotypic HCV clones have been 
identified with the same recombination cross over point located within the NS2 region 
(Kalinina et al., 2002; Legrand-Abravanel et al., 2007). In addition to this strategy some 
groups have also focused on studying the role of specific non structural proteins in terms of 
their importance in replication and as a potential target for developing HCV infection 
inhibitors. Imhof and Simmonds, 2010, generated a panel of chimeras using the Jc1 
genome as the backbone and replacing the NS3 protease with the homologous NS4A 
cofactor from different genotypes (Imhof & Simmonds). These HCV recombinants were 
98 
 
generated with the aim of evaluating the effect of different PIs on various NS3/4A 
genotypes. Similarly, Scheel and colleagues generated a panel of NS5A chimeras 
representing all the HCV genotypes 1-7 by replacing the entire NS5A region in J6/JFH1 
genome (Scheel et al., 2011). These recombinants were used to examine the antiviral 
effects of an NS5A inhibitor and interferon-α. Furthermore, to study the role of HVR1 in 
neutralisation, HVR1 was mutated or deleted from Core-NS2/JFH1 chimeras representing 
genotypes 1-6 (Prentoe et al., 2011). Nevertheless, in order to obtain high efficiency in cell 
culture most of the recombinant viruses in the studies described above required cell culture 
adaptation. The inability of the E1E2/JFH1 chimeras generated in this study to adapt in cell 
culture suggests that replacing the JFH1 envelope glycoproteins with those from other 
genotypes may confer total incompatibility for virus assembly.  
 
5.1.3.2. Compensatory Mutations Enhance Chimeric Virus Production 
The successful generation of an infectious 4a/JFH1 chimera in this study relied on the 
selection of six compensatory mutations. All of the functional Core-NS2/JFH1 
intergenotypic chimeric viruses described to date required compensatory mutations located 
at different sites throughout the genome. Table 5.4 lists the Core-NS2/JFH1 chimeras 
representing all genotypes and the mutations identified for their efficient replication. As is 
notable from the table the compensatory mutations appear in both the structural and the 
non structural proteins. In particular, mutations that improve virus production tend to be 
clustered within the NS2 region (Gottwein et al., 2009; Jensen et al., 2008; Scheel et al., 
2008; Yi et al., 2007).  One of the cell culture adaptive mutations identified in 4a/JFH1 at 
T827A within the N- terminal of NS2 protein has also been reported by Scheel and 
colleagues in their genotype 4a intergenotypic chimeric construct (Scheel et al., 2008). In 
their study they demonstrated that introducing this single mutation into the parental 
genome significantly improved the virus infectivity. In addition Yi and colleagues 
identified a mutation at M827V which also enhanced the infectivity of their H-(NS2)-J 
(1a/2a) chimeric virus (Yi et al., 2007). The latter study also identified a cell culture 
adaptive mutation at residue T889A, which was never characterised, while in this study a 
T889I change has been described. The effects of individual compensatory mutations or the 
effect of mutations in different combinations on 4a/JFH1 replication and infectivity was 
not tested due to time constraints. It may be possible that the T827A change alone could be 
responsible for increase in virus released observed with Ad4a/JFH1. Located in the TMD 
of NS2 this substitution is believed to possibly facilitate intramembranous interaction 
between HCV proteins (Jirasko et al., 2008). Altogether three compensatory mutations 
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emerged in the NS2 region and one in NS3 during long term passaging of the 4a/JFH1 
genome. These changes may be necessary to compensate for any incompatibilities between 
the two genotypes and confer essential protein-protein interactions necessary for virus 
assembly and release. In line with this, several recent studies have highlighted the role of 
NS2 as the key component in promoting virus assembly. Defects in infectious virus 
production caused by substitution, point mutations or deletion in the NS2 region could be 
restored by second site mutations emerging within E2, P7 and NS3 proteins (Dentzer et al., 
2009; Jirasko et al., 2008; Phan et al., 2009; Yi et al., 2009). The locations of these 
mutations imply direct interactions between these proteins are required for virus assembly. 
Indeed, more recent studies have shown that NS2 directly interacts with E1/E2, P7 and 
NS3 and recruits the complex to the assembly site in near vicinity of LDs (Jirasko et al., 
2010; Ma et al., 2011; Popescu et al., 2011; Stapleford & Lindenbach, 2011).  
 
5.1.3.3. Characteristics of Ad4a/JFH1 
Following introduction of cell culture adapted mutations within the 4a/JFH1 genome, the 
Ad4a-ED43/JFH1 virus revealed following phenotype:- 
• Comparable infectivity to JFH1WT 
• Reduced affinity to the CD81 receptor 
• Enhanced sensitivity to antibody-mediated neutralization 
• Reduced cell-to-cell transfer 
 
The Ad4a/JFH1 virus displayed a heightened sensitivity to neutralisation against a panel of 
anti-E2 antibodies. As discussed in chapter 3, this could possibly be due to an enhanced 
exposure of antibody binding epitope on the virus particle as a result of the mutation within 
the E2 glycoprotein. Based on sequence comparison (Appendix 7) and migration of E2 on 
a polyacrylamide gel (Figure 4.6C) the heightened sensitivity observed is unlikely due to 
any difference in the glycosylation, as all the potential N-linked glycosylation sites in E1 
and E2 proteins are preserved in the  genotype 4a sequence (Goffard & Dubuisson, 2003). 
The threonine to alanine substitution at residue 416 (T416A) in the JFH1 genome resulted 
in heightened sensitivity of JFH1 virus to nAbs, presumably by enhancing exposure of the 
virion glycoproteins (Section 5.1.2.3). Within the 4a/JFH1 E2 sequence threonine at 
residue 416 is substituted to serine (T416S). Although speculative, this change may also 
enhance the exposure of the virion glycoprotein.  
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Inhibition of virus infectivity by anti-CD81 antibody confirms previous results that CD81 
is an essential co-receptor required for virus entry into cells. However the difference in 
neutralisation observed with anti-CD81 MAb and soluble CD81 molecule suggest that the 
interaction of Ad4a/JFH1 with CD81 may be reduced. Given the enhanced sensitivity of 
Ad4a/JFH1 virions to nAbs, it is unlikely that the lower affinity to CD81 is caused by a 
reduced exposure of CD81 binding epitope(s) on virus particle. In contrast, based on the 
AP33 mutants data discussed in section 5.1.2.3, if the glycoproteins on Ad4a/JFH1 virion 
surface were more exposed then one would expect the virus to be more sensitive to 
inhibition by hCD81-LEL. Therefore, the altered CD81 interaction could be related to the 
two amino acid differences in the CD81 binding residues between JFH1 and ED43 
sequence at A440S and Y622F (Appendix 7). In support of this argument, Drummer and 
colleagues reported a >50 % reduction in hCD81-LEL binding between A440 and S440 
mutant in the HCVpp cell lysate derived E1E2 of the H77c (1a) strain (Drummer et al., 
2006). Furthermore the reduced dependency to the CD81 receptor might explain the 
reduced spreading of Ad4a/JFH1 in cells following infection and the poor cell-to-cell 
transfer, as both infection routes are dependent on CD81 usage.  
 
 
5.1.4. Finishing Statement 
The two major aims of this work were as follows: 
a) Utilize E2 cell culture adaptive mutations to better understand why residues within 
the AP33 epitope are highly conserved. 
b) Generate functional intergenotypic HCVcc chimeras and examine their viral entry 
properties. 
 
Despite the different subject areas, both projects identified viruses that were more sensitive 
to nAb inhibition of infection. This phenotype is particularly common among the cell 
culture adaptive viruses harbouring E2 mutations. Evidence from the literature and this 
work suggest that these mutations lessen the interplay between virus particles and host 
lipoproteins. It is attractive to assume that the latter feature is directly related to the 
enhanced glycoprotein exposure. However, evidence from this work argues that these two 
features may be purely coincidental and not directly linked. Utilizing the virus generated in 
this study to understand the mechanisms that are responsible for this intriguing phenotype 
will form the basis of our future work. 
 Table 5.1.  Mutations identified in JFH1 or J6/JFH1 genome during persistent infection 
 
Virus  Cells 
Virus 
Passage 
C  E1  E2  P7  NS2  NS3  NS4B  NS5A  NS5B  Ref 
D119 P.I  K74T    G451R      M1051T    C2219R   
JFH1  Huh7.5.1 
D160 P.I  V22A  K74Q   
V388P 
I414T 
L644I
           
Zhong et al., 
2006 
Exp 1 
(cp8/sp8) 
N16D 
I372V 
I374T  I422L 
 
 
 
 
 
 
V2153A 
V2440L 
V2941M 
JFH1  Huh7.5 
Exp 2 
(cp6/sp4) 
      N765D    I1316V    Y2103H   
Kaul et al., 2007 
JFH1  Huh7.5  D20 PT      N417S  N765D  Q1012R      L2175V   
Russell et 
al.,2007 
P27      
T396A 
T416A 
N534H 
A7 2V 1
 
 
Y852H 
W8 9R 7
 
   
F2281L 
 
M2 6L 87
 
J6/JFH1  Huh7.5 
P47  K78E   
T396A 
T416A 
N534H 
A712V 
 
 
Y852H 
W879R 
 
   
F2281L 
 
M2876L 
T2925A 
 
Bungyoku et al., 
2009 
J6/JFH1 
Lunet‐
CD81 
sp18  K78E        W879R    V1761L     
Pokrovskii et al., 
2011 
 
List of genetic mutations identified during long term passaging of JFH1 or J6/JFH1 virus. Red highlights the mutations characterised in this 
study.  
P.I is post infection; P.T is Post Transfection; P is passage; D is day; cp is cell passage; sp is cell free passage 
Table 5.2.  Naturally occurring substitutions in 1311 HCV E2 protein sequences. 
Position JFH1 
Residue 
Varianta No.b Totalc Prop.d Accession numbere 
414 I T 3 864 0.003 EU155238 (1a), FJ205869 (1a), GQ356306 (3a) 
415 N D 1 37 0.03 EU482838 (1a) 
415 N Y 10 37 0.27 AF207762 (1b), AY615798 (1a), AY878651 (6k), DQ278893 (6k), EF560519-21 (1a), EU155275 (1a). FJ025856 
(4b), GQ356574 (3a) 
416 T A 13 182 0.07 AY956468 (1a), AY958005 (3a), EU155215 (1a), EU155249 (1a), EU155282 (1a), EU155285 (1a), 
EU155288 (1a), EU155379 (1a), EU255930 (1a), EU255980 (1a), EU482845 (1a), EU482836 (1a), 
EU643835 (6). 
417 N S 17 27 0.63 EU256046 (1a), EU256031 (1a), EU255964 (1a), EU255952 (1a), EU255943 (1a), EU155354 (1a), 
EU155347 (1a), EU155297 (1a), EU155274 (1a), EU155215 (1a), EF407468 (1b), EF407466 (1a), 
EF407477 (1a), EU407415 (1a), EF026073 (2/5 natural recombinant), AY957988 (3a), AM408911 (2/5) 
418 G D 0 2 0.00  
422 I L 5 38 0.13 AB047643 (2a), AF271632 (1a), FJ828970 (1a), FJ828971 (1a), M62321 (1a) 
 
aSubstitutions described in this paper.  bTotal number of sequences in a sample of 1311 HCV E2 proteins with same substitution.  cTotal number 
of substituted residues in the sample of 1311 (see Table 3).  dProportion of naturally occurring substitutions that are identical to the substitutions 
produced in this paper. eAccession number of HCV sequences (genotypes shown in parenthesis) carrying the relevant varianta
Table 5.3. Total number of naturally occurring substitutions in 1311 HCV E2 protein 
sequences. 
 
Positions 414 415 416 417 418 422
JFH1 Residues I N T N G I 
Variantsa V K N S S L 
  M Y S D  V 
  T H A H  T 
   S I G    
   T K T    
   R R      
   D        
Totalb 864 37 182 27 2 38 
 
aSubstitutions occurring in the sample of 1311 E2 protein sequences.   
bTotal number of sequences with a substitution.  Position 416 is the most polymorphic 
in terms of total number of substitutions at 14% (182 in 1311 sequences).  However, 
position 415 has a greater diversity of variants (8 amino acids used at least once, 
despite only 37 substitutions). 
Table 5.4. List of adaptive mutations identified in different studies for all the Core‐NS2/JFH1 intergenotypic chimeras 
GT  Virus  Viral Passage  C  E1  E2  P7  NS2  NS3  NS5A  Ref. 
H‐NS2/NS3‐J  sp3    Y361H        Q1251L   
Exp 1 (sp3)        Y777C  I839T     
1A 
H‐(NS2)‐J 
Exp 2 (P.T)        Y777C 
M827V 
(T889A) 
T945A 
   
Yi et al., 2007 
1B  J4/JFH1  cp1/cp2    N576S      F886L  Q1496L   
Gottwein et al., 
2009 
Exp 1 (cp1)  F130L    M405V 
I793S 
Y794C 
  Q1502L  S2274P 
Exp 1 
(cp2/cp3) 
F130L   
M405V 
K523Q 
I793S 
Y794C 
  Q1502L  S2274P 3A  S52/JFH1 
Exp 2 (cp1)        I793T    K1404Q   
Gottwein et al., 
2007; 2009 
ED43/JFH1‐β 
  sp2/sp3         
T827A 
E989K 
 
T1989I 
V2436L 
ED43/JFH1‐γ  sp3   
A216T 
T329S 
   
T827A 
T977S 
  C2270R 
Scheel et al., 2008 
 
4A 
gt4a‐ED43/JFH1  sp2 (cp4/cp5)      I690M   
T827A 
T889I 
M956L 
A1271V  Y2289H  This study 
5A  SA13/JFH1            A1022G  K1119R    Jensen et al., 2008 
Exp 1    F350S  N417T         
6A  HK6a/JFH1 
Exp 2    F350S 
I414T 
T416A 
      E2249K 
Gottwein et al., 
2009 
Exp 1  V157F    I414T         
Exp 2      I414T    L882P     
Exp 3      N428S         
7A  QC69/JFH1 
Exp 4      R391G         
Gottwein et al., 
2009 
 
Amino acid positions are numbered according to the HCV sequence of the isolate used to generate the recombinant clone. Mutations found in the current 
study in gt4a‐ED43/JFH1 are highlighted in bold. cp is cell passage and sp is cell free passage. 
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Appendices 
 
Appendix A. Primers used for generating E1E2/JFH1 chimeric clones. FW, sense; RV, 
anti-sense. Yellow highlights the overhang sequence in each primer. 
 
 Primer Sequence (5’-3’) 
 
   
Frag 1 
 
  
 FW-JFH1 TGAGTGTCGTACAGCCTCCAGGCC 
   
 RV-JFH1-UKN1B.12.6 CAGGATAGCAAAGCCAAGAGGAAGATAGA 
GAAGGGGAAACCGGGTAGGTTCCCTGTTG 
 
 RV-JFH1-UKN2A2.5 CAAGACAGAACGGCCAGTAAGAAGATAGA 
AAAGGGGAAACCGGGTAGGTTCCCTGTTG 
 
 RV-JFH1-UKN3A1.28 GGCAAGAGAACAGAGCAAGAAGGAAGATA 
GAAAAGGGGAAACCGGGTAGGTTCCCTGTTG 
 
 RV-JFH1-UKN5.15.7 CACGAGAGAAGTGCAAGGATGAAGATAGA 
GAAGGGGAAACCGGGTAGGTTCCCTGTTG 
 
 RV-JFH1-UKN6.5.340 CACGAGAGTAGTGCCAAAAGGAAGATAGA 
GAAGGGGAAACCGGGTAGGTTCCCTGTTG 
   
Frag 2 
 
  
 FW-UKN1B12.6-JFH1 
 
ACAGGGAACCTACCCGGTTTCCCCTTCTCT 
ATCTTCCTCTTGGCTTTGCTATCCTGT 
 
 FW-UKN2A2.5-JFH1 
 
ACAGGGAACCTACCCGGTTTCCCCTTTTCT 
ATCTTCTTACTGGCCCAAGTGTGAACCAT 
 
 FW-UKN3A1.28-JFH1 
 
ACAGGGAACCTACCCGGTTTCCCCTTTTCT 
ATCTTCCTTCTTGCTCTGTTCTCTTGCC 
 
 FW-UKN5.15.7-JFH1 
 
ACAGGGAACCTACCCGGTTTCCCCTTCT 
CTATCTTCATCCTTGCACTTCTCTCGTG 
 
 FW-UKN6.5.340-JFH1 
 
ACAGGGAACCTACCCGGTTTCCCCTTCT 
CTATCTTCCTTTTGGCACTACTCTCGTG 
 
   
 RV-UKN1B12.6-JFH1 
 
CAAGACGACCAACTTCTCCAATGCTGCCT 
CAGCCTGGGCTACCAGCAGCATCATC 
 
 RV-UKN2A2.5-JFH1 
 
CAAGACGACCAACTTCTCCAATGCTGCTT 
CGGCTTGGCCCAATATGATGAGCATC 
 
 RV-UKN3A1.28-JFH1 
 
CAAGACGACCAACTTCTCCAATGCTGCTTC 
CGCCTGTGAAATCAGCAGCATCAG 
 
 RV-UKN5.15.7-JFH1 
 
CAAGACGACCAACTTCTCCAATGCTGCTTC 
AGCCTGGCAAACTAGGAGCATGATC 
 
 RV-UKN6.5.340-JFH1 
 
CAAGACGACCAACTTCTCCAATGCTGCTTC 
AACGTTGGTTATGAGCAGCATTAACCAG 
 
   
Frag 3 
 
  
 FW-JFH1-UKN1B12.6 
 
CTGCTGGTAGCCCAGGCTGAGGCAGCATTG 
GAGAAGTTGGTCGTCTTGCAC 
 
 FW-JFH1-UKN2A2.5 
 
GCTCATCATATTGGGCCAAGCCGAAGCAGC 
ATTGGAGAAGTTGGTCGTCTTGCAC 
 
 FW-JFH1-UKN3A1.28 
 
CTGATGCTGATGATTTCACAGGCGGAAGCA 
GCATTGGAGAAGTTGGTCGTCTTGCAC 
 
 FW-JFH1-UKN5.15.7 
 
CATGCTCCTAGTTTGCCAGGCTGAAGCAGC 
ATTGGAGAAGTTGGTCGTCTTGCAC 
 
 FW-JFH1-UKN6.5.340 
 
GGTTAATGCTGCTCATAACCAACGTTGAAG 
CAGCATTGGAGAAGTTGGTCGTCTTGCAC 
 
 RV-JFH1 
 
GAATATAGTGACGGCCCACGCGATGC 
   
Fusion PCR Primers 
 
  
   
 FW-JFH1 
 
TGAGTGTCGTACAGCCTCCAGGCC 
 
 RV-JFH1 
 
GAATATAGTGACGGCCCACGCGATGC 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
Appendix B. Sequencing Primers for E1E2/JFH1 Chimeric Product. 
 
 
Primer Sequence (5’-3’) Description 
   
All UKN CATCCCCGTCGTAGGCGCCC Forward primer for 
JFH1 core  
   
1B12.6 (143) GTATGAGGCAGCGGACGTGATCAT Forward primer for 
1B12.6 E1 
1B12.6 (684) CAAACCACCTATGGGCTTACATCCCTCTTTAG Forward primer for 
1B12.6 E2 
1B12.6 (1159) GTACATGGATGAATGGCACCGGGTTTAC Forward primer for 
1B12.6 E2 
1B12.6 (1655) GTATATCGTGCTGCTCTTCCTCCTCCTG Forward primer for 
1B12.6 E2 
   
2A2.5 (350) TGTTCCATCTACGCGGGCCA 
 
Forward primer for 
2A2.5 E1 
2A2.5 (851) GGCGTTTTGACACATGAAGAGAACGT 
 
Forward primer for 
2A2.5 E2 
2A2.5 (1351) ACGTGGGAGGAGTCGAGCATAGGCT Forward primer for 
2A2.5 E2 
   
3A1.28 (167) GCACACACCTGGCTGTATACCTTGTG Forward primer for 
3A1.28 E1 
3A1.28 (649) ATACACCACCGGTGGCCAAGCAGCT Forward primer for 
3A1.28 E2 
3A1.28 (1204) ACGGGGTTTACCAAGACGTGCG Forward primer for 
3A1.28 E2 
   
5.15.7 (170) GGTTGTGTGCCTTGTGTTAGGACAGG Forward primer for 
5.15.7 E1 
5.15.7 (649) AACCCACTCAGTGGGCGGTGTTGTC Forward primer for 
5.15.7 E2 
5.15.7 (1176) GGTTTGTGAAGACTTGCGGAGCC Forward primer for 
5.15.7 E2 
   
6.5.340 (174) GCTTGCCTTGTGTGAGGGTCGATAA Forward primer for 
6.5.340 E1 
6.5.340 (677) GCTACTGCCGGCTTCGTTGGG Forward primer for 
6.5.340 E2 
6.5.340 (1172) ACGGGCTTTACCAAGACCTGTGG Forward primer for 
6.5.340 E2 
   
 
 
 
 
 
 
 
Appendix C. Primer list for Site Directed Mutagenesis (SDM). FW, sense; RV, anti-
sense. 
 
Primer Sequence (5’-3’) 
 
Description 
N415D-FW ATTCAGCTCATTGACACCAACGG 
CAGTTGG 
Forward primer for SDM N415D in 
JFH1 plasmid 
N415D-RV CCAACTGCCGTTGGTGTCAATGA 
GCTGAAT 
Reverse primer for SDM N415D in 
JFH1 plasmid 
   
T416A-FW ATTCAGCTCATTAACGCCAACGG 
CAGTTGG 
Forward primer for SDM T416A in 
JFH1 plasmid 
T416A-RV CCAACTGCCGTTGGCGTTAATGA 
GCTGAAT 
Reverse primer for SDM T416A in 
JFH1 plasmid 
   
N417S-FW CATTCAGCTCATTAACACCAGCG 
GCAGTTGG 
Forward primer for SDM N417S in 
JFH1 plasmid 
N417S-RV CCAACTGCCGCTGGTGTTAATGA 
GCTGAATG 
Reverse primer for SDM N417S in 
JFH1 plasmid 
   
I422L-FW GGCAGTTGGCACCTCAACCGTAC 
TGCC 
Forward primer for SDM I422L in 
JFH1 plasmid 
I422L-RV GGCAGTACGGTTGAGGTGCCAAC 
TGCC 
Reverse primer for SDM I422L in 
JFH1 plasmid 
   
   
I690M-FW TCCACCGGCTTGATTCACCTCCA 
CCAAAATATCG 
Forward primer for SDM I690M in 
4a/JFH1 plasmid 
I690M-RV CGATATTTTGGTGGAGGTGAATC 
AAGCCGGTGGA 
Reverse primer for SDM I690M in 
4a/JFH1 plasmid 
   
T827A-FW ATCGTTGTCATGCTGGCCATTCT 
GACACTGTCTCCGC 
Forward primer for SDM T827A in 
4a/JFH1 plasmid 
T827A-RV GCGGAGACAGTGTCAGAATGGCC 
AGCATGACAACGAT 
Reverse primer for SDM T827A in 
4a/JFH1 plasmid 
   
T889I-FW CCACACCTAGTATTTGACATCATAAAAT
ATCTTCTGGCCATCTTAGGG 
Forward primer for SDM T889I in 
4a/JFH1 plasmid 
T889I-RV CCCTAAGATGGCCAGAAGATATTTTATG
ATGTCAAATACTAGGTGTGG 
Reverse primer for SDM T889I in 
4a/JFH1 plasmid 
   
M956L-FW GACCACCTTACTCCCCTGTCAGA 
TTGGGCCGCTACGG 
Forward primer for SDM M956L 
in 4a/JFH1 plasmid 
M956L-RV CCGTAGCGGCCCAATCTGACAGG 
GGAGTAAGGTGGTC 
Reverse primer for SDM M956L in 
4a/JFH1 plasmid 
   
A1271V-FW GGGGCGTACCTATCCAAGGTACA 
TGGCATCAATCCCAACATTAGG 
Forward primer for SDM A1271V 
in 4a/JFH1 plasmid 
A1271V-RV CCTAATGTTGGGATTGATGCCAT 
GTACCTTGGATAG GTACGCCCC 
Reverse primer for SDM A1271V 
in 4a/JFH1 plasmid 
   
Y2289H-FW ACGGCCTGACCACAACCCGCCGC 
TCGTG 
Forward primer for SDM Y2289H 
in 4a/JFH1 plasmid 
Y2289H-RV CACGAGCGGCGGGTTGTGGTCAG 
GCCGT 
Reverse primer for SDM Y2289H 
in 4a/JFH1 plasmid 
   
 
 
 
Appendix D. Primers used for cDNA synthesis, amplification and Sequencing of 
JFH1 and 4a/JFH1 plasmid. FW, sense; RV, anti-sense. 
 
 
Primer Sequence (5’-3’) Description 
JFH1  
NegRT 
TTGCGAGTGCCCCGGGA Used to reverse transcribe 
negative strand HCV JFH1 AND 
ED43 core to NS5A sequence 
SD1 TGTGGTACTGCCTGATAGGG Used to reverse transcribe 
negative strand HCV ED43 core 
sequence 
NA41 GGAGGCAGTTTTCACCG Used to reverse transcribe 
negative strand HCV JFH1 NS4A 
to 3’ NTR sequence 
SD1-FW TGTGGTACTGCCTGATAGGG Used to sequence HCV ED43 
core gene 
SD2-FW ATCCATGGCCTCTTTACGG Used to sequence HCV ED43 
core gene 
SD3-RV CCGTAAAGAGGCCATGGAT Used to sequence HCV ED43 
core gene 
SD5-FW GGCGGCTTGTTCCTAGTTGG Used to sequence HCV ED43 E1 
gene 
SD7-FW ATGACAGGCCTTATTGCTG Used to sequence HCV ED43 E2 
gene 
SD8-FW CCACCGATTGCTTCAGGAAG Used to sequence HCV ED43 E2 
gene 
SD9-FW TTTACCTGCCCTCTCCACCG Used to sequence HCV ED43 E2 
gene 
SD10-FW TTGTCTGGCATGTCAAGGGC Used to sequence HCV ED43 P7 
gene 
SD11-RV TGATGTCAAATACTAGGTGTG Used to sequence HCV ED43 
NS2 gene 
SD13-FW GACGTTAAGTTCCCGGGTGG Used to amplify HCV ED43 core 
gene 
SD14-RV TGGATCAAGCCGGTGGAG Used to amplify HCV ED43 E2 
gene 
SD15-FW TGTGGATGAACAGTACCGGG Used to amplify HCV ED43 E2 
gene 
SD16-RV CCTGTTCTGTCCTGTCACGC Used to amplify HCV ED43 NS2 
gene 
SD17-FW AGGGGTGGAGACTCCTTGCC Used to amplify HCV JFH1 NS3 
gene 
SD18-RV ATCCAGTCGCCAGGCAATAT Used to amplify HCV JFH1 
NS4A gene 
NA6-RV GCAGAGAGACCAGTTACGGC 
 
Used to amplify HCV JFH1 
NS5A and 3’NTR gene 
NA11-FW GTCTCGTAGACCGTGC Used to amplify and sequence 
HCV JFH1 core gene 
NA12-RV GCCAGTGGAGCGCCGATCTTTG Used to sequence HCV JFH1 
core gene 
NA13-FW CAAAGATCGGCGCTCCACTGGC 
 
Used to sequence HCV JFH1 
core gene 
NA15-FW CCTGTTGTCCTGCATCACCG Used to sequence HCV JFH1 E1 
gene 
NA17-FW CCAGGTGTTCATCGTCTCGC 
 
Used to sequence HCV JFH1 E1 
gene 
NA19-FW GTCATTGTCATCCTTCTGCTGGC Used to sequence HCV JFH1 E2 
gene 
NA21-FW GGATATGAGGCCGTACTGC Used to sequence HCV JFH1 E2 
gene 
NA24-RV CGTGGTAGAGTGCAACAGAG Used to sequence HCV JFH1 E2 
gene 
NA25-FW CTCTGTTGCACTCTACCACG 
 
Used to sequence HCV JFH1 P7 
gene 
NA29-FW CTTCTGCCTACTGCTCATGG 
 
Used to amplify and sequence 
HCV JFH1 NS2 gene 
NA30-RV GCAACGCCAAAAGCCAT 
 
Used to amplify HCV JFH1 NS2 
gene 
NA31-FW ATGGCTTTTGGCGTTGC 
 
Used to amplify HCV JFH1 NS2 
gene 
NA32-RV GAGGCCTCGTGTTTGCTG Used to sequence HCV JFH1 
NS2 gene 
NA33-FW CAGCTGATGGCTACACCTC Used to sequence HCV JFH1 
NS3 gene 
NA34-RV CGTTCCGCGTGACCAGATATAG 
 
Used to sequence HCV ED43 
NS2 gene 
NA35-FW CTATATCTGGTCACGCGGAACG Used to sequence HCV JFH1 
NS3 gene 
NA37-FW GCCATCACGTACTCCACATATG 
 
Used to amplify and sequence 
HCV JFH1 NS3 gene 
NA39-FW CGTGATCGACTGCAATGTAGC Used to sequence HCV JFH1 
NS3 gene 
NA40-RV CGGTGAAAACTGCCTCC Used to amplify and sequence 
HCV JFH1 NS3 gene 
NA41-FW GGAGGCAGTTTTCACCG 
 
Used to sequence HCV JFH1 
NS4A and NS4B gene 
NA43-FW ACGTCAACCAGCGAGTCG 
 
Used to amplify and sequence 
HCV JFH1 NS4B gene 
NA44-RV GGACTTCAACATCTCGGCTATC 
 
Used to amplify HCV JFH1 NS3 
and NS4A gene 
NA47-RV GGAAGCAAAGGCAATAAGC 
 
Used to sequence HCV JFH1 
NS4B gene 
NA48-FW GCTTATTGCCTTTGCTTCC 
 
Used to sequence HCV JFH1 
NS4B gene 
NA49-RV CTGTCAAGATGGTGCAAAC Used to amplify HCV JFH1 
NS4B gene 
NA51-RV CAGATGGCGGTCTTGTAGTTCG Used to sequence HCV JFH1 
NS5A gene 
NA52-FW CGAACTACAAGACCGCCATCTG Used to sequence HCV JFH1 
NS5A gene 
NA55-RV GAGAGCACAACCAGCAACG Used to sequence HCV JFH1 
NS5A gene 
NA56-FW CGTTGCTGGTTGTGCTCTC 
 
Used to amplify and sequence 
HCV JFH1 NS5B gene 
NA57-RV CGGAGCAAGTAGACCAAGACC 
 
Used to sequence HCV JFH1 
NS5A gene 
NA58-FW GGTCTTGGTCTACTTGCTCCG 
 
Used to sequence HCV JFH1 
NS5B gene 
NA59-RV GCCGCTAGCTTGATGTCCT 
 
Used to amplify HCV JFH1 
NS5A gene 
NA62-FW GAAACCAGCTCGCCTCATCG 
 
Used to sequence HCV JFH1 
NS5B gene 
NA66-FW CTCAAATGTGTCTGTGGC 
 
Used to sequence HCV JFH1 
NS5B gene 
NA68-FW GCACACATACTCTCACCACG 
 
Used to sequence HCV JFH1 
NS5B gene 
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Appendix 1. Reactivity’s of WT and Mutants Glycoproteins to Linear and 
Conformation Sensitive Anti-E2 Antibodies 
 
Cell lysates harvested at 72 h post-electroporation with appropriate viral RNAs were 
captured onto GNA-coated plates and the bound E2 was detected using either (A) the 
conformation-sensitive human mAb CBH-4B or (B) the anti-E2 mouse mAb D3.7 
that recognizes a linear epitope in E2. Error bars represent variability of the assays. 
WT 
N415D 
T416A 
N417S 
I422L 
Mock 
0.0010.010.11
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0.0010.010.11
0
1
2
3
4
A
B
Lysate Dilution
Lysate Dilution
A
bs
or
ba
nc
e 
(4
50
nm
)
A
bs
or
ba
nc
e 
(4
50
nm
)
WT 
N415D 
T416A 
N417S 
I422L 
Mock 
Appendix 2. Reactivity’s of WT and Mutants Glycoproteins to Mouse mAb AP33 
 
Cell lysates harvested at 72 h post-electroporation with appropriate viral RNAs were 
captured onto GNA-coated plates. The bound E2 was detected and the lysate was 
normalised using CBH-4B. (A and B) Dose curves of lysates normalized for E2 
(based on their reactivity to CBH-4B) were then tested in two independent 
experiments for their ability to bind to mouse mAb AP33 by ELISA. Error bars 
represent variability of the assays. 
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Appendix 3. Reactivity’s of WT and Mutants Glycoproteins to Rat mAb 3/11 
 
Cell lysates harvested at 72 h post-electroporation with appropriate viral RNAs were 
captured onto GNA-coated plates. The bound E2 was detected and the lysate was 
normalised using CBH-4B. (A and B) Dose curves of lysates normalized for E2 
(based on their reactivity to CBH-4B) were then tested in two independent 
experiments for their ability to bind to rat mAb 3/11 by ELISA. Error bars represent 
variability of the assays. 
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Appendix 4. Reactivity’s of WT and Mutants Glycoproteins to hCD81-LEL  
 
Cell lysates harvested at 72 h post-electroporation with appropriate viral RNAs were 
captured onto GNA-coated plates. The bound E2 was detected and the lysate was 
normalised using CBH-4B. (A and B) Dose curves of lysates normalized for E2 
(based on their reactivity to CBH-4B) were then tested in two independent 
experiments for their ability to bind to hCD81-LEL by ELISA. Error bars represent 
variability of the assays. 
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Appendix 5. HCVpp Lysate Reactivity in ELISA 
 
The intracellular glycoproteins within cell lysates harvested from HEK-293T at 48 h 
post-transfection were captured onto GNA-coated plates and the bound E2 was 
detected using either (A) CBH-4B or (B) D3.7. Error bars represent variability of the 
assays. 
 
Appendix 6. The Infectious Co-Culture Assay.  
 
Flow chart outlining the method adapted from Brimacombe et al, (2010). 
Huh-7 cells transfected with JFH1WT and 
ad4a/JFH1 RNA
Transfected cells labelled with CMFDA (donor cells)
CMFDA labelled cells mixed and co-incubated 
with naïve Huh-7 cells (target cells) at a ratio of 
1:1 in the presence of AP33 antibody
72 h @ 37oC
30 min @ 37oC
48 h @ 37oC
Analysis
Harvest  cell 
supernatant
Harvest 
cells 
Determine 
virus infectivity 
by SEAP assay
Determine ratio 
of infected 
target cells by 
FACS
JFH1  1      MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGGVYLLPRR GPRLGVRTTR KTSERSQPRG  60 
              .......... .........M .......... .......... .......A.. .......... 
gt4a  1       MSTNPKPQRK TKRNTNRRPM DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG  60 
      
JFH1  61     RRQPIPKDRR STGKAWGKPG RPWPLYGNEG LGWAGWLLSP RGSRPSWGPT DPRHRSRNVG  120 
              .......A.. PE.RS.AQ.. Y......... C......... .........N ...R....L. 
gt4a  61      RRQPIPKARR PEGRSWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPSWGPN DPRRRSRNLG  120 
        
JFH1  121     KVIDTLTCGF ADLMGYIPVV GAPLSGAARA VAHGVRVLED GVNYATGNLP GFPFSIFLLA  180 
              .......... .......... ...VG.V... L.....A... .I........ .CS....... 
gt4a  121     KVIDTLTCGF ADLMGYIPLV GAPVGGVARA LAHGVRALED GINYATGNLP GCSFSIFLLA  180 
 
JFH1  181     LLSCITVPVS AAQVKNTSSS YMVTNDCSND SITWQLEAAV LHVPGCVPCE RVGNTSRCWV  240 
              ....L...A. .VNYR.V.GI .H.....P.S ..VYEADHHI ..L......V .E..Q..... 
gt4a  181     LLSCLTVPAS AVNYRNVSGI YHVTNDCPNS SIVYEADHHI LHLPGCVPCV REGNQSRCWV  240 
 
JFH1  241     PVSPNMAVRQ PGALTQGLRT HIDMVVMSAT FCSALYVGDL CGGVMLAAQV FIVSPQYHWF  300 
              ALT.TV.APY I..PLES..S .V.LM.GA.. V..G..I... ...LF.VG.M .SFR.RR..T 
gt4a  241     ALTPTVAAPY IGAPLESLRS HVDLMVGAAT VCSGLYIGDL CGGLFLVGQM FSFRPRRHWT  300 
 
JFH1  301     VQECNCSIYP GTITGHRMAW DMMMNWSPTA TMILAYVMRV PEVIIDIVSG AHWGVMFGLA  360 
              T.D......T .H........ .........T .LV..Q...I .TTLV.LL.. G....LV.V. 
gt4a  301     TQDCNCSIYT GHITGHRMAW DMMMNWSPTT TLVLAQVMRI PTTLVDLLSG GHWGVLVGVA  360 
 
JFH1  361     YFSMQGAWAK VIVILLLAAG VDAGTTTVGG AVARSTNVIA GVFSHGPQQN IQLINTNGSW  420 
              .....AN... ..LV.F.F.. ...E.HVS.A ..G...AGL. NL..S.SK.. L....S..... 
gt4a  361     YFSMQANWAK VILVLFLFAG VDAETHVSGA AVGRSTAGLA NLFSSGSKQN LQLINSNGSW  420 
 
JFH1  421     HINRTALNCN DSLNTGFLAA LFYTNRFNSS GCPGRLSACR NIEAFRIGWG TLQYEDNVTN  480 
              .......... .........S ....HK.... ..SE..AC.K SLDSYGQ... P.GV-A.ISG 
Gt4a  421     HINRTALNCN DSLNTGFLAS LFYTHKFNSS GCSERLACCK SLDSYGQGWG PLGV-ANISG  479 
 
JFH1  481     PEDMRPYCWH YPPKPCGVVP ARSVCGPVYC FTPSPVVVGT TDRRGVPTYT WGENETDVFL  540 
              SS.D...... .A.R...I.. .S........ .......... ..HV...... .......... 
gt4a  480     SSDDRPYCWH YAPRPCGIVP ASSVCGPVYC FTPSPVVVGT TDHVGVPTYT WGENETDVFL  539 
 
JFH1  541     LNSTRPPQGS WFGCTWMNST GFTKTCGAPP CRTRADFNAS TDLLCPTDCF RKHPDATYIK  600 
              .......H.A ....V..... .......... .EVNTN---N GTWH...... ....ET..A. 
gt4a  540     LNSTRPPHGA WFGCVWMNST GFTKTCGAPP CEVNTN---N GTWHCPTDCF RKHPETTYAK  596 
 
JFH1  601     CGSGPWLTPK CLVHYPYRLW HYPCTVNFTI FKIRMYVGGV EHRLTAACNF TRGDRCDLED  660 
              ......I..R ..ID...... .F...A..SV .N..TF...I ...MQ....W ...EV.G..H 
gt4a  597     CGSGPWITPR CLIDYPYRLW HFPCTANFSV FNIRTFVGGI EHRMQAACNW TRGEVCGLEH  656 
 
JFH1  661     RDRSQLSPLL HSTTEWAILP CTYSDLPALS TGLLHLHQNI VDVQYMYGLS PAITKYVVRW  720 
              ...VE..... LT..A.Q... .SFTT..... ...I...... .....L..VG S.VVSWALK. 
gt4a  657     RDRVELSPLL LTTTAWQILP CSFTTLPALS TGLIHLHQNI VDVQYLYGVG SAVVSWALKW  716 
 
JFH1  721     EWVVLLFLLL ADARVCACLW MLILLGQAEA ALEKLVVLHA ASAANCHGLL YFAIFFVAAW  780 
              .Y...A.... .....S.... .MFMVS.V.. ..SN.ININ. ....GAQ.FW .AIL.ICIV. 
gt4a  717     EYVVLAFLLL ADARVSACLW MMFMVSQVEA ALSNLININA ASAAGAQGFW YAILFICIVW  776 
 
JFH1  781     HIRGRVVPLT TYCLTGLWPF CLLLMALPRQ AYAYDAPVHG QIGVGLLILI TLFTLTPGYK  840 
              .VK..FPAAA A.AAC....L F...LM..ER .....QE.A. SL.GAIVVML .IL..S.H.. 
gt4a  777     HVKGRFPAAA AYAACGLWPL FLLLLMLPER AYAYDQEVAG SLGGAIVVML TILTLSPHYK  836 
 
JFH1  841     TLLGQCLWWL CYLLTLGEAM IQEWVPPMQV RGGRDGIAWA VTIFCPGVVF DITKWLLALL  900 
              LW.ARG...I Q.FIART..V LHVYI.SFN. ..P..SVIVL AVLV..HL.. ....Y...I. 
gt4a  837     LWLARGLWWI QYFIARTEAV LHVYIPSFNV RGPRDSVIVL AVLVCPHLVF DITKYLLAIL  896 
 
JFH1  901     GPAYLLRAAL THVPYFVRAH ALIRVCALVK QLAGGRYVQV ALLALGRWTG TYIYDHLTPM  960 
              ..LHI.Q.S. LRI......Q ..VKI.S.LR GVVY.K.F.M VV.KA.AL.. .......... 
gt4a  897     GPLHILQASL LRIPYFVRAQ ALVKICSLLR GVVYGKYFQM VVLKAGALTG TYIYDHLTPM  956 
 
JFH1  961     SDWAASGLRD LAVAVEPIIF SPMEKKVIVW GAETAACGDI LHGLPVSARL GQEILLGPAD  1020 
              .....T.... ....L..VV. T......... ..D....... IR........ .N........ 
gt4a  957     SDWAATGLRD LAVALEPVVF TPMEKKVIVW GADTAACGDI IRGLPVSARL GNEILLGPAD  1016 
 
JFH1  1021     GYTSKGWKLL APITAYAQQT RGLLGAIVVS MTGRDRTEQA GEVQILSTVS QSFLGTTISG  1080 
              TE.....R.. .......... .......... .......... .......... .......... 
gt4a  1017     TETSKGWRLL APITAYAQQT RGLLGAIVVS MTGRDRTEQA GEVQILSTVS QSFLGTTISG  1076 
Appendix 7. Amino Acid Alignment Comparing the Core to NS2 Regions of 
genotype 4a ED43 sequence to JFH1 
 
The core to NS2 region of genotype (gt) 4a (bottom row) was aligned to the JFH1 
sequence (top row). Dots represent amino acids that are identical in both sequences 
(middle row). Blue highlights the critical CD81 binding residues in E2 (Owsianka et 
al., 2006; Drummer et al., 2003; Yagnik et al., 2000). Red highlights the 
glycosylation sites in E1E2 (Goffard and Dubuisson, 2003). The cell culture adaptive 
mutations identified in this study are indicated in bold and underlined. 
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